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Summary
The application of health technology assessment in Egypt: 
case study using hepatitis C
The staggering prevalence of Chronic hepatitis C virus (HCV) infection in Egypt 
ranging from 15-20% places tremendous demands on the health care system and the 
society. This fact made it a good example to use to measure the feasibility of 
pharmacoeconomic and health assessment research in Egypt. The study attempted to 
answer some of the questions that policy makers and physicians need to address and 
patients need to consider when undertaking treatment of HCV infection. A critical 
appraisal was also included to confront and to highlight some additional issues that 
need be addressed, amended and/or altered when undertaking treatment decisions 
regarding HCV.
In this study, cost of the disease was calculated as well as the cost effectiveness of the 
various treatment options available: the supportive treatment pathway and both 
standard interferon and pegylated interferon combination treatment pathways. 
Outpatients and inpatients with chronic hepatitis C liver cirrhosis frequenting the 
National Liver Institute, Menoufia, Egypt's largest and busiest public tertiary referral 
government health subsidized center. The mean annual cost per patient was assessed 
and the data computed using computer cohorts of 100 patients following the Markov 
models of the natural history of disease progression. It was found that the cost of 
pegylated interferon combination therapy over the full cycle of the disease was the 
most cost effective alternative amounting to 75 704.61 LE versus 144 872.23LE and 
92 155.61LE for the supportive and the standard interferon treatment pathways 
respectively and thus its cost effectiveness values were negative compared to the other 
pathways. The same results were true for patients visiting private profit and non profit 
medical settings. This in turn helps to emphasize the importance o f adopting health 
economic evaluations in the determination of efficiency of the health care services 
and policies in Egypt.
It was concluded that it was more cost effective to use antiviral therapy in relation to 
the cheaper supportive option where not only cost effectiveness ratio was negative for 
both the regular interferon and the pegylated interferon alternatives but also 10% and 
14% of lives were saved respectively. The study proves the feasibility and the 
importance of implementing health economics and health technology assessment 
studies towards health improvement in Egypt. It further highlights that informed 
decision makers can have a positive effect on the health budget and consequently on 
unwritten social contract and ethical guidelines they have with their communities and 
society at large.
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Introduction & Aim o f  Work
Health services and the amount of resources required for their provision is among the 
most controversial and debatable social and political issues of our time. However, 
aside from the short-term political controversies, the more fundamental issue of the 
health service dilemma has been taxing the minds of all governments in the developed 
world and is increasingly becoming apparent in developing countries (Phillips and 
Prowle, 1992; Phillips, 2003 and Palfrey et al, 2004). This health service (or 
healthcare) dilemma is part of a wider economic problem which affects individuals, 
organizations, societies, economies and ultimately the global community. The 
attempts to deal with health and healthcare problems, to reduce the magnitude of their 
negative effects and to achieve a closer fit between the supply o f services and demand 
for healthcare both constitute a challenge for healthcare officials and decision makers. 
Egypt, unlike developed and western countries, has veiy little practical or theoretical 
experience to incorporate cost issues within clinical decisions and guidelines. Taking 
into consideration that rich countries able to devote significantly greater levels of 
resources to healthcare services provision, are increasingly utilizing health economic 
techniques alongside evidence based approaches to inform decision-making bodies 
and to establish priorities in relation to healthcare. The question arises whether 
developing countries, such as Egypt, where the levels of resources are even more 
limited should consider the need to embrace such techniques in seeking to maximize 
the healthcare benefits for their societies / residents. In addressing this issue, the 
feasibility of employing evidence-based approaches and health economic techniques 
in the decision-making process, within a culture not only dominated by the perception 
of the medical community to provide treatment for all, but also which is severely 
constrained by resource availability, has to be established.
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It is important to stress at the outset that health economics as emphasized in this 
research is not necessarily concerned about controlling expenditure, but it is rather a 
set of tools or a technique which can be utilized to ensure that whatever available 
resources are allocated to generate the maximum benefits for society (Jefferson et al, 
2000). In addition, these tools and/or technique can be regarded as key for doctors, 
decision-makers and other healthcare professionals ensuring that they do the most 
good that could be done with the available resources (Williams, 1993). Moreover, the 
adoption of these tools does not compromise the medical profession’s desire to 
provide treatment as such, but encourages healthcare professionals to address the 
existence of ineffectiveness and inefficiencies in service provision and to consider costs 
issues in their clinical decisions. This leads to best allocate the available resources and 
to secure the greatest health benefits for their patients and ultimately their whole 
community.
The adoption of a more evidence-based perspective alongside health economic 
techniques by policy makers will result in an explicit approach to priority setting 
becoming evident. This in turn may affect current thinking and decision-making at all 
levels and will require a fundamental cultural change. Alternatively it will yield a 
more efficient allocation of healthcare resources. Being a developing country, Egypt 
and its government, is no exception in its attempts to offer remedies and solutions for 
an increasingly complex set of problems.
Aims and objectives
This project aims to assess the extent to which health technology assessment might 
contribute to the decision-making process relating to healthcare provision and 
delivery in Egypt, using hepatitis C as a case study. In addition this project aims to
3
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identify treatment alternatives of HCV, measure and value their costs and compare 
them against each other. The specific objectives are to:
■ assess the cost of hepatitis C virus (HCV) treatment in Egypt
■ evaluate the effectiveness of treatment strategies for HCV in Egypt by 
adopting evidence-based guidelines
■ calculate the cost effectiveness of the various treatment options
■ apply health technology assessment as a methodology aid to healthcare policy 
and decision making in Egypt
■ maximize effective delivery of appropriate healthcare methodology in Egypt
■ explore means for increasing the use of health technology assessment 
techniques in healthcare policy making and expenditure decisions in Egypt.
■ answer some of the questions that physicians need to address and patients need 
to consider relating to the cost of the disease and effectiveness of treatment 
when undertaking treatment of HCV infection.
The rationale for using HCV as a case study, derives from the significant burden that 
it places on the Egyptian healthcare system (Strickland, 2006), and the exorbitant 
costs of alternative treatment strategies available for managing the condition. This 
study, to the best knowledge of the author, is amongst the first studies to assess cost 
effectiveness of HCV treatment in Egypt. In essence, this study provides both the 
theoretical background and the practical applications required to assess the value of 
HCV treatment in Egypt.
The literature review begins with introducing health economics as a concept; and 
health technology assessment as an essential methodology aid for dealing with 
healthcare issues and for capitalizing on healthcare systems' effectiveness worldwide. 
This is then followed by a dissertation on HCV, as a disease and its health
4
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implications from a global perspective. The systematic review of evidence in this 
study then considers the available interventions for HCV treatment and examines their 
effectiveness. The explanation of the uniqueness of the Egyptian situation comes next 
in terms of the prevalence of HCV, the reasons for it, the implications and burden of 
HCV and finally current treatment patterns and services. The proposed design and 
methodology starts with choosing the medical settings for the field research, it then, 
leads to assessing the cost components of treatment which include drugs and services 
given to HCV patients in Egypt and ends with the estimation of the disease cost. The 
Markov models from published literature were used for the analysis of the cost 
effectiveness of available treatments. The collected data was computed and costs’ 
components of the treatment alternatives were first calculated and then discussed in 
relation to the international costs of HCV treatments. The cost components and 
effectiveness data calculated emphasized the importance of health assessment benefits 
within the boundaries of the Egyptian healthcare system. The conclusion ends with 
the implications of assessing the effectiveness of HCV’s best treatment alternative 
and its cost effectiveness. The study highlights the feasibility and the importance of 
implementing health economics and technology health assessment studies towards 
health improvement in Egypt. This fact is accentuated by the initiation and 
implementation of the national new mandatory HCV interferon treatment centres 
throughout the country.
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2.1. Background
Resource allocation and healthcare
The exponential augmentation of demands placed on healthcare services against 
limited resources available to meet them, is the core of the decision making dilemma 
and a major concern for those at all echelons of policy and decision-making. The 
global problem the decision-maker faces is too complicated to solve directly, he 
should reduce it to a series of simpler problems, solve each of them, and then combine 
these solutions in a consistent and reasonable way to solve the original problem 
(Williams, 1974). In any decision making situation, choosing an option depends on 
two key factors: the decision maker’s uncertainty about what will happen if an option 
is chosen; and the relative desirability of the possible outcomes (Robinson, 1993 a). 
The utilization of economic evaluation techniques and other approaches, in the form 
of health service research which most directly pertains to decisions about the 
allocation of resources, should be explored and indeed be used by Egyptian decision 
makers, to assist them in their struggle to balance the competing claims made on 
limited resources by a variety of parties, each of whom have strong and worthy 
rationales to underpin their particular case (Drummond, 1987).
Health economics is a logical and explicit framework to aid healthcare workers, 
decision makers, governments, or societies at large, to make decisions on how best to 
use resources (Jefferson et al, 2000). It represents a way of thinking about the 
problems relating to the allocation of limited healthcare resources and how to generate 
the most beneficial outcomes for society as a whole.
Health economics is itself relatively young; the first book on this subject was 
published in 1973 with barely any systemic reference mention before the mid sixties 
(Cooper and Culyer, 1973). The term pharmacoeconomics has an even more recent
8
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history, and although primarily used by the pharmaceutical industry and academic 
institutions, it was later used with outcomes research by pharmacy practitioners to 
assess the value of pharmacy compared to the rest of the healthcare system and to 
society. Pharmacoeconomics and outcomes research identify, measure and compare 
the cost (all resources consumed both direct and indirect ones) and consequences 
(clinical, humanistic, economic and social) of pharmaceutical products and medical 
services. Clemens et al, (1993) reported a definition that incorporated 
pharmacoeconomic research into the process of drug development from inception (pre 
phase one) up to phase four when post marketing surveillance is taking place. They 
reported that pharmacoeconomics research “assesses the implications of projected 
outcomes and costs of pharmaceutical products for the decision whether to continue 
or to stop development of a drug and for global pricing strategy” (Clemens et al, 
1993). Furthermore, with soaring healthcare budgets, attention has turned to the 
economic efficiency or so called “cost-effectiveness” of diagnostic and therapeutic 
medical interventions; consequently pharmacoeconomics has emerged as an 
increasingly important area of research.
New drug evaluations traditionally involved phase I studies of drug safety and dosing 
for a particular condition, followed by phase II and III randomized controlled trials to 
evaluate drug efficacy. Occasionally, a post marketing surveillance study might be 
performed to evaluate drug effectiveness in a less controlled setting (Wong, 1999). 
Pharmacoeconomics research has been directed towards not only the refinement of 
the research methods and their application to evaluating pharmaceutical services and 
specific drug therapies, but also towards helping in making important clinical and 
managerial decisions, whereupon pharmacoeconomics’ role does not remain the same 
during the different phases of drug development. In the early phases, it helps the
9
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identification of commercially viable options with their respective market niches 
which could be profitably exploited (commercially) emphasizing on informing pro 
and con decisions about product development. While in later phases (stages), it affects 
decision making by supplying the necessary information regarding both the 
appropriate use and the rational prescription of the developed drugs, thus acting as a 
tool of management used in strategic and operational decisions about pharmaceutical 
development, production or consumption and ultimately ensuring the most efficient 
use of limited resources.
As such pharmacoeconomics is evolving as a new discipline that can help many 
people, every day, with many important health and lifestyle decisions. 
Pharmacoeconomics is a branch of health economics which aims to address the 
concern of the value of drug and medical therapy, which is a function of its benefits as 
well as its costs, and it also aims to ensure that resources are allocated to effective 
interventions. To continue to define pharmacoeconomics and what it means to do 
high-quality health economic research; there is an opportunity and indeed an 
obligation to apply knowledge and skills at the patient's bedside, work place, and 
home. Knowledge of economics, outcomes, and quality of life is taken, and involved 
with patients directly and more completely in their healthcare decision making 
(Drummond, 1996).
Prioritizing healthcare resources has become both inevitable and necessary. A harsh 
fact that is emphasized by the scarcity of resources and the almost insatiable demands 
made on them (Spiegelhalter et al, 1992). To effectively prioritize, some measures of 
output from healthcare must be first established; bearing in mind that in choosing to 
use resources in one healthcare program or treatment, the opportunity is sacrificed to 
use the same resources in another competing activity and to obtain some other benefit.
10
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Hence, the idea of opportunity cost; that is the cost of using healthcare resources in 
one area or field is the value of the benefits they would have generated in their best 
alternative use (Drummond et al, 1987). The aim of providing “the best” within the 
constraint of available resources is, however, an objective to which the health service 
ought to ascribe. The definition of best here allows for scarcity of means and policy­
making (Mooney et al, 1986). The three fundamental issues confronting the policy 
makers and decision-makers in the health service are:
(1) The need to determine what services to provide, when and at what level of 
provision
(2) The need to determine how and where to provide such services
(3) The need to determine who should get the services (Mooney et al, 1986)
In essence, there is scope for considerable improvement in decision making and that 
the issues of what to provide, how and to whom, which are central to both the 
problems of the health service and the discipline of economics, can be helped by 
injection of both the philosophy and the techniques of economics (Mooney et al,
1986) bearing in mind that the issue in this research relates to a developing country 
still experimenting this "new" philosophy and "modem" techniques. Extra 
complications arise because there is essentially a mix of systems and methods for 
decision making, among which are planning decisions, made on behalf o f the 
community by healthcare jurisdictions. These decisions concern issues such as 
whether particular public health programs (such as screening or immunization 
schemes) should be funded and occasionally decisions concerning individual medical 
procedures. In addition, there is resource allocation process which involves clinical 
decisions, made by practitioners on behalf of individual patients (Drummond et al,
1987). Although clinical decisions may be partially constrained by the facilities
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provided, they are mainly made without reference to those planning, managing or 
funding the healthcare system. This presents obvious problems for those trying to 
ensure a rational use of healthcare resources.
Samuelson’s definition of economics goes a long way to explain why economic 
theory is relevant to the evaluation of new drugs and therapies, “Economics is the 
study of how men and society end up choosing, with or without the use of money, to 
employ scarce productive resources that could have alternative uses, to produce 
various commodities and distribute them for consumption, now or in the future, 
among various people and groups in society. It analyses the costs and benefits of 
improving patterns of resource allocation” (Samuelson, 1976). Put in these terms, 
economics should not appear threatening. It is not primarily concerned with reducing 
financial costs but considers both costs and benefits in broader terms than simply 
money. The key issue is that economics focuses on productive resources and their 
scarcity (demand exceeds supply) and therefore someone must make a choice about 
how the resources can be used to produce as much benefit as possible. Economics can 
help in making these decisions by clarifying what the costs and benefits of different 
interventions may be (McGhan, 1996). In economics there are two types of choice to 
be made. First, when the decision to meet need X has been taken and we are 
evaluating the most efficient way of meeting it. This is called technical or X 
efficiency evaluation (Williams, 1974). Economic evaluation has a large part to play 
in such technical decisions. Then when the many needs to be met have to be defined 
and we must compare the costs and benefits of each alternative, this is called 
allocative efficiency evaluation (Williams, 1974 and Jefferson et al, 2000).
As Maynard, (1994) remarked that "the pursuit of efficient practice is not merely 
about reducing costs. If it were, the most efficient procedure would be to do nothing,
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as that pushes costs to zero”. To this should be added the concepts of equality and 
equity, along with effectiveness and efficiency recognized by Cochrane, (1972) and 
other think-tanks and bodies (Commonwealth Fund Commission on a High 
Performance Health System, 2006 and Gauthier et al, 2006). One such body - the 
Institute of Medicine in the US -  has outlined a useful agenda for healthcare system 
improvement (Institute of Medicine, 2001), known as the “S-T-E-E-E-P” goals 
(Berwick, 2004):
•  safety (reducing medical injuries to patients);
• timeliness (reducing waits and delays throughout the system);
• effectiveness (increasing the reliability of evidence based care);
• efficiency (reducing the total cost of care); and
• equity (closing racial and socioeconomic gaps in health status)
• patient centeredness (giving patients and carers far more voice, control and 
competence in self-management);
The existence of ineffectiveness and inefficiencies in service provision presents serious 
obstacles to delivering better healthcare. Irrespective of funding levels, choices always 
have to be made regarding the allocation of resources. In making such choices, decision­
makers need to establish a definite set of priorities while professionals' and societies' 
attitudes need to be changed. The recognition of the need to generate evidence relating 
to resource utilisation and the most beneficial utilisation of available resources is also 
very important.
In making decisions about the allocation of resources, health authorities need to draw 
on several sources of information (Cochrane et al, 1991 and Gilbody and Petticrew, 
1999). These may be summarized as top down priorities, bottom up consultation, 
professional opinion, and research based evidence (figure 1).
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Figure 1: Health authorities’ sources of information
Top-down priorities
National & Regional targets
Research based evidence 
&
Cost effectiveness data
Professional opinions 
District Health Authority clinical practitioners
& other providers
Bottom-up consultation
Public consultation, 
Community health council 
& pressure groups
Derived from Cochrane et a/, (1991)
2.2. Health Technology Assessment
HTA dates from the late 1970s when the expansion of technology and health-care 
costs began to capture the attention of decision-makers (Jonsson, 2002). Decision­
makers needed a more comprehensive approach to set priorities and obtain maximum 
benefit from limited resources, without compromising the ethical and social values 
underpinning health systems (Hutton et al, 2006). The growth and development of 
HTA reflected this demand for well-founded information to support decisions on the 
development, uptake and diffusion of health technologies.
Assessment in healthcare has developed greatly in the last decade; it became a process 
with methodological concepts underlying its many stages. Health economic 
assessments coupled with portfolios of effectiveness evidence have been 
progressively used in recent years by decision-making bodies that increasingly relied 
on such evaluations. Eventually, health technology assessment has become a 
recognized academic discipline and a recipient of large scale research funds. An
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HTA’s principal aim is to provide a range of stakeholders (typically those involved in 
the funding, planning, purchasing and investment of healthcare) with accessible, 
usable and evidence-based information to guide decisions about the use and diffusion 
of technology and the efficient allocation of resources. In light of these objectives, 
HTA has been called “the bridge between evidence and policy-making”, as it provides 
information for health-care decision-makers at macro-, meso- and micro-levels 
(Battista & Hodge, 1999). HTA also contributes greatly to the knowledge base for 
improving quality of care, especially by supporting the development (or updating) of 
clinical practice guidelines and standards for health-service provision (Zentner et al, 
2005). HTA provides important benefits by empowering governments to make value- 
driven decisions, supporting innovation and providing patients and physicians with 
the information for making the best treatment choices.
On a broad level, HTA was regarded by Sorenson and colleagues as ’’The systematic 
evaluation of the properties, effects, and/or other impacts of healthcare technology" 
(Sorenson et al, 2008).
More specifically, HTA involves the evaluation of an intervention through the 
production, synthesis and/or systematic review of a range of scientific and non- 
scientific evidence. The type of evidence considered typically includes the safety, 
efficacy, cost and cost-effectiveness of a product. However, HTA is also concerned 
with the societal, organizational, legal and ethical implications of implementing health 
technologies or interventions within the health system (Velasco-Garrido & Busse, 
2005). For example, HTA often considers health technologies’ broader 
macroeconomic impacts on national health-care budgets; resource allocation among 
different health programs; regulation; and other policy changes for technological 
innovation, investment, technology transfer and employment (Goodman, 1998).
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In addition to ascertaining technologies of value, an effective HTA can reduce or 
eliminate the use of interventions that are not safe and/or effective, or have 
insufficient cost-benefits. HTA can also be used to identify existing technologies that 
may be harmful or ineffective. Less commonly, HTA can also identify underused 
technologies (e.g. preventive screening, smoking-cessation interventions) and the 
reasons for this (Asch et al, 2000 and McNeil, 2001).
Since the 1970s, HTA has broadened to encompass a wide range of health 
technologies including drugs; medical devices; medical and surgical procedures; and 
the organizational and support systems for care provision (Jonsson, 2002). However, 
the majority of HTAs have been conducted on pharmaceuticals rather than other 
technologies such as medical devices and surgical procedures (Hutton et al, 2006).
In particular, assessments often differ according to the:
• type of economic assessment required
• classification of product benefit (benefit versus harm) -  hierarchy of evidence
• choice of comparator
• specification of the outcome variable
• costs included in the analysis
• discounting
• use of cost effectiveness threshold
• allowance for uncertainty
• missing and incomplete data
(Zentner et al, 2005)
Methodologies can also differ on sub-group analyses; time horizons; instruments to 
measure quality of life; and methods for calculating costs (Sorenson et al, 2008).
The appraisal or assessment of a health technology is divided into three distinct 
phases starting with the scoping, passing through assessment and ending with 
appraisal.
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A. Scoping
During this process, not only are the issues of interest defined as clearly as possible to 
have clear boundaries for the appraisal, but also the parameters to be investigated are 
stated plainly. The scope is then developed into a protocol, the main frame for the 
technology assessment.
B. Assessment
This process is a systematic and independent evaluation of the relevant evidence 
available on the technology. The aim is to produce an estimate, including uncertainty, 
of its clinical and cost effectiveness for a specific indication. Assessment has two 
mutually dependent components: a systemic review of the evidence and an economic 
evaluation. This process requires an understanding of the appraisal question and the 
context within which it is addressed, covering for example, currently available care, 
any alternative technologies, and appropriate methods of comparing the technologies 
etc.... This assessment, therefore, consists of an objective analysis o f the quality, the 
findings, and the implications of the (mainly research) evidence available as it relates 
to the appraisal question and context, strengths, weaknesses and gaps in the evidence 
which are identified and evaluated.
C. Appraisal
The appraisal process is a consideration of the outputs of the assessment process 
within the context of the additional information supplied by consultants, 
commentators, clinical specialist and patient experts. The appraisal committee first 
considers the evidence available in the assessment reports and elsewhere, it then 
formulates an appraisal decision, applying judgments on the importance of a range of 
factors differing from one appraisal to the next. The boundary between assessment
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and appraisal, while present is not clearly defined; the judgment in the assessment 
process will influence the appraisal process.
The wide variation in approaches and methods employed in economic evaluation and 
HTAs has led to the adoption of a reference case of core methods to be used (Gold et 
al, 1996 and National Institute of Clinical Excellence, 2004). In some instances, there 
may be some barriers to the application of the reference case methods, and data 
required to present reference case results may not be available. In such situations, 
NICE and other similar bodies requires the submission of well specified and justified 
reasons for the inability to meet the reference case requirements along with the 
quantification of the likely implications.
However, the success of such approaches is highly dependent on other factors 
influencing the quality of the decision-making process. Among which are (Moore et 
al, 2006):
•  evidence on effectiveness;
• evidence on cost; and
• evidence on how to make a change
The reference case specifies the methods considered by the NHS to be the most 
appropriate for the appraisal purpose and consistent with the objective of maximising 
health gain from limited resources. The key elements are summarized in table 1.
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Tablel: NICE Reference Case
(from National Institute of Clinical Excellence, 2004)
Element of Health Technology 
Assessment
Reference Case
Defining the decision problem The scope developed by NICE for the appraisal
Comparator Alternative therapies routinely used in the NHS
Perspective on costs National Health Service and Personal Social Services
Perspective on outcomes All health effects on individuals
Type of economic evaluation Cost-effectiveness analysis
Synthesis of evidence on outcomes Based on systematic review
Measure of health benefits QALYs
Description of health states for calculation of 
QALYs
Health states described using a standardized and validated 
generic instrument
Method of preference elicitation for health state 
valuation
Choice-based method, for example, time trade-off, standard 
gamble (not rating scale)
Source of preference data Representative sample of the public
Discount rate An annual rate of 3.5% on both costs and health effects
Equity position
An additional QALY has the same weight regardless of the 
other characteristics of the individuals receiving the health 
benefit
It is essential, to think about the use of evidence relating to effectiveness and cost- 
effectiveness without considering the organizational context is ‘to miss a good part of 
the story’ (Weiss 1998), for example, that the organizational climate is conducive to 
ensure that ‘patients get the right care at the right time and in the right setting’ 
(McCannon et al, 2006) and what constitutes best evidence within the context of the 
evidence-based organization must take into account the circumstances and conditions 
prevailing within the organization's environment (Palfrey et al, 2004). While evidence 
answers the question does it work, and economics will inform whether it is worth it, 
the can it work question is where quality decision-making comes in (Haynes, 1999).
2.3. Health economics and evidence-based healthcare
The ever increasing demands placed on healthcare services against limited resources 
available to meet them, continues to be a major concern for those at all echelons of
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policy, decision-making, and delivery of healthcare services. This fact helps to 
highlight the contribution of economic techniques and approaches in relation to 
decision making. It initially considers the relationship between economics and 
evidence-based healthcare, and the need for both to be involved in the decision­
making process if some degree of quality is to be achieved. The development of 
policies and strategies based on what has been proven to be clinically effective has 
been advocated for some time on the international arena. Terms such as evidence- 
based healthcare and clinical effectiveness are now common in healthcare circles. The 
need to ensure that limited resources are channelled into effective interventions 
coupled by the belief that the way to reduce cost pressures in healthcare is to focus on 
effectiveness and proven quality has both provided the incentive to promote evidence- 
based practice (Marwick, 1997).
Health management requires what Phillips, (2005) referred to as joined-up thinking, 
and employs a whole-systems approach, one which is broadly focused and not only 
driven by budgets, and with due consideration for the impact of decisions on the 
consequences for patients and healthcare provision in general. The burgeoning 
growth in the quantity and quality of evidence available for decision-makers has not 
removed the need for a whole systems approach to decision-making (Bell et al, 2006; 
Commonwealth Fund Commission on a High Performance Health System, 2006 and 
Gauthier et al, 2006). Berwick, (2005) have concisely and conveniently summarized 
what a quality health system should aim to represent:
• No needless deaths -  don’t kill me
• No needless pain -  don’t hurt me
• No helplessness -  do help me
• No unwanted waiting -  don’t keep me waiting
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•  No waste -  don’t waste resources 
The relationship between health economics and evidence-based medicine is one that 
has aroused interest among health economists (Maynard, 1996; Vale et al, 2000 and 
Birch, 2002) and leading advocates of evidence-based healthcare (Sackett et al, 1996). 
Evidence based healthcare (EBHC) and health technology assessment (HTA) play a 
significant role in informing decision-making bodies at an organizational and 
healthcare system level across many countries.
The widely used definition of evidence based medicine (EBM,) which has been 
widely used, is that provided by Sackett and colleagues (1996): “Evidence-based 
medicine is the conscientious, explicit and judicious use of current best evidence in 
making decisions about the care of individual patients” (Sackett et al, 1996).
Hill, (1997) along with Nutley and Webb, (2000) both described the rational policy 
process cycle, by including the notion of evaluation and review, as well as the notion 
of implication research and evidence. Evaluation is defined as being “concerned with 
judging merit against some yardstick” and involving “the collection, analysis and
interpretation of data attempts to measure the extent to which certain outcomes
can be validly correlated with inputs and/or outputs” (Phillips et al, 1994).
The EBM movement has gone through the stage of being an evolutionary process 
which then led policy-makers to create the notion of clinical governance among other 
facets of healthcare policy to establish and deliver quality and monitor performance 
against agreed standards. This notion was introduced in 1998 as a new approach to the 
quality improvement in the UK NHS, on the basis that it would be the framework 
within which healthcare organisations at every level of the NHS would be 
“accountable for monitoring and improving the quality of their services” and it was 
also intended to “safeguard high standards of care by creating an environment in
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which excellence in clinical care will flourish” (NHS Executive, 1998). It should be 
noted, however, for the sake of the argument that a search of the literature concluded 
that “as yet, there are no studies providing evidence showing that the adoption of 
clinical governance improves the quality of healthcare and of patient care (Thomas, 
2001).
2.3.1. Characteristics and application of good evidence
The success of quality initiatives is highly dependent on the quality of the information 
sources which are available. In its attempt to stimulate ‘professional policy making’; 
the Cabinet Office, (1999) in England, sought to emphasize the importance of 
evidence and defined the range of sources as expert knowledge; existing domestic and 
international research; existing statistics; stakeholder consultation; evaluation of 
previous policies; new research, if appropriate; or secondary sources, including the
Internet outcome of consultation, cost calculation of policy options and the results
of economic or statistical modelling. (Cabinet Office, 1999; paras 7.1 and 7.2) 
However, the debate regarding the attributes of good evidence reflects the wide range 
of views relating to the particular hypothesis and perspective employed in medical 
and social science research.
Type and strength of evidence (from McQuay and Moore, 1998)
I. Strong evidence from at least one systematic review o f multiple well- 
designed randomized controlled trials
II. Strong evidence from at least one properly designed randomized controlled 
trial of appropriate size
III. Evidence from well-designed trials without randomization, single group pre­
post, cohort, time series or matched case-controlled studies
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IV. Evidence from well-designed non-experimental studies from more than one 
centre or research group
V. Opinions of respected authorities, based on clinical evidence, descriptive 
studies or reports of expert committees
Nevertheless, the increase in quality reviews in other fields might contribute to 
“improve the evidence base and increasing its influence on policy and practice in the 
public services” (Davies et al, 2000). It is also important to emphasize whether the 
evidence can fulfil three basic requirements:
(1) Are the results valid? Can they be believed, have the studies conformed to 
recognized practice and procedures, to what extent have bias and other 
external factors impacted on the research, which outcomes were considered 
and are they meaningful?
(2) What are the results: does the intervention work as intended, what are the risks 
that the intervention will cause harm, how precise are they, is there wide 
variation across the findings?
(3) How relevant are the results: can they apply in different environments and 
different settings?
Moreover, within the evidence-based organization, if an intervention is unsuccessful, 
the evidence should help to determine whether the intervention was inherently faulty 
(that is, failure of intervention concept or theory), or just badly delivered (failure of 
implementation)” (Rychetnik et al, 2002).
Concisely, what constitutes best evidence within the context of the evidence-based 
organization takes into account the circumstances and conditions prevailing with the
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organization and its environment. Furthermore, the three requirements highlighted 
above need to be supplemented by other factors such as:
•  What are the implications of applying these findings within the current 
organizational dynamics?
• To what extent would the implications of findings cause de-stabilisation 
within the organization?
• Would there need to be significant change if these findings were to be 
implemented?
• What would be the reaction of service users and other stakeholders to the 
findings?
•  What are the resource implications resulting from implementing such 
evidence?
• Are there alternative perspectives that need to be considered?
A major stipulation, to the success of evidence and quality in policy documentation, is 
organizational environments. The adjustability of those environments to facilitate 
policy approaches along with the implementation of suitable guideline 
recommendations and relevant research findings to become part of standard policy 
making practice is also an issue. More effort and studies are still needed to assess the 
effectiveness of intra-organizational, inter-organizational, inter-professional, 
collaborative and partnership approaches to the organization and delivery of services 
(El Ansari et al, 2001 and El Ansari and Phillips, 2001), to complement the wealth 
of research evidence relating to practice. In spite of this, Weiss, (1998) demonstrated 
that the quantity of research information appears to have very little or no impact on 
practice because availability does not mean accessibility by practitioners (NHS CRD, 
1999). Then again, Nutley and Davies, (2000) concluded that, “there is much to be
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gained from viewing evidence-influenced practice as a partnership activity” and 
advocated an approach that combines:
• insights from systems thinking (in terms of setting the contexts within which 
evidence is to be used);
• understanding of individual decision making and behaviour change (which 
acknowledges the importance of craft routines and tacit knowledge by 
professionals);
• awareness that the nature of the innovation being promulgated will influence 
its diffusion (and in particular, the ‘fit’ between the innovation, the context 
and those who are potential adopters);
• ownership of evidence through partnerships in the evidence generation 
process.
The evidence-base for the effectiveness of interventions and management strategies 
should be continuously developed. However, health economics alone is not going to 
result in better decisions being made. Health economists tend to fall into the trap of 
being narrowly focused on efficiency issues, by condensing outcomes into a single 
measure and failing to grasp the bigger picture (Phillips, 2005). Coast, (2004) 
advocated a broader perspective and set of approaches, whereby the economic 
framework would enable decision makers (on behalf of society) to assign their own 
values to the profile of costs and consequences, which could and would differ 
according to the context, and where decision makers would be able to clearly identify 
alternatives.
The integration of evidence relating to effectiveness and resource utilisation can be 
brought together in a matrix (Donaldson et al, 2002) as shown in figure 2 below.
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Figure 2: Integration of effectiveness and resource utilisation evidence 
[based on Donaldson et al, 2002]
Declining effectiveness
1 2 3 4
Increasing cost A
Y Y J n
B Y y/n N N
C J N N N
r D N N N N
y  -  yes  adopt 
n = no reject 
y / n  -  indifferent 
j = judgement needed 
EFFECTIVENESS
Compared w ith control the intervention has:
1 evidence of greater effectiveness
2 evidence of no difference in effectiveness
3 evidence of less effectiveness
4 not enough evidence of effectiveness
COST
Compared w ith  control the intervention has:
A evidence of cost savings 
B evidence of no difference in costs 
C evidence of greater costs 
D  not enough evidence on costs
There are many criteria that should be considered before making clinical decisions: 
including comparison for the suffering, the likelihood of benefit and the effectiveness 
and efficiency of the intervention. The use of decision matrices as important tools for 
decision makers due to their emphasis on integrating effectiveness and resource 
utilization evidence as well as their recognition of the importance of trade-offs 
(Stevens et al, 1995 and Donaldson et al, 2002).
Phillips, (2005) commented on the exponential increase in demand for healthcare 
services concurrently occurring with increased pressures on governments and funding 
agencies to carefully manage the resources available for healthcare services. Phillips 
added that as the addition of resources would help, it would not completely solve the 
problem. Decision-makers need to apply themselves to removing hurdles to new 
adaptive ways of working, to change attitudes and to supply supportive structures to
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explicit set of priorities, which integrate and sustain new initiatives and modem 
activities if the benefits resulting from evidence-based healthcare and health 
economics are to accrue (Weiss, 1998). In addition, the enhanced recognition of the 
need to generate evidence relating to resource utilization, effectiveness of 
interventions and the most beneficial utilization management strategies of available 
resources is encouraging and the emphasis attached to evidence-based medicine and 
evidence-based healthcare has, in all likelihood, reduced the size of the service 
provision gaps and defects, but efforts need to be maintained to ensure that the right 
momentum is preserved (Donald, 2001 and Walshe, 2001), and that the journey along 
the road to better healthcare is not merely based on hope, but on secure knowledge 
that the proportion of resources allocated to interventions and services that are 
effective, is continually increasing.
2.4. Doctors and health economists: Different perspectives
Health professionals, administrators and the policy-makers as well as the 
pharmaceutical industry shapers are all concerned with the use of the economics in 
relation to drug therapy and policy (McGhan, 1996). The professionals and healthcare 
administrators are both keen to make best use of limited resources. They can use 
health economics to define the areas where resources can best be used for maximum 
health gain. Far from cutting costs, health economics, may identify areas where there 
is under supply of resources and may even increase costs in some areas. Health 
professionals and healthcare administrators bring different perspectives as the former 
will tend to consider the benefit of the individual patient as most important, while the 
latter tend to consider the benefit of populations of patients. There are tensions 
between these two perspectives, and a balance must be struck between the two 
(McGhan, 1996). Doctors sometimes think it unethical to consider the economics of
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treating a patient: but in reality, not to consider this, risks the inefficient and wasteful 
use of limited resources. What more could be unethical? Clinicians frequently equate 
health economics with rationing or cost cutting and fail to perceive its potential value 
in improving patient care and exposing areas of deficiencies and under funding 
(Walley and Davey, 1995). Many doctors, therefore, reject as a matter of principle the 
whole process and condemn its application as being unethical (Walley and Davey, 
1995). While such an approach does not stand up to serious analysis (Walley and 
Davey, 1995 and McGhan, 1996), it must be recognized that there is a potential 
conflict between the traditional Hippocratic medical ethic (what is best for the 
individual patient) and the less traditional utilitarian ethics (what is best for any given 
population of patients). The tension between the two approaches must not be allowed 
to stifle debate but rather can be constructive in advancing our thinking on the future 
o f health services. Ultimately, health economics’ mission is to promote health and 
alleviate suffering (Williams, 1974). The pharmaceutical industry is increasingly 
aware of the need to provide not just evidence of safety and efficacy of their products 
but also of their costs effectiveness. The use of health economics in industry is quite 
comprehensive. It includes identifying markets, supporting promotional activities, 
making or justifying pricing decisions, and possibly making crucial go or no go 
decisions in drug development
Health economists are often perceived by doctors as not appreciating the complexity 
of clinical decisions. Ironically, health economists are most likely to criticize doctors 
for not appreciating the complexity of healthcare as a whole (McGhan, 1996) 
Furthermore tensions, do exist on how resources are allocated, not only because of 
incompatibility between the ethics of two sciences, medicine and economics, but also 
because of tensions between different perspectives within the same science: medicine.
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Culyer, (1991) defined two forms of medical narrow mindedness: monotechnics and 
romantics. The former are obsessed with technology to the extend that they fail to 
consider any of the other complex elements which determine need for treatment, 
while the latter refuse to face the fact that decisions about resource allocation must 
and will be made.
In somewhat similar tones, the British Medical Association’s Handbook of Medical 
Ethics makes essentially the same point: “As the resources available are limited, the 
doctor has a general duty to advice on their equitable allocation and efficient 
utilization. “ It then adds: “This duty is subordinate to the doctor’s professional duty 
to the individual who seeks his clinical advice” (British Medical Association, 1984). 
Mooney, (1992) made a few observations from an economist standpoint on the 
subject and practice of medical ethics. He highlighted the “uncomfortable fact” that, 
as practiced, medical ethics, particularly in the form of clinical freedom, tends to 
breed inefficiency. He went on to say that it sometimes provides a convenient escape 
mechanism for the romantic member of the medical profession neither to pursue 
efficiency nor to attempt any rationalization at all of the potential of pursuing 
efficiency in healthcare. In the absence of such clear thinking, doctors may make 
illogical decisions based on personal opinion, on prejudice, even, for instance, 
influenced by a patient’s socioeconomic circumstances (McGhan, 1996). Six potential 
strategies are considered when seeking to minimize the extent of the conflict between 
a doctor’s responsibilities to the individual patient and his responsibilities to society 
all of which require “more and better evidence,” (Sackett, 1996):
1. eliminate useless or harmful clinical manoeuvres;
2. expand effective, cost-saving clinical manoeuvres;
3. use equally effective but less expensive alternative clinical manoeuvres;
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4. determine and apply the cost-utility properties of clinical manoeuvres;
5. inform the public;
6. be explicit about the presence and nature of conflicts.
Conversely, the aspect and point of view, where the aims of medical practice is to 
achieve best results for patients, match those of health economics, which are to 
achieve greatest benefits for given resources (McGhan, 1996). Both require evidence 
of clinical outcomes, and both will help to improve the quality o f patient care. 
Nonetheless, clinical pharmacologists have recognized the complexity of clinical 
decision making, and the need for a systemic approach to analysis of response to 
treatment. Systemic studies of outcomes of treatment, both clinical and social, help to 
define the benefits of interventions, and are the beginning of the process which will 
allow us to identify priorities in treatment.
However, economists go further than considering outcomes: they also identify the 
costs of interventions, not in financial terms but in terms of what have been decided to 
forgo so as to use resources in one particular way: economists term this “opportunity 
cost”. They recognize that when resources are used for one intervention, there is less 
available for others. One of the great values of health economics to clinicians is that it 
makes such costs of a treatment explicit, so that they can weigh its value in 
comparison with other interventions. The description o f the alternative uses of 
productive resources is clearly relevant to practical drug therapy, including decisions 
about whether benefits should occur now or in the future (e.g. prevention versus 
treatment of established disease). Moreover, economics offers a range of rigorous 
research techniques for investigating complex clinical and resource allocation 
problems. It can also provide clinical pharmacologists with some very practical 
techniques which are essential to a realistic understanding of the costs and value of
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drug therapy, including the costs of treatment failure and adverse reactions (Davey et 
al, 1994; MacDonald et al, 1995 and McGhan, 1996).
The increasingly commonplace discussions among clinicians regarding the economic 
consequences of clinical decision making is evidence that the fields of economics and 
clinical medicine are rapidly moving toward the common goal of cost-effective 
medical practice (McKinlay, 1981; Eddy and Billings, 1988; Sloan, 1995 and 
McCombs, 1998). The increase in the frequency of involvement of healthcare workers 
and doctors in the process of economic evaluation is due to several reasons. While 
resources dedicated to healthcare may have increased, they are still limited and under 
increasing pressure, as such doctors and healthcare providers and payers find 
themselves frequently asking which technology should be provided and to what point 
the need for healthcare should be met. This is due to the constantly changing state of 
medical technology, which has made it incumbent on medical professionals to 
evaluate the cost-effectiveness of new medical technologies and innovation to update 
and improve clinical practice guidelines. Health economists have become an integral 
factor in this new dialogue. Though some scepticism still remains regarding this role, 
economists are rapidly becoming accepted as vital to furthering the discussion on 
health-care resource allocation. Although physicians remain the key decision makers 
in this deliberative process, economists provide data and insights (McCombs, 1998). 
The healthcare workers involvement should ensure that all dimensions of evaluation 
are taken into account in a multidimensional approach which includes equity and 
humanity as well as effectiveness and economic convenience. The value health 
economists bring to the thorny issue of how to allocate limited healthcare resources 
across the competing patients' needs in a fiscally restrained healthcare environment is 
valuable and is proven by the fact that treatment decisions are now known as rational
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resource allocation decisions (McCombs, 1998). As such, this study with its very 
integrative Hepatitis C virus example emphasizes that the healthcare worker holding 
managerial functions of ever-increasing complexity has to acquire a basic 
understanding of the principles underlying economic evaluations and is forced to 
become the health economist with the increasingly important role o f providing data 
and insights key to the deliberative process of comparing the costs and benefits of 
medical care, not just in terms of reduced healthcare costs but also in terms of 
efficiency of treatment.
2.5. Methods of healthcare economic evaluation
Methods of economic evaluation have been developed to assist the choices that 
inevitably must be made about the allocation of scarce resources. Within the 
healthcare sector there have been considerable advances in developing methods of 
increasing sophistication to provide a firmer evidential basis for a growing number of 
decisions in the health sector (Drummond et al, 1997; Duthie et al, 1999; Hill et al, 
2000; Hoffman and Graf von der Schulenburg, 2000; Hoffman et al, 2002; 
Drummond, 2003; Speigel et al, 2004 and Wu et al, 2004).
Within the healthcare sector, economic evaluation (or economic appraisal as it is 
sometimes called) is used as a generic term for a range of techniques that may be used 
to assemble evidence on the expected costs and consequences of different procedures 
or programs. All methods of economic evaluation have this principle in common as 
they examine one (or more) possible interventions and compare the inputs or 
resources necessary to carry out such interventions with their consequences or effects 
(Williams, 1974 and Langley, 1997). Those who plan, provide, receive, or pay for 
health services face an incessant barrage of questions about:
• Who should do what to whom,
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• With what healthcare resources, and
• With what relation to other health services?
The answers to these questions are strongly influenced by estimates of the relative 
merit or value of the alternative courses of action they pose. There are strategies and 
tactics whereby these estimates of relative value can be ascertained and interpreted, 
that is, with the evaluation of health services. In this type of evaluation many 
questions are asked (Drummond et al, 2001):
• Is this health procedure, service, or program worth doing compared with other 
things that could be done with these same resources?
• Is there satisfaction that the healthcare resources (required to make the
procedure, service, or program available to those who could benefit from it)
should be spent in this way rather than some other way?
It is imperative to note that although economic evaluation provides important 
information to decision-makers, it addresses only one dimension of healthcare 
program decisions. Nevertheless, economic evaluation is most useful and appropriate 
when preceded by three other types of evaluation, each of which addresses a different 
question (Williams, 1974; Mooney etal, 1986 and Drummond etal, 2001):
1 - Can it work? Does the health procedure, service, or program do more good than 
harm to people who fully comply with the associated recommendations or 
treatments? This type o f evaluation is concerned with efficacy.
2- Does it work? Does the procedure, services, or programs do more good than 
harm to those people to whom it is offered? This form of healthcare evaluation, 
which consider both the efficacy of a service and its acceptance by those to whom 
it is offered, is the evaluation o f effectiveness or usefulness.
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3- Is it reaching those who need it? Is the procedure, service, or program 
accessible to all people who could benefit from it? Evaluation o f  this type is 
concerned with availability.
Methodological criteria for assessing efficacy, effectiveness, and availability 
evaluations, from which the above questions have been drawn, have been described 
by Sackett, (1980).
The use of economic analyses as they pertain to the practice of medicine has become 
increasingly common place; these analyses have the potential to answer many of the 
questions posed by the delivery of healthcare in light of the accountability demanded 
by both the public and the funders of healthcare in a fiscally responsible era; but 
considerable scepticism as to their relevance and role in the assessment and evaluation 
of healthcare technologies and programs still remains due to major obstacles to 
increasing their usage and contribution to the decision-making process relating to the 
accessibility, generalisability, validity and quality of health economic studies 
represent (Drummond et al, 1997; Duthie et al, 1999; Hoffman and Graf von der 
Schulenburg, 2000; Hoffman et ah 2002 and Wu et al, 2004).
To this end, there are a number of tools in the practice of pharmacoeconomics having 
as their outcome the development of a medical decision model or decision tree (Sloan, 
1995 and McCombs, 1998).
The various methods of economic evaluation differ in the way they itemize and value 
inputs and consequences. Such differences reflect different aims and view points of 
the decision-making problems (Williams, 1974). The four main approaches that are 
currently in use are (Alan, 1974 and Robinson, 1993 a, b, c and d):
• Cost-minimization analysis
• Cost-effectiveness analysis
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• Cost-utility analysis
• Cost-benefit analysis
Each of these approaches involves the systemic identification, measurement, and, 
where appropriate, valuation of the all relevant costs and consequences of the various 
options (table 2).
The issue of cost is one which is often at the forefront of decisions made in relation to 
healthcare service provision. However, it is essential to stress that cost, in economic 
terms, is not only concerned with the financial imperatives. Health economics is not 
necessarily about saving money and reducing expenditure. If it was it would only 
focus on programs and policies that contributed to achieving an improvement in 
financial budgets, rather than an improvement in the health of patients. In purely 
monetary terms the cheapest patient is a dead patient!
Therefore, the costs of an intervention or service are not only the staff inputs, 
materials, drugs and equipment contributed by providers; the costs to other agencies 
resulting from healthcare provision; and, the costs to patients and their families due to 
travel to and from healthcare facilities among other expenses. There are, in addition, 
the indirect costs or productivity costs associated with healthcare. These occur outside 
the healthcare sector and relate to losses of production, due to absenteeism and 
reduced productivity. The costs incurred through the informal care process should 
also be taken in consideration -as a result of a carer giving up paid employment to 
provide care, which would otherwise have been provided by formal care agencies. 
However, it is the impact of health problems on the quality of life of patients, their 
families and communities that provide the biggest headache in determining the real 
cost. These aspects cannot be contained within any financial statement but are 
essential components of the balance-sheet connected with healthcare services.
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Table 2: Methods of economic evaluation and the consequences (outcomes)
measured
Type of study Measurement of consequences
Cost minimization analysis
Outcome the same between options; no 
measurement necessary
Cost effectiveness analysis
Outcomes measured in natural units e.g. life 
years gained e.g. mm of Hg
Cost utility analysis Utility measures e.g. QALYs
Cost benefit analysis Outcomes valued in money terms
All relevant costs are measured in monetary terms.
2.6. Perspective of healthcare economic evaluation
It is important to determine at the outset from whose viewpoint an economic 
evaluation is to be carried out (Robinson, 1993e and Walley and Davey, 1995). The 
viewpoint or vantage point, known as perspective establishes the context for the 
appraisal by determining which types of outcome measures and which categories of 
cost are relevant and meaningful (Elshakhs, 2001). It may be based on one or more of 
the following: the view point of an individual patient, the hospitals or other providers, 
the government, or the society in general. The broadest perspective is that of society 
in general, as this will include all the costs and benefits leading to optimal decisions, 
given that the aim of economic analysis is to make the best use of all of society’s 
resources. Bonk (1999), classified the different perspectives for an economic 
evaluation and came out with four Ps; the patient receiving the service or treatment, 
the provider of the service, the payer who covers expenditures and the public in 
general (Table 3). In each perspective category different issues take precedence over 
others. Hence defining perspective at the outset of pharmacoeconomic studies remains 
crucial to obtaining useful results (Bonk, 1999 and Elshakhs, 2001).
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Table 3: Relevant Issues by Perspective
Perspective Relevant Issue
Patient
Which therapeutic option works best for me? 
What costs must I pay?
How will I feel if I subject myself to this therapy?
Provider
How will my patient fare with the chosen therapy? 
Will the patients insurance cover these expenditures? 
Will the patient be compliant with this treatment?
Payer
Which treatment should we cover in our formulary? 
How do we adjust actuarial tables for high risk 
groups?
How do legislation and lawsuits affect our decisions?
Public
Will our tax base handle costs for the indigent?
Does this disease decrease worker productivity?
Could we better expend our limited funds for other 
uses?
Source: Adapted from Bonk (1999).
Adopting a broad approach has two main implications which distinguish it from 
approaches with more limited perspectives. Firstly, it usually involves measuring and 
valuing items that do not have market prices attached to them, such as the time costs 
that patients incur when undergoing treatment and recuperating. Secondly, it means 
that certain costs, or cost savings, or both, should not be included in the evaluation 
because they are transfers from one sector to another rather than a net cost on society 
(Robinson, 1993 a and e).
However economics is not about cutting cost, it is about securing the maximum 
benefits and efficiency given the level of resources available. This directly relates to 
the aim of this study in terms of assessing HCV costs, highlighting how to handle the 
produced results to maximize the benefit of expenditures and informing decision 
makers as to the impact of their policies on the performance of the financial process 
of the Ministry o f Health and Population and consequently on the general societal and 
ultimately on the national health benefit. The nature of information resulting from this 
study would depend on the standard of the health outcome evidence it uses (Moore et
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al, 2006) and would be essential as long as it is evidenced that correct methodologies 
and sound techniques have been followed and as long as the integrity of the team 
members and their adherence to the research and scientific ethics is not in question. 
This economic study would act as a framework that would enable decision makers (on 
behalf of society) to accredit values to the profile of costs and consequences of HCV, 
which could differ from other profiles elsewhere according to Egyptian local context, 
whereby the evidenced results would be a good guide to emphasize weak points or 
strengths in the implications of followed health policies.
2.7. Cost Categories
Categories o f costs often termed expenditures do not explicitly depend on a specific 
type of pharmacoeconomic evaluation. Instead, costs provide a commonality across 
the study types and despite their different outcomes component; they all include some 
quantification of costs (Robinson, 1993 a).
Drummond et al, (1997) and Bonk, (1999) divided costs into four basic categories, 
stratified by two parameters: directly or indirectly (intangible) related to the disease, 
to the treatment, or to the program, and medical or non-medical in nature (Table 4).
Table 4: Examples of categorized costs
Relationship to disease, 
treatment, or program
Relevant issues
Medical Non-medical
Direct
Hospital fees, drugs, 
equipment, supplies, and 
professional fees.
Transportation, lodging for 
family, and additional 
homecare.
Indirect
Earnings lost during illness 
or treatment, and from 
disability.
Intangible effects such as 
quality o f life and 
psychological tolls.
Source: Adapted from Bonk [1999)
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2.7.1. Direct costs and benefits
These terms have been used in the past to denote the resources consumed (costs) or 
saved (benefits) by the program. In general these would be resources in the healthcare 
sector, but sometimes would include patients’ out of pocket expenses, resources from 
other statutory agencies and voluntary bodies. However, use of the term is not 
consistent across studies, which sometimes causes confusion.
2.7.2. Indirect costs and benefits
These terms have been used in the past to denote patients' time consumed or freed by 
the program. In general focus has been on work time and indirect costs and benefits 
have been synonymous with productivity gains and losses. The term has often caused 
confusion as it is used by accountants to denote overhead costs. Strictly speaking, 
economic evaluation should seek to value all inputs in terms of their opportunity 
costs, that is, their value in their next best use. Indirect costs, for which there are no 
market prices, pose a more difficult problem of valuation. Shadow pricing and time 
costs provide a good example of methods used to impute indirect cost values. When 
time is spent in hospital by a patient, or on caring at home by a relative and this 
displaces work time, it is usual practice to use the relevant wage to value the lost time 
(Robinson, 1993 a).
2.7.3. Average costs
The major significance of the average-cost distinction to the evaluation is as follows 
First, when making a comparison of two or more programs it is worth asking 
independently of each, what would be the costs (and consequences) of having a little 
more or a little less? Second, when examining the effects (on cost) of small changes in 
output, it is likely that these will differ from average costs (Drummond et al, 1997).
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For example, the extra cost of keeping patients in hospital for another day at the end 
of their treatment might be less than the average daily cost for the whole stay.
2.7.4. Marginal or incremental costs
The terms marginal and incremental are often used interchangeably in the literature. 
They both refer to a change in the scale of an activity. Strictly speaking, the marginal 
cost relates to the cost of producing one extra unit of output (Drummond et al, 1997). 
However, it is often used to refer to the cost of producing the next logical batch of 
output. The term incremental is sometimes also used to refer to such a change, but 
more often used to refer to the difference, in cost or effect, between the two or more 
programs being compared in the evaluation.
Various definitions of cost
Total cost (TC): Cost of producing a particular quantity of cost.
Fixed cost (FC): Costs which do not vaiy with the quality of output in the short
run. That is, costs which vary with time, rather than quality. 
Variable cost (VC): Costs which vary with the level of output.
Average cost (AC): TC/Q, the average cost per unit of output.
Marginal Cost (MC): (TC of X + 1 units) -  (TC of X units)
The extra cost of producing one extra unit of output.
2.7.5. Overhead and shared costs
The term overhead cost is an accounting term for resources that serve many different 
departments and programs. If individual programs are to be costed, these shared costs 
may need to be attributed to programs. The main point at the outset is that there is no 
unambiguously right way to apportion such costs. The approach favoured by 
economists is to employ marginal costs (Drummond et al, 1997).
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2.7.6. Capital costs
Investments in buildings, plant, and equipments that yield a flow of services over a 
number of years give rise to capital costs. Generally, investment expenditure will be 
undertaken at the beginning of a project but the use of items of capital equipment will 
generate annual capital costs over the lifetime of the asset (Robinson, 1993 a).
These costs have two components, namely, interest and depreciation. Interest costs 
should be included even if the asset was not acquired with borrowed money because 
tying up money in an item of capital equipment involves an opportunity cost, that is, 
interest forgone. Depreciation costs arise because of the wear and tear that an asset 
receives through use and consequent reduction in the length of its useful life. 
Sometimes an item of capital expenditure is unique to a particular use and has little or 
no alternative use value (opportunity cost). In such cases, it is referred to as a “sunk 
cost”.
2.7.7. Measures of Cost in This Study
The international cost parameters were identified and defined in the above section. 
The actual on the ground availability of data and its sorting made the abiding to the 
international known nomenclature difficult. This led to the following division of costs 
(Figure 3). The direct costs were broken down to direct medication cost (actual drugs 
prescribed to each patient and hand copied from their prescriptions) and direct non 
medication costs which included tests, diagnostics and procedures performed to the 
patients under study as well as the consultation fees paid (in case of private patients). 
It is noteworthy to mention that there were no kept records anywhere to prescriptions 
data or procedures performed so physical presence in the outpatient clinics in NLI 
was necessary to obtain this data; some data was available in accounting sheets for the 
inpatients which made the job of cost calculation a little easier for that sector.
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Constant costs were also included instead o f  indirect costs to cover all overhead costs 
that are not directly paid for by the patient nor by the payer o f  the service, such as the 
subsidy paid by the government to each patient. There were no indirect costs 
identifications in the research because in the case o f  public sector there were no such 
data available and in the case o f  the private sector such detailed information was too 
financially classified to impart with.
Figure 3: Cost categorization (special adaptation for the study)
Identification of Cost
for both outpatients and m TW r Blood cost
Direct Cost
Non Medication 
Consultation and
Medication
inpatients
Only for inpatients
All costs other than the medication, 
consultation, diagnostic examination 
and imaging costs
Indirect Cost valuation could not be identified; neither in Public hospitals, settings 
that lacked actual data, nor private institutions (particularly for profit), settings that 
did not want to impart with classified financial data
2.7.8. Discounting
The current operating costs associated with most projects can be expected to extend 
over a number o f  years into the future, but their time profiles may differ. Where a 
condition impacts health and treatment utilization for over one year it is considered 
good practice to employ discounting to assess appropriately the changes in costs and 
benefits over time (OECD, 2003). Discounting offers a means o f  standardizing 
different cost time profiles so that total costs can be compared (Robinson, 1993 a and
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Drummond et al, 1997). Discounting is based on the assumption that costs incurred in 
the immediate future are of greater importance than costs incurred in the distant 
future. This is because earlier access to finance would permit investment at a positive 
rate of interest, thereby yielding a larger sum in the future (opportunity cost) or 
simply because people and society attach more importance to current opportunities 
than to future ones “positive time preference”. For these reasons, economic evaluation 
“weights” costs by a discount rate, according to the year in which they accrue, before 
adding them up and expressing total costs in present value terms. Discounting is 
particularly relevant to analyses of the cost of HCV because anti-HCV infection 
treatment costs occur now, and the costs of potential end-stage liver disease occur in 
the future. This was considered due to the long life cycle of the disease and the high 
immediate cost of the treatment.
Almost all HTA bodies employ discounting in assessments, typically applying an 
annual rate between 2.5% and 10% to both costs and benefits (Zentner et al, 2005 and 
OECD, 2003).
2.7.9. Inflation
Most programs that extend over several years will be affected by inflation. It is 
important, however to distinguish between changes in the general price level and 
changes in relative prices. For the general level, there will be no change in the relative 
cost of inputs and all future inputs can be valued at current prices and discounted by a 
real (excluding inflationary effect) rate of interest (Robinson, 1993a). If, however, 
some input prices are expected to increase more than others there will be relative 
changes in their opportunity costs and these need to be taken into account (Robinson, 
1993a).
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2.8. Development of drugs and role of technology appraisal
Evaluation designs that have been described value consequences either by assuming 
them as equivalent such is the case of cost-minimization analysis (CMA) or in utilities 
as is the case for cost-utility analysis (CUA) or in natural units for the cost- 
effectiveness analysis (CEA), while cost benefit analysis (CBA) values them in 
monetary units. Several approaches to valuation have been used. These falls into two 
broad categories: individual or societal preference and human capital. The human 
capital approach to valuation is based on the fact that human beings are similar to 
capital equipment as they represent a productive resource to society and this worth is 
calculated on the basis of their present and future earnings. Illness diminishes that 
person’s productive capacity, which is usually valued in this approach by the loss of 
earnings. Life, for instance, has been valued on the basis of its expectancy multiplied 
by the annual average income of that person or that social class. Loss of life has been 
valued as the loss of projected earnings from the date of death to the projected date of 
retirement.
2.9. Cost-minimization Analysis
It is an appropriate form of evaluation to use when there is reason to believe that the 
outcomes of the procedures under consideration are the same or similar, whether 
through established literature or from parallel clinical trials (Robinson, 1993 a; 
Drummond et al, 1997 and ElShakhs, 2001). Only then should treatment costs be 
compared, thereby identifying the treatment associated with the lower cost; albeit with 
the same likelihood of producing the intended therapeutic outcome. In this case, 
minimization of costs refers not to techniques for driving down expenditures 
explicitly, but rather to a comparison of costs for alternative interventions with 
equivalent outcomes (Bonk, 1999 and ElShakhs, 2001). Incorrect supposition of
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outcome equivalency, however, could indeed, undermine the validity of an otherwise 
sound pharmacoeconomic study. It is noteworthy to mention that Walley and Haycox, 
(1997) indicated that it is the most restrictive form of analysis that focuses entirely 
upon costs, usually only to the health service (Walley and Haycox, 1997); and 
McCombs, (1998) supported this by saying “it is the most limited type o f health 
economic analysis" (McCombs, 1998).
2.10. Cost-benefit analysis
At times it is necessary to take decisions on the allocation of resources of large and far 
reaching interventions which have costs and consequences for more than one section 
of society. We may also have to make decisions about whether an intervention is 
worth making at all. Healthcare interventions may be competing for resources with 
other programs, not necessarily directly linked to health. The type of economic 
evaluation which can assist planners and decision-makers on such issues is cost- 
benefit analysis (CBA), which is the first analytical study design to have been 
introduced in health economics (its origins date back to the 1930s) (Williams, 1974). 
CBA compares the discounted future streams of incremental program benefits with 
incremental programs costs; the difference between these two streams being the net 
social benefit of the program (Drummond et al, 1997). In simple terms, the goal of 
this analysis is to identify whether a program’s benefit exceeds its costs. A positive 
net social benefit indicating that a program is worthwhile and its outcomes exceed 
requisite financial investment for its implementation. CBA aims to compare all social 
costs and consequences across different interventions or against a “do nothing” 
option. At the basis of CBA is the concept that social welfare exists and can be 
maximized by moving additional productive resources to aspects o f production where 
there is greater social benefit at the margin. The key to CBA is the systematic
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calculations of all costs and consequences accruing to society from different options 
and the expression of their values in monetary terms. Translating health consequences 
in monetary values is far from easy, and such difficulties have contributed to the 
relative fall from grace of CBA design. Usually, healthcare programs evaluated by 
CBA extend several years into an uncertain future and have immediate sizeable effect 
on resources but long-term effects on health. These types of programs may still have 
to be compared and their values translated into a single current measure which 
represents their present value. Such a value is usually calculated by discounting their 
future costs and consequences in time. Discounting takes account of observed 
economic behaviour which shows a positive preference for benefits now and costs 
later. Discounted benefits and costs are valued less the further onto the future they 
accrue (Williams, 1974).
2.11. Cost-effectiveness analysis
The term refers to a particular type of evaluation in which the health benefits can be 
defined and measured in natural units (e.g. years of life saved, life years gained, ulcers 
healed, pain or symptom free day, blood pressure mm Hg decreased ...) and the costs 
are measured in monetary terms (Walley and Haycox, 1997). CEA therefore 
compares therapies which can be measured on a common scale of outcomes but 
perhaps exhibit different success rates (Williams, 1974; Robinson, 1993 b and Walley 
and Haycox, 1997). Unlike CBA, it avoids the complication of reducing all outcomes 
to a monetaiy basis (ElShakhs, 2001). The typical logical setting for CEA is one in 
which a decision to intervene in a particular problem has already been taken and CEA 
is carried out in order to identify the most efficient way of achieving the desired 
objective, and it is for this reason that economists say that CEA is used to assess 
“technical efficiency”(Williams, 1974).
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CEA, bom in 1960’s (Williams, 1974 and Gold et al, 1996) has quickly supplanted 
cost-benefit analysis popularity up to the point where the term “cost-effectiveness 
analysis” is often used as synonymous with economic evaluation (Williams, 1974; 
and Walley and Haycox, 1997), and at times, North American economists use the 
term CEA to include both CMA and CUA. Furthermore, Walley and Haycox, (1997) 
mentioned that CEA is the most commonly applied form of economic analysis but it 
does not allow comparisons to be made between two totally different areas of 
medicine with different outcomes (Walley and Haycox, 1997). It is also noteworthy to 
report that Mooney, Russel and Weir, (1986) wrote in their book that cost 
effectiveness analysis is essentially concerned with the “how” of policy. It can assist 
in decisions on the techniques of care delivery (Mooney et al, 1986).
McCombs, (1998) noted the limitation of this approach by emphasizing the fact that 
all years of life as a unit of outcome are valued equally without adjustment; for the 
quality of life enjoyed by the patient. Clearly, society values a year of life at full 
function higher than a year of life in a comatose state. To account for this, economists 
and other practitioners of patient outcome research are attempting to measure the 
utility of the effects achieved in an analysis referred to as cost-utility analysis.
2.12. Measures of effectiveness
Decision about resource allocation must be made, and indeed are made, every day by 
all healthcare workers. As economics is but one of the many dimensions that decision­
makers have to take into consideration, often economics play “second” to or “third 
fiddle” to other dimensions such as effectiveness, safety of interventions and politics. 
In order to carry out a cost-effectiveness analysis it is necessary to have suitable 
measures of effectiveness. These will depend on the objectives of the particular 
interventions under review. In all cost effectiveness analyses, however, measures of
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effectiveness should be defined in appropriate natural units and, ideally, in a single 
dimension which would permit direct comparison between alternative procedures in 
terms of their marginal cost per unit of outcome. Sometimes, however, the 
alternatives under examination have multiple outcomes (Table 5). Nonetheless, many 
of these choices can be dealt with within the cost-effectiveness analysis framework 
(Robinson, 1993 b). Furthermore, economic evaluation should be undertaken 
alongside clinical trials so that the appropriate data collection can be built in as an 
integral part of the study. Unfortunately this is rarely the case, and hepatitis C virus is 
but one example and so existing medical publications usually provides the main 
source of data on effectiveness and outcomes (Robinson, 1993 a).
Table 5: Examples of measures of effectiveness used in literature
•  Cases treated appropriately
• Lives saved
Examples of
• Life years gained
measures of
• Pain or symptoms free days
effectiveness
• Cases successfully diagnosed
• Complications avoided
2.13. Obtaining effectiveness data
Ideally, economic evaluation should be built alongside clinical trials so that relevant 
data on costs and effectiveness can be collected at the same time. However, setting up 
and conducting appropriate trials is often time consuming and expensive (Robinson, 
1993b). Another route for obtaining effectiveness data for CEA is from the existing, 
medical literature.
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Unfortunately though, there is often a lack of good epidemiological evidence relating 
health inputs to outputs, particularly in the case of new technologies, which are the 
focus of economic evaluation (Culyer, 1982 and Robinson, 1993b). Even when data 
are available it is important to ensure that they are relevant to the context in which an 
evaluation is being carried out. If neither specifically designed clinical trials nor the 
existing published work provide the necessary data in full, an economic evaluation 
may have to rely on assumptions about clinical evidence (Robinson, 1993b and 
Drummond et al, 1997). Although this may seem like a dangerous practice, there is 
often a range of situations in which cost considerations dominate, and so variations in 
effectiveness are unlikely to alter the preferred option. In such cases, however, the 
results must be subjected to a range of different assumptions about effectiveness. This 
is done by sensitivity analysis. McCombs, (1998) adds a few other data sources 
among which are retrospective data, which are a good source of healthcare costs and 
effectiveness reflecting real world practice. In particular, real world transition 
probabilities (effectiveness) may vary significantly from the efficacy measured in 
RCT. “Prospective studies that mimic real world practice and measures definitive 
patient outcomes in addition to clinical outcomes are becoming the gold standard in 
cost effectiveness analysis”, he wrote. McCombs, (1998) also mentions expert 
opinion to fill in missing data (McCombs, 1998).
The validity of data for this study is sound even though this is not a randomized 
clinical trial (RCT) nor the data has been previously published. Moreover, the 
evidence of the effectiveness of treatment is also seen in the difference between the 
health state and quality of life (QOL) experienced by the patient receiving it; this is 
endorsed by clinicians and expert opinion as well as the medical norms and literature
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and international consensus. These endorsements have quality, relevance and 
reliability (Palfrey et al, 2004).
2.14. Sensitivity Analysis
The final piece of any good clinical economic analysis is the sensitivity analysis 
(Mulahy and Manning, 1995 and McCombs, 1998). Much of the data necessary to 
completely specify the medical decision analytic model are not available, thus 
requiring that gaps in knowledge be fitted in by assumptions and expert opinion 
(Briggs, 2001). A good clinical evaluation will clearly identify those assumptions that 
are critical to the results and test the sensitivity of the results to changes in these 
assumptions (McCombs, 1998).
2.15. Cost-utility Analysis
Cost-utility is a form of economic evaluation in which the outcomes of alternative 
procedures or programs are expressed in terms of a single, “Utility based” unit of 
measurement. Utility is a term used by health economists to refer to the subjective 
level of well being, or improvement in health status, as measured by the preferences 
of individuals or society (Robinson, 1993c). It actually derives from the work of the 
early nineteenth century economist and philosopher Jeremy Bentham, who developed 
the “utilitarian” school o f thought (Robinson, 1993 a). The most widely used utility 
based measure in cost-utility analysis is the quality-adjusted life-year (QALY) but 
that does not exempt other utility based measures and variants such as healthy years 
equivalent (YHE) (Robinson, 1993 c and Drummond et al, 1997). To calculate the 
number of QALYs resulting from a particular intervention, the number of additional 
years of life obtained is combined with a measure of the quality of life in each of 
these years to obtain a composite index of outcome. Comparison between alternative
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procedures or programs can then be based on the marginal cost per QALY gained 
(Robinson, 1993 c).
In cost-efFectiveness analysis, typically the main outcome (measured in program 
specific unit) is designated as the primary effectiveness measure and used as the 
denominator in the cost/effectiveness ratio. There are three problems; first, because 
the measure of primary effectiveness may differ from program to program, cost- 
efifectiveness analysis cannot be used to make comparisons across a broad set of 
interventions. Second, in any one program there is often more than one outcome of 
interest. In fact, normally there are a large number of relevant outcomes; for example, 
outcomes of any specific intervention often include life extension, long term quality 
of life changes, side effects both major and minor from the interventions, as well as 
the short term quality of life effects of the intervention itself. Third, some outcomes 
are more important, or more valued, than others. Cost-utility analysis was developed 
to address these problems. It enables a broad range of relevant outcomes to be 
included by providing a method through which the various disparate outcomes can be 
combined into a single composite summary outcome. This, in turn, allows broad 
comparisons across widely differing programs. And, finally, cost-utility analysis 
provides a method to attach values to the outcomes so the more important outcomes 
are weighted more heavily (Drummond et al, 1997). By converting the effectiveness 
data to a common unit of measure, like QALYs gained, CUA is able to incorporate 
simultaneously both the changes in the quality of life (morbidity) and the changes in 
the quality of survival (mortality), considering that this type of consequence is not 
rare in health interventions (Drummond et al, 1997). In the QALY approach, the 
quality adjustment is based on an act of values or weights called utilities, one for each 
possible health state, that reflect the relative desirability of the health state.
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Drummond and colleagues, reported, that technically, CUA can be seen as simply a 
specific type of CEA (Drummond et al, 1997). Jefferson and colleagues, (2000) wrote 
that CUA is a specialized variant of CEA in which consequences are expressed in 
utilities instead of in natural units as in CEA (Jefferson et al, 2000). However, unlike 
authors in the United States, Gold et al, (1996) as well as Weinstein and Stason, 
(1997), continued to use the separate label, giving several reasons for their choice. 
First, they mentioned that the separate label clearly distinguishes between those 
studies that use a generic measure of outcome and thus are potentially comparable 
across studies (CUA), and those that use a measure of outcome specific to the 
program under study (CEA). They added that it highlights the crucial role of 
consumer preferences (utilities) in valuing the outcomes. They concluded their 
reasoning by emphasizing the need to incorporate the consumer preferences, which 
makes CUA special (Gold et al, 1996 and Weinstein and Stason, 1997).
2.16. The role of randomized controlled trials and modelling 
In the evaluation of pharmaceutical interventions the most usual way to undertake 
economic assessments has been randomized controlled trials (RCTs). However, the 
limited scope for generalization to every-day patient management of RCTs) results 
and the fact that they may not represent the real world of clinical practice. In addition, 
the follow-up period within a RCT is often relatively short in relation to the natural 
progression of the disease (Phillips, 2005).
The limitations of randomized controlled trials lead to the notion of lifetime or long­
term modelling being “an important and necessary component of cost effectiveness 
analysis” (Kuntz and Weinstein, 2001) and health economics (Rittenhouse, 1996; 
Sheldon, 1996; Buxton etal, 1997; Kuntz and Weinstein, 2001; Weinstein et al, 2001 
and Siebert et al, 2003).
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A model is a simplified picture of reality providing useful frameworks for 
understanding the important parameters involved in achieving a certain outcome. 
There are several reasons for building models; they start with the fact that models help 
in describing problems, leading to models helping in analyzing problems. A Markov 
charts patient progression and then through the model layout seeing how treatment 
will impact patient progression. Furthermore Markov is a way to assess effectiveness 
as once the treatment comes in it induces a different profile because the probability of 
a patient moving from one stage to the next will change.
Models, defined by Bender, (2000) as simply “something that mimics relevant 
features of a system being studied” can assist with decision making in a descriptive, 
heuristic, or prescriptive (identifying optimal choice) sense (Bender, 2000). Models 
can also help to integrate data from different sources, as well as assist with disease 
risk assessment and the formulation of hypotheses, and can additionally act as a 
bridge between pharmacoepidemiological data and the processes of decision-making. 
A specialized set of models called decision analytic models go a step further than this 
by assisting with the identification of optimal choices in decision modelling scenarios 
(Patten and Lee, 2002).
Some chronic diseases are not reversible, and some are recurrent. In these 
circumstances prevalence will be determined by incidence and duration. Models that 
incorporate these concepts may be termed “incidence-prevalence models. Changes in 
probability of disease and nature of health status over time are evaluated using 
Markov models and stochastic (probabilistic) models.
Models and their use in disease risk assessment and medical decision making are 
discussed in many papers (Beck and Pauker, 1983; Moolgavkar et al, 1988; Dewanji 
et al, 1989; Sonnenberg and Beck, 1993 and Dewanji etal, 1999).
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2.17. Case Study Approach
Use of the case study originated only in the early 20th century as a distinct approach 
to research and their popularity as research tools has developed only in recent 
decades. The Oxford English Dictionary traces the phrase case study or case-study 
back as far as 1934, after the establishment of the concept of a case history in 
medicine. Case study methods involve an in-depth, longitudinal examination of a 
single instance or event: a case (HCV health burden in Egypt). They also provide a 
systematic way of looking at events, collecting data (cost of various treatment 
pathways) and, analyzing information (processed, calculated data and evidence), and 
reporting the results. As a result a sharpened understanding is gained of what and/or 
why might become important to look at more extensively in future research (Stake, 
1995). As Flyvbjerg, (2006) put it; case studies lend themselves to both generating 
and testing hypotheses (Flyvbjerg, 2006), and in this study, the implementation of 
HTA within the Egyptian healthcare system. Case studies can generate a great deal of 
data that may defy straightforward analysis a fact that comes in handy with HCV as 
an expensive disease and heavy burden on the Egyptian government. Yin and Lamnek 
both noted that case studies can be based on any mix of quantitative and qualitative 
evidence (Yin, 2002 and Lamnek, 2005).
2.18. Debating health economics and issues in evaluating healthcare 
interventions from the economic perspective
The decision-making process to determine which services and treatments should be 
provided is highly complex and involves a number of different, often conflicting, 
factors. Health economic techniques help to contribute to the process o f healthcare 
priorities determination and to ensure the most efficient use of available resources 
within the limited healthcare budgets. Most importantly those techniques assist
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decision makers to assess information relating to the effectiveness and efficiency of 
an intervention. However, limitations to application of economic evaluations include 
both the cost and the time required render them unfeasible in the context of many 
decisions (Mitton and Donaldson, 2004). It has also been argued that the assumptions 
underlying the current methods fail to consider all society's health objectives and are 
too complex for policy makers to use. In addition, it is argued that “Even aside from 
doubts over the existence of this mythical decision maker with a clear set of 
objectives, the desire to maximize health seems to be largely the objective of 
economists rather than society” and “by generating a pseudoscientific aura around 
economic evaluation, they camouflage critical weaknesses in current techniques” 
(Coast, 2004).
Ideally, resource allocation decisions should not be solely based on the capitalization 
of healthcare benefits, rather, on many other factors such as equity, need, access, and 
others. If not resources would never be allocated to services provided for extremely 
rare conditions, with poor survival and quality of life outcomes. In addition, attempts 
to restrict the benefits derived from healthcare services into a single outcome measure 
also fail to do justice to the wide ranging impact that healthcare improvements can 
have on the other determinants of health model (Evans and Stoddart, 1990), among 
which are patients, their families, their communities and ultimately society as a 
whole. Furthermore, the emphasis on cost-effectiveness may lead paradoxically to 
over-spending (Mitton and Donaldson, 2004). The limitations of health economic 
evaluations highlighted above, together with the time and resources involved in their 
production, mean that while they can provide useful information relating to specific 
interventions or programs, they are of less use in the context of decision making, 
especially in relation to making choices as to where additional resources should be
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placed, or which areas should bear the brunt of any cutbacks, within healthcare 
organizations.
The human capital approach has been applied in the valuation of health benefits in 
cases of both avoidable morbidity and mortality. There have, however, been various 
criticisms, as many people have strong ethical objections to monetary values being 
placed on human life. Other criticisms have centred on the use of rates of pay as a 
measure of value. At the same time, valuing benefits in terms of rates of pay, neglects 
the health benefits that accrue to people who are not employed. It also ignores the 
non-flnancial costs of pain, suffering and grief often associated with illness (Alan, 
1974). This human capital method of valuing health status has been used for many 
years (Mushkin, 1978 and Drummond etal, 1997).
There are technical issues surrounding economic approaches to priority setting but 
they should not be allowed to detract from the fact that they provide a rational 
framework within which other concerns, such as considerations of equity and public 
and professional opinions can be embraced and priorities established. Irrespective of 
how crude or limited the techniques and tools of health economics are, as Maynard, 
(1994) put it attempts to set priorities within the context of a transparent and relatively 
rational framework “should be welcomed as a challenge to the covert, imprecise and 
inconsistent practice of prioritization which exist in all healthcare systems today” 
(Maynard, 1994).
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3.1. Introduction: History and epidemiology
Hepatitis C virus is an enormous present and future health burden to the world (Wong 
et al, 2000). Choo et al, in 1989, identified hepatitis C virus and found it to be the 
cause of disease for the majority of patients with non A non B hepatitis (Choo et al, 
1989). It is estimated that 170 million people worldwide approximately 3% of the 
world’s population is infected with hepatitis C virus (Alter, 1997; WHO, 1997 and 
Thomas et al, 2000) and this population approximately approach 2.7 million 
infections in the USA (Alter et al, 1999), an estimated 5 million are in Western 
Europe, and 7.8 million infections in Egypt, nearly 12.8 % of the population, this is 
the highest prevalence of HCV in the world. Hepatitis C virus represents the most 
frequent etiology of cirrhosis in the developed world (Alter et al, 1999; WHO, 1999; 
Thomas et al, 2000 and Alberti et al, 2002) and is the leading cause of liver 
transplantation in Europe and the USA (Alter et al, 1999). Fortunately the incidence 
of Hepatitis C virus infection appears to be declining since its peak in 1989. 
Currently, approximately 30,000 acute new infections are estimated to occur each 
year, about 25% - 30% of which are diagnosed (Wong et al, 2000). Allowing for 
failing prevalence, a huge backlog of infected patients will still be progressing 
towards cirrhosis and hepatocellular carcinoma. Even if it were possible at the present 
time to treat all those infected and to slow down the progression towards chronic 
severe liver disease, the cost of such large scale investigations and therapy would be 
enormous. One of the most prominent characteristics of HCV infection is its high rate 
of evolution to chronicity. The virus is cleared only in less than 15% of exposed 
individuals; in the remaining, the infection produces chronic hepatitis, which can lead, 
later on, to cirrhosis and eventually, hepatocellular carcinoma (Di Bisceglie, 1998 and
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Thomas et al, 2000). In contrast to hepatitis A and B, there is no effective vaccine to 
prevent acquisition of Hepatitis C virus infection.
3.2. The Natural history of hepatitis c virus
3.2.1. The Virus
HCV is a small enveloped RNA virus belonging to the family flaviridae (Dusheiko et 
al, 2000). The replication of HCV takes place in the cytoplasm (Di Bisceglie, 1998). 
Individual isolates consist of closely related yet heterogeneous populations of viral 
genomes (quasispecies) (Domingo et al, 1996). Comparing the genomic nucleotide 
sequences from different HCV isolates enables classification of viruses into several 
genotypes and many more subtypes. The mutations rate of the polymerase RNA- 
dependent of HCV is of 1/104 to 1/105 nucleotides; that means one mutation per each 
genome is transcribed (Rodriguez-Rosada et al, 2001). This diversity has allowed the 
distinction of genotypes and subtypes. For HCV six main genotypes and at least 30 
subtypes have been described by Brechot, (1994) and Simmonds, (1995) within three 
subtypes, the viruses’ pond in one infected subject also show significant differences 
among their sequences. The great genetic variability allows HCV to quickly develop 
mechanisms to improve its adaptation to the environment, and in this way evade any 
immune surveillance or pharmacologic pressure, leading to a high rate of chronic 
infection. This is the reason why the most heterogenous regions of both viruses are 
those codifying the envelope, which is the most immunogenic part (Brechot, 1994; 
Simmonds, 1995 and Rodriguez-Rosada et al, 2001). The extensive genetic 
heterogeneity of HCV has important diagnostic and clinical implications, perhaps 
explaining variations in clinical course, difficulties in vaccine development, and lack 
of response to therapy.
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3.2.2. Transmission
Hepatitis C virus is transmitted primarily by the parenteral route, and sources of 
infection include injection drug use, needle-stick accidents, and transfusion of blood 
or blood products. Since 1990, following the introduction of sensitive and effective 
blood tests for the detection of HCV, the risk of new cases of post transfusion HCV 
have virtually disappeared (NIH, 1997). The majority of HCV infections in 
developed and developing countries are, or have been, caused by intravenous drug 
use, transfusion of unscreened blood and blood products, nosocomial transmission 
from inadequately sterilized instruments or unsafe injections, chronic haemodialysis, 
and possibly high risk sexual practices (Dusheiko et al, 2000). Vertical transmission 
rates drive the trends among children and adolescent, with active carriers bom to 
mothers with HCV infection with 1 % to 5% likelihood (Younossi et al, 1999). 
Prospective studies could help determine the relative contribution of vertical and 
horizontal transmission of HCV infections observed in these children (Zanetti et al, 
1999).
3.2.3. Vaccination
HCV is a worthy adversary, changing continually to avoid immune surveillance by 
the host. A traditional vaccine is unlikely to become available in the foreseeable 
future. HCV infrequently induces an effective protective immune response. 
Neutralizing antibodies, CD4 and CD8 T cells are poorly elicited by natural infection. 
The difficulties of preparing a protective vaccine are:
(a) Only man and the chimpanzee are infected, and better animal models are needed;
(b) HCV replicates poorly in vitro;
(c) The viral envelope proteins (E1/E2) are highly mutable; antibodies against them 
fail to provide long term protective immunity.
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3.3. A “Typical” patient with chronic HCV infection
The typical patient for whom therapy is well established is an adult who has a chronic 
HCV infection (evidence o f infection for at least 6 months) and increased serum 
levels of transaminases, detectable serum HCV RNA, and histologic evidence for 
liver injury in the absence of cirrhosis. Also, other liver diseases and compounding 
co-morbid conditions have been excluded (Zein and Zein, 2002).
3.4. Course of infection and disease progression
The health states were based on liver histology, presence or absence of hepatitis C 
viraemia, decompensated liver disease, hepatocellular carcinoma, or liver 
transplantation. The three histologic states considered were mild hepatitis, moderate 
hepatitis and a cirrhotic stage (Alter and Mast, 1994).
From each histologic state, individuals could progress over time to a more advanced 
clinical or histologic state or remain in the same state of health. For example, each 
year, individuals with mild chronic hepatitis could develop moderate chronic hepatitis 
or remain stable with mild chronic hepatitis.
Likewise, individuals with moderate chronic hepatitis could progress to either 
hepatocellular carcinoma or one of three modes of hepatic decompensation: (1) 
ascitis, (2) variceal hemorrhage, or (3) hepatic encephalopathy. Once individuals 
developed decompensated cirrhosis, they could die from liver disease, receive a liver 
transplant, or remain alive with liver failure. The likelihood of these health status 
transitions was based on probabilities derived from a review of the literature in which 
actuarial techniques were used; expert opinion was used when such data was 
unavailable. The natural history of this disease appears to differ according to 
geography, alcohol use, virus characteristics (e.g., genotype, viral load), co infection
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with other viruses, and other unexplained factors (Hoofnagle, 1997 and Centres for 
disease contol and prevention, 1998).
3.4.1. Acute infection
After initial exposure, HCV RNA can be detected in blood in one to three weeks. 
Within an average of 50 days (ranges betwen 15 - 150 days), virtually all patients 
develop liver cell injury, as shown by elevation of serum alanine aminotransferase 
(ALT). The majority of patients are asymptomatic and anicteric. Only 25% - 35% 
develops malaise, weakness, or anorexia, and some become icteric. Fulminant liver 
failure following HCV infection has been reported but is a rare occurrence.
Antibodies to HCV (anti-HCV) almost invariably become detectable during the 
course of illness. Anti-HCV can be detected in 50% - 70% of patients at the onset of 
symptoms and in approximately 90% of patients 3 months after onset o f infection. 
HCV infection is self-limited in only 15% of cases. Recovery is characterized by 
disappearance of HCV RNA from blood and return of liver enzymes to normal 
(Hoofnagle, 1997; NIH, 1997 and EASL, 1999).
3.4.2. Chronic infection
About 85 % of HCV-infected individuals fail to clear the virus by 6 months and 
develop chronic hepatitis with persistent, although sometimes intermittent, viremia. 
This capacity to produce chronic hepatitis is one of the most striking features of HCV 
infection. The majority of patients with chronic infection have abnormalities in ALT 
levels that can fluctuate widely. About one-third of patients have persistently normal 
serum ALT levels. Antibodies to HCV or circulating viral RNA can be demonstrated 
in virtually all patients. Chronic hepatitis C virus is typically an insidious process, 
progressing, if at all, at a slow rate without symptoms or physical signs in the majority 
of patients during the first two decades after infection. A small proportion of patients
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with chronic hepatitis C virus, perhaps less than 20% develops nonspecific symptoms, 
including mild intermittent fatigue and malaise. Symptoms first appear in many 
patients with chronic hepatitis C virus at the time of development of advanced liver 
disease (NIH, 1997 and EASL, 1999).
In chronic hepatitis, inflammatory cells infiltrate the portal tracts and may also collect 
in small clusters in the parenchyma. The latter instance is usually accompanied by 
focal liver cell necrosis. The margin of the parenchyma and portal tracts may become 
inflamed, with liver cell necrosis at this site (interface hepatitis). If and when the 
disease progresses, the inflammation and liver cell death may lead to fibrosis. Mild 
fibrosis is confined to the portal tracts and immediately adjacent parenchyma. More 
severe fibrosis leads to bridging between portal tracts and hepatic veins. Such fibrosis 
can progress to cirrhosis, defined as a state of diffuse fibrosis in which fibrous septae 
separate clusters of liver cells into nodules. The extent of fibrosis determines the stage 
of disease and can be reliably assessed. Severe fibrosis and necro inflammatory 
changes predict progression to cirrhosis. Once cirrhosis is established, complications 
can ensue that are secondary to liver failure and / or to portal hypertension, such as 
jaundice, ascitis, variceal hemorrhage, and encephalopathy. The development of any 
of these complications marks the transition from compensated to decompensated 
cirrhosis.
The rate of progression is highly variable, long-term studies suggest that most patients 
with progressive liver disease who develop cirrhosis have detectable ALT elevations; 
these can, however, be intermittent. The relationship is inconsistent between ALT 
levels and disease severity as judged histologically. Although patients with HCV 
infection and normal ALT levels have been referred to as “healthy” HCV carriers,
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liver biopsies can show histological evidence of chronic hepatitis in many of these 
patients.
3.4.3. Cirrhosis
Chronic HCV infection leads to cirrhosis in at least 20 % of patients within two 
decades of the onset of infection. Cirrhosis and end-stage liver disease may 
occasionally develop rapidly, especially among patients with concomitant alcohol use.
3.4.4. Hepatocellular carcinoma
Chronic infection by HCV is associated with an increased risk of liver cancer. The 
prevailing concept is that hepatocellular carcinoma (HCC) occurs against a 
background of inflammation and regeneration associated with chronic hepatitis over 
the course of approximately three or more decades. Most cases of HCV related HCC 
occur in the presence of cirrhosis. The risk that a person with chronic HCV will 
develop HCC appears to be 1% - 5% after twenty years, with striking variations in 
rates in different geographic areas of the world. Once cirrhosis is established, the rate 
of development of HCC increases to 1% - 4% per year. Among patients with cirrhosis 
due to hepatitis C virus, HCC develops more commonly in men than in women and in 
older than in younger patients (NIH, 1997 and EASL, 1999).
3.4.5. Extra hepatic manifestations of HCV
Patients with chronic HCV occasionally present with extra hepatic manifestations or 
syndromes considered to be of immunologic origin, including arthritis, 
keratoconjunctivitis sicca, lichen planus, glomerulonephritis, and essential mixed 
cryoglobulinemia. Cryoglobulins may be detected in the serum of about one third of 
patients with HCV, but the clinical features of essential mixed cryoglobulinemia 
develop in only about 1% - 2% of patients. Chronic HCV may be a major underlying 
cause of porphyria cutanea tarda (NIH, 1997 and EASL, 1999).
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3.4.6. Mortality
After an average follow up of eighteen years, a prospective study of patients who 
received blood transfusions showed no difference in overall mortality between HCV- 
infected cases and non infected controls. Liver-related mortality, although rare, was 
twice as high in the cases (3.2 % versus 1.5 %) (Wong et al, 2000).
A European study showed that survival among HCV patients with compensated 
cirrhosis was 91 % after five years and 79 % after ten years. Among patients 
developing decompensated cirrhosis, however, five years survival was only 50% 
(Thomas et al, 2000).
3.5. Clinical implications of hepatitis C viral kinetics
From serial measurements of changes in viremia, kinetic information on the dynamics 
of HCV replication was obtained. Calculations revealed a minimum virus production 
and clearance per day in patients with chronic HCV of approximately 1010 x 2013; 
1012 virions per day and an in vivo half life of the virus is measured in the order of a 
few hours. The high turnover rate of HCV explains the rapid generation of viral 
diversity and the opportunity for viral escape from the host immune surveillance and 
antiviral therapy (Thomas et al, 2000 and Zeuzem, 2002). The implications derived 
from HCV kinetics comprise the consideration of more aggressive initial design 
regimens, the possibility to optimize therapy individually not only according to 
pretreatment parameters but also according to the initial decline of viral load and the 
perception that eradication of the virus will rely on the half life of infected cells.
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Figure 4: Simplified schematic of M arkov model (Wong e t  a l, 2000)
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Note: O verall, there w ere 190 states o f  health. Each circle represents a state o f  health for a segm ent o f 
the population w ith chronic HCV. Each arrow represents possible changes in health status that m ay 
occur each year. Dotted arrow represent lower probabilities o f  transition, reflecting the viral-negative 
state (the odds-likelihood ratio for progression is reduced by 0.0002 for mild hepatitis, 0.001 for 
m oderate hepatitis. 0.4 for cirrhosis to hepatocellular carcinom a, and 0.32 for cirrhosis to 
decom pensated cirrhosis). The decom pensated cirrhosis state represents separate states o f  health in the 
model for diuretic-sensitive and diuretic refractory ascites, first year and subsequent years after initial 
variceal hem orrhage, and first year and subsequent years after initial hepatic encephalopathy. Sim ilarly, 
the liver transplant state has separate status o f  health for the first year and subsequent years 
postransplant. For individuals who are Hepatitis C virus R NA -positive w ith mild hepatitis, m oderate 
hepatitis or com pensated cirrhosis, additional separate states o f  health exist for those with normal 
transam inases and those with elevated transam inases. For those w ith elevated transam inases, separate 
states o f  health exist for those known to have chronic HCV and those w hose infection is unknown and 
clinically silent unless they develop decom pensated cirrhosis o f  hepatocellular carcinom a. Individuals 
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population, and individuals with decom pensated cirrhosis or hepatocellular carcinom a may die from 
liver-related causes.
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3.6. Treatment and management of hepatitis C Virus
3.6.1. Treatment considerations
Not all HCV-infected individuals develop complications, so treating all patients 
subjects some individuals to unnecessary treatment has potential adverse effects. 
However, except for alcohol ingestion, male sex, older age and elevated 
transaminases, it is not currently possible to reliably identify those individuals likely 
to progress. Moreover, the degree of transminase elevation does not consistently 
indicate the severity of the underlying liver histology (Bacon, 2002). Patients with 
low platelet counts, elevated prothrombin times and low albumin levels already have 
results suggesting advanced liver disease. Noninvasive measures of liver 
inflammation and fibrosis remain under investigation. Consequently, liver biopsy with 
its attendant risks for morbidity, mortality and costs is necessary to accurately assess 
the extent o f the hepatic inflammation and, more importantly, fibrosis (Dienstag, 
2002). The necessity of liver biopsy prior to antiviral treatment is controversial (Bain 
et al, 2004; Almasio et al, 2005 and Herrine and Friedman, 2005) as although liver 
biopsy might avoid treatment for patients with healthy histology and maybe those 
with mild histology, one study suggests that pre-treatment liver biopsy might increase 
the cost of managing patients with chronic HCV infection and would not necessarily 
improve health outcomes unless the patient or physician valued the prognostic 
information afforded by the biopsy (Wong et al, 1998).
Once decompensated cirrhosis occurs, treatment options are limited to liver 
transplantation and by the availability of donor organs. Ideally, antiviral drug 
treatment should be initiated prior to the development of compensated cirrhosis or 
bridging fibrosis because the likelihood of response is lower once histologic 
progression has occurred added to the fact that is going to be proven in the course of
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this research that the overall cost of treatment with the less than perfect effectiveness 
percentages are cheaper in the long run than the cost of no treatment. The results 
shown below would agree that patients with elevated transaminases and moderate 
inflammatory or fibrotic hepatitis should be treated because they may progress to 
bridging fibrosis or cirrhosis (Wong and Koff, 2000 and National Institutes o f Health, 
2002). On the other hand they would disagree with the fact that those with healthy 
liver biopsies would be unlikely to be treated unless their QOL was felt to be severely 
impaired by HCV and viral eradication was expected to improve patient symptoms 
(Foster, 1999 and National Institutes of Health, 2002). The agreement and 
disagreement with the literatures mentioned is a general pro treatment for patients 
without decompensated liver cirrhosis.
The most controversial indication for antiviral drug treatment involves patients with 
mild hepatitis, where some advocate monitoring with periodic liver biopsies for those 
patients unwilling to undergo treatment but for others, biopsy adds costs and a small 
risk for morbidity and mortality. Moreover, the potential for advancing liver disease 
and age while undergoing biopsy management may decrease the likelihood of 
response to subsequent antiviral drug treatment (Foster et al, 1997; Levine, 1998; 
Wong and Koff, 2000 and Freeman et al, 2001). These recommendations are 
somewhat outdated and were made when interferon monotherapy was the standard 
treatment and without looking at costs as was done on this research, which was done 
using combination therapy of both interferon and peginterferon with ribavirin. This 
was reinforced by the fact that despite numerous drugs under development, no further 
therapeutic innovations appear imminent, beyond peginterferon combined with 
ribavirin (Wong, 2006).
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3.7. Should patients with chronic HCV be treated?
Progress in our understanding of HCV infection has depended on the support of the 
pharmaceutical industry, particularly in physician education and in evaluating therapy 
in large clinical trials.
Theoretically, all patients with chronic HCV infection are candidates for antiviral 
therapy. However, only a subgroup of these patients has a clear indication for therapy. 
The restriction for treatment arises due to the naturally slow progression course of the 
infection (Buti et al, 1998 and Buti et al, 2000), the expense of the treatment, the 
occurrence of adverse effects, and the relative ineffectiveness of the treatment. 
Currently, treatment is recommended for patients with persistently elevated 
aminotransferase levels, HCV viremia, and findings of fibrosis and inflammation on 
liver biopsy (Buti et al, 2000).
Patients with detectable levels of HCV RNA and persistently high concentrations of 
aminotransferase or transaminase, and with liver biopsy specimens that show fibrosis 
or at least moderate necrosis and inflammation have a high risk of disease 
progression. The standard recommended therapy consists of the combination of 
interferon a-2b, 3 million units three times weekly, plus ribavirin, 1000 -1200 mg 
daily for 6 - 12 months. For other groups of patients, the indications for treatment are 
less clear and decisions should be made on a case-by-case basis (Zaraski, 1999; 
Dusheiko et al, 2000 and Zein and Zein, 2002).
There are several drugs available for the treatment of this disease, the most ubiquitous 
is interferon. Hypothetically, all patients should be given 24 weeks of treatment. If 
HCV RNA is detected at 24 weeks, therapy should be discontinued. Patients infected 
with HCV genotypes II or III usually can stop therapy if the PCR assay for HCV is 
negative at 24 weeks. An additional 24 weeks of treatment is suggested for patients
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with other genotypes (I, IV, V and VI) and a negative PCR assay. Further 
recommendations can be made about the length of therapy depending on other factors 
associated with a favorable response to therapy such as the pretreatment HCV RNA 
level. However, it should be taken into consideration that combination therapy given 
for 48 weeks entails more severe adverse effects and the risk that therapy will be 
discontinued (Zein and Zein, 2002).
The etiology for 40 % of all chronic liver disease, hepatitis C virus accounts to some 
extend for the increasing incidence of hepatocellular carcinoma (El-Serag and Mason, 
1999 and Wong, 1999), and it is the leading cause for liver transplantation. It can 
result in decompensated cirrhosis and ultimately liver-related death (Wong, 1999). 
Infection with hepatitis C virus does not usually resolve, and 60% - 80% of acute 
infections persist. Chronic hepatitis can cause progressive fibrosis of the liver, leading 
to cirrhosis in 20% - 30% (Dienstag, 1997 and Dusheiko et al, 2000) which rarely 
becomes detectable before the second or third decade of infection (Poynard et al, 
1997 and Dusheiko et al, 2000). It is argued that as a slowly progressive disease, 
requiring twenty to thirty years for some patients to develop cirrhosis; treatment is 
effective in only a proportion of patients entailing potential side effects; and current 
treatments are relatively expensive. Others, however, contend that interferon 
treatment can eliminate viraemia, improve or stabilize histology, decrease the risk for 
hepatocellular carcinoma, and perhaps prolong survival (Wong, 1999 and Colombo, 
2000).
3.8. Interferon
Interferons are a group of low-molecular-weight proteins produced by leukocytes 
(interferon-a), fibroblasts (interferon -(3), and T lymphocytes (interferon-y). 
Interferons have antiviral effects that seem to operate through several mechanisms,
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including inhibition of viral replication, inhibition of viral protein production, and 
prevention of the release of virions from infected cells. In addition, the 
immunoregulatory property of interferons facilitates viral eradication. Interferon-a 
has been the basis of all effective regimens against HCV infection since the discovery 
of the virus.
Four types o f interferon-a are available commercially: recombinant interferon-a-2a 
(Roferan, Hoffman-La-Roche Inc., Nutley, NJ), recombinant interferon-a - 2b (Intron 
A, Schering -  Plough, Kenilworth, NJ), natural interferon a-n3 (alferon N, Purdue 
Fredrich Company, Norwelly, CT), and consensus interferon (In Pergen, Aurgen Inc., 
Thousand Oaks, CA).
3.8.1. Interferon’s side effects and shortcomings
Interferon based therapy is expensive, has to be administered subcutaneously, has 
limited efficacy and is associated with numerous side effects (table 6) (Dusheiko, 
1997 and Dusheiko et al, 2000). Many, but not all, of the side effects are dose 
dependent. A flu like syndrome is the most common side effects of interferon and 
occurs in 60% - 80% of patients but usually disappears after 2 - 4  weeks of therapy. 
These flu like symptoms can be ameliorated with acetaminophen given before 
interferon is injected. Long-term side effects include fatigue, weight loss, alopecia 
(reversible), and psychologic changes. Autoimmune phenomena may develop, 
especially in patients who have underlying autoimmune thyroditis may develop in 
2.5% -  20% of patients and may not be reversible after treatment has stopped. 
Although most of these side effects are dose-dependent and reversible, they lead to 
noncompliance by some patients. The rate of noncompliance has been estimated to be 
between 5 and 10%. Due to potential adverse effects of interferon treatment, careful 
screening and monitoring of the patient’s condition is needed. Monitoring should
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include a complete blood count, serum chemistry panel, and liver function tests 
performed monthly. The level of thyroid-stimulating hormone should be checked 
periodically and, for women of childbearing age, a serum pregnancy test performed 
while the patient is receiving interferon (Zein and Zein, 2002).
Recombinant alpha interferon (IFN) monotherapy was hitherto the only licensed 
treatment for chronic hepatitis C virus. A proportion of patients show a remarkable 
response to treatment with rapid normalization of alanine aminotransferase (ALT) and 
loss of HCV RNA in serum. However, relapse rates limited the efficacy of alpha IFN 
monotherapy. Given, these earlier responses, the primary objective of treatment 
remains sustained virological response where HCV RNA remains negative by 
polymerase chain reaction (PCR) (albeit PCR sensitivity varies) for six months and 
longer after treatment has been discontinued (Dusheiko et al, 2000).
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Table 6: Frequency of side effects in patients with chronic viral hepatitis treated
with interferon (Zein and Zein, 2002)
Side effect Patients %
-Flu-like syndrome -  fever, headache, chills, myalgia, fatigue 60-80
-Bone marrow hypoplasia -  manemia, leucopenia, thrombocytopenia <5
-Cardiovascular disorders -  arrhythmia, cardiomyopathy, hypertension <5
-Endocrine disorders -  exacerbation of diabetes mellitus, thyroid, <5
gyncomastia
-Gastrointestinal disorders -  taste alteration, anorexia, diarrhea 15-25
-Liver and biliary -  jaundice, liver failure/encephalopathy <5
-Neuropsychiatric disorders -  depression, amnesia, confusion, paresthesia 10-30
-Musculoskeletal disorders -  arthritis, leg cramps, muscle weakness <5
-Reproductive system disorders -  amenorrhea, pimportence, uterine bleeing <5
-Skin disorders -  alopecia, pruritis, rash, dry skin 5-15
-Others -  respiratory, urinary, vision <5
3.9. Pegylated interferon
Peg-interferons are produced by the addition of a polyethylene glycol molecule to 
standard interferon (Dusheiko et al, 2000). This addition results in substantial changes 
in the metabolism of the drug. These drugs were approved in Europe for the treatment 
of chronic HCV infection before the more recent approval by the United States Food 
and Drug Administration (FDA). Two companies simultaneously developed peg­
interferon forms of their existing non-pegylated interferons. Schering-Plough 
Pharmaceuticals developed peg-interferon-a-2b (Peg-Intron), and Hoffman La Roche
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Pharmaceuticals developed peg-interferons-a-2a (Pegasys). By conjugating the 
molecule o f polyethylene glycol and interferon, the half life of interferon was 
prolonged substantially because of decreased renal clearance of the new substance.
The rational also for developing antiviral agents with a longer half life for the 
treatment of chronic HCV infection is based on the dynamics of the viral response to 
interferon. Because of the prolongation of the half-life of interferon attained with 
pegylation, only one dose per week is required to maintain effective blood level of the 
medication which decreases viral replication that occurs on days without treatment 
during the standard thrice weekly dosage of conventional interferon (Zein and Zein, 
2002).
An enhanced IFN molecule produced by the covalent attachment of a branched 
polyethylene glycol moiety to interferon a-2a exhibits sustained absorption, a 
restricted volume of distribution, and reduced clearance compared with unmodified 
IFN a-2a (Roche) (Parkin, 2002) or to interferon a-2b. The pegylation of interferon 
a-2b produces a molecule with a mean clearance one tenth of a non pegylated IFN a - 
2b and a sustained maximal serum concentration for 48 to 72 hrs after administration 
versus eight to twelve hours of IFN a-2b (Glue et al, 2000).
3.10. Combination therapy for hepatitis C virus infection
Combination therapy with interferon - a  and ribavirin which until recently, was 
considered the treatment of choice for chronic hepatitis C is relatively ineffective 
(Poynard et al, 1998; McHutchison et al, 1998 and Poynard, 1999), 40% of those 
given this treatment have a durable benefit, and most patients continue to have 
viraemia after the treatment has been stopped (Zein and Zein, 2002). Also, this 
combination therapy has numerous and frequent side effects (table 6). Moreover, at 
the present time, the cost of combination therapy is too great for the large numbers of
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patients in Europe and other continents who will require it. The cost of monitoring 
therapy must be considered. Detection of HCV RNA by PCR is the ~gold standard” 
and has been recommended to monitor treatment. Genotyping and quantification of 
viraemia are useful but remain costly. These tests must be made more generally 
available. The use of other combinations of drugs presently available is unlikely to 
achieve much better results than the combination of interferon and ribavirin. 
Importantly, combination therapy has been shown to double sustained virological 
response rates in previously untreated patients. Large studies in the USA and Europe 
indicate that sustained virological response rates of 31% - 35% occur in patients 
treated with a combination of ribavirin and alpha 2b IFN given for 24 weeks, and in 
38% - 43% given for 48 weeks (compared with 13% and 19% for alpha 2b alone 
given for 48 weeks (Dusheiko et al, 2000).
3.11. Ribavirin
The added efficacy of ribavirin is interesting and somewhat surprising given that 
treatment with ribavirin alone in controlled trials had little antiviral effect (Dusheiko 
et al, 1996). Ribavirin is a purine nucleoside (guanosine) analogue with 
immunomodulatory effects, increasing the production of type 1 cytokines (interleukin 
2 (IL-2) and gamma IFN) and suppressing type 2 (IL-4) cytokines in a dose dependent 
manner. These shifts to a Thl profile may be important in reducing the pro- 
inflammatory response of IFN and possibly reducing bystander damage hence the 
reduction in ALT in ribavirin treated patients. These changes cannot account for all of 
the observed effects however. Analysis of the viral kinetics observed after 
combination therapy with ribavirin and alpha IFN suggests a synergistic action, and a 
critical block on viral replication and release of virions from infected cell observed in 
the first phase of viral decline after antiviral treatment. Ribavirin inhibits inosine
76
Chapter 3
HCV & its management
monophosphate dehydrogenase and thereby biosynthesis of guanosine triphosphate 
(GTP) in cells, decreasing the intracellular GTP pool. However, the major antiviral 
effect may not be related to GTP pool depletion. Ribavirin triphosphate binds to HCV 
NS 5b polymerase as a nucleotide substrate and is mis-incorporated into nascent RNA 
(Dusheiko et al, 2000).
3.12. Effectiveness and cost effectiveness of treatment
Randomized clinical trials are the traditional approach to addressing questions about 
the effectineness of treatment. Based on the fact of the prolonged natural history of 
hepatitis C virus, such trials would require ten to twenty years or more of follow-up 
and would necessitate a substantial enrollment of patients at considerable expense. 
Some might even argue the ethics of such a study, because of the known 
complications resulting from chronic hepatitis C virus and the availability of 
treatments for it. Moreover the patient recruitment with informed consent might be 
problematic (Bennett et al, 1996 and Wong, 1999). As an alternative decision 
analysis, computer cohort simulation techniques, and mathematical models are used to 
estimate the lifelong clinical and economic outcomes resulting from interferon for 
patients with chronic hepatitis C virus, comparing those results with that expected to 
occur with conservative care (i.e., no interferon treatment) (Bennett et al, 1997 and 
Wong, 1999). Thus, the current cost and benefit of interferon treatment can be 
weighed against the economic and health burden of potential future complications. 
The decision to treat patients with chronic HCV infection should be made after many 
factors have been considered and each case has been individualized (Zein and Zein, 
2002). This study has the aim of investigating this in Egypt.
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3.13. Advances and other themes for future therapy
Slower progress has been made in the development of non interferon-based therapies 
for HCV infection, including protease inhibitors, helicase inhibitors, ribozymes, 
antisense therapies, cytokine-based therapies, and T-cell based therapeutic vaccines 
(Zein and Zein, 2002). Anti sense oligonucleotides targeted against the ribosomal 
binding site of the 5’ non translated region of the HCV genome are being 
investigated. A new ribozyme specific approach to treatment is also under study. 
Helicase inhibitors and protease inhibitors are not yet available. Overall, advances in 
the development of therapies for hepatitis C virus have been hindered by the lack of 
dependable cell cultures systems and an adequate animal model (Zein and Zein, 
2002). Furthermore, variation in the response to interferon treatment by different viral 
genotypes or by differences in the type or vigor of an immune response has been 
observed and may be another obstacle in the development of uniformly effective 
therapy or vaccine.
Other themes fo r  the future might include the following: In the field of diagnosis: 
surrogate markers of fibrosis, the role of hepatocellular carcinoma screening, and 
standardization of HCV testing. In the field of natural history: the long term outcome 
of patients with persistently normal aminotransferase levels, predictors of fibrosis, and 
predictors of hepatocellular carcinoma. In the field of virology: the development of in 
vivo models to assess HCV replication and to assess the effectiveness o f the drugs, 
and the development of alternative animal models to study new antivirals and 
vaccines. In the field of therapy: the benefit of treatment in special groups (acute 
hepatitis, patients with normal amino transferase, patients with mild disease, extra 
hepatic syndromes, compensated cirrhosis, non-responders to current therapy patients
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with HBV or HIV co-infection), and the benefits of maintenance therapy in non­
responders (Zaraski, 1999).
79
Chapter 4
HCV in Egypt
Chapter 4 
Hepatitis C Virus in Egypt
HCV in Egypt
Contents of Chapter
4.1. Hepatitis C virus in Egypt 
Background, epidemiology and transmission
4.1.1. Egypt’s high prevalence
4.1.2. Epidemiology
4.1.3. Marital status and Vertical transmission
4.1.4. Seroprevalence by Age and Gender
4.1.5. Schistosomiasis and hepatitis C virus infections
4.2. HCV, cirrhosis and other chronic disease implications
4.3. Guidelines in Egypt
4.3.1. Protocol of diagnosis and treatment of HCV, EGYPT 2001
81
^napier 4  
HCV in Egypt
4.1. Hepatitis C virus in Egypt 
Background, epidemiology and transmission
4.1.1. Egypt’s high prevalence
From the literature review it is concluded that hepatitis C virus is a major health 
problem in Egypt. The population of Egypt has a heavy burden of liver disease mostly 
due to chronic infection with hepatitis C virus (HCV). Overall prevalence of antibody 
to HCV in the general population is around 15% - 20% (Angelico et al, 1997; Frank 
et al, 2000 and Rao et al, 2002). Since its discovery in 1989 (Choo et al, 1989), the 
HCV has been found to cause significant morbidity and mortality in tropical settings 
(Di Bisceglie, 1998). The prevalence of HCV antibodies (anti-HCV) is reported to be 
higher in Egypt than in any other country (Arthur et al, 1997 and Hepatitis C global 
prevalence, 1997), with an estimated 8 - 10  million among a population of 68 million 
having been exposed to the virus and 5 - 7  million active infections. An important 
cause for the high exposure to HCV was the establishment of a large reservoir of 
infection as a result of extensive schistosomiasis control programs that used 
intravenously administered tartar emetic for forty years starting in the 50s to the 80s 
(Frank et al, 2000 and Strickland et al, 2002). Blood transfusion and illicit drug use 
are rare in Egypt. HCV infection is more common among adults, males, those with a 
history of schistosomiasis, and those living in rural communities of Egypt (Darwish et 
al, 1993 a; Mohamed et al, 1996 a and Arthur et al, 1997).
Studies of the epidemiology of HCV infections have suggested that the Nile delta 
region of Egypt has among the highest prevalence rates of HCV in the world 
(Darwish et al, 1993 a and 1996). Blood bank and community-based surveys 
conducted have reported sero-prevalence rates of HCV to be as high as 40 % in some 
parts of the country and in villagers over the age of 30 years (Darwish et al, 1993 a
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and 1996; Arthur et al, 1997 and Abdel-Aziz et al, 2000). These rates are 
substantially higher in the Nile Delta region compared with the rest of the country 
(Frank et al, 2000). The prevalence in rural communities in Upper Egypt was 
approximately 10 %, which was much lower than in inhabitants of villages in Lower 
Egypt (Abdel-Wahab et al, 1994; Darwish et al, 1996; Arthur et al, 1997 and Frank et 
al, 2000). Among the reasons for this geographic variation in prevalence of HCV 
infection in Egypt may be the difference in the intensity and duration of intravenous 
tartar emetic schistosomiasis control programs in Upper and Lower Egypt, with the 
programs in Lower Egypt affecting a larger proportion of the population over a longer 
period o f time and administering a greater number of doses (Nafeh et al, 2000).
The overall anti-HCV prevalence in Egypt was 24.3 % and prevalence was nearly 
equal among males and females 24.9 % and 23.8 %, respectively (table 7). Anti-HCV 
prevalence, however, was much higher among individuals older than twenty years of 
age, with the highest level, 56.7 %, in those over forty years. Among subjects older 
than twenty years, the small group with at least some university education had a lower 
prevalence than the remaining subjects. Anti-HCV was found in 12.1 % of primary 
schoolchildren, 18.1 % of residents of rural villages, and 22.1 % of army recruits, as 
well as in 31 % of Egyptians applying to work abroad (Mohamed et al, 1996 b). In 
contrast, a high prevalence of antibodies to HCV has been found among apparently 
healthy Egyptian populations, such as expatriate workers in the Gulf Region 
(31 %)(Mohamed et al, 1996 a), blood donors (10 % - 28 %)(Mohamed et al, 1996 a 
and Arthur et al, 1997), military recruits (22 % - 33 %)(Farghaly and Barakat, 1993 
and Abdel-Wahab et al, 1994), rural primary-school children (12 %), and rural village 
inhabitants (16%-18%) (Farghaly and Barakat, 1993; Abdel Wahab et al, 1994 and 
Kamel et al, 1994). In the largest published study, Mohamed et al, (1996) assessed
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anti HCV in five thousand Egyptians undergoing pre-employment examination, and 
the prevalence increased with age, peaking at 55 % among those 45 to 49 years old 
(Mohamed et al, 1996 b).
Table 7: Anti-HCV prevalence by age, gender, and education (Habib et al, 2001)
Number Anti-HCV Positive number (%)
Total 3,999 973 (24.3)
Age (yr)
0-9 712 50 (7.0)
10-19 1.298 128 (9.9)
20-39 1.142 315(27.6)
40+ 847 480 (50.7)
Gender
Females 2.172 518(23.8)
Males 1.827 455 (24.9)
Education
(for those >20 years)
University attendance 67 12(17.0)
School attendance 678 253 (37.3)
No school attendance 1.244 529 (42.5)
4.1.2. Epidemiology
The epidemiology of, and specific risk factors for, HCV infection in developing areas 
such as Egypt is quite different from that of the West (Wasley and Alter, 2002), and 
given the high prevalence of HCV, it is of utmost importance to identify past and 
current risk factors for infection so that intervention programs may be appropriately 
focused (Lavanchy, 1999 and Rao et al, 2002). Infection with the HCV occurs 
primarily through percutaneous exposure to contaminated blood or blood products, 
unlike most other viral hepatitis infections that tend to be acute, hepatitis C virus
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infections are often chronic and persist for decades (Yano et al, 1996 and Di 
Bisceglie, 1998). The long-term sequalae of chronic HCV infections include increased 
risks of liver cirrhosis and hepatocellular carcinoma (Kaklamani et al, 1991 and 
Kuper et al, 2000).
Intravenous tartar emetic was used in large campaigns to control schistosomiasis as 
early as 1921. The Egyptian Ministry of Health and Population during an assessment 
of the country’s health problems in the mid twentieth century, the 1960s, 1970s and 
early 1980s decided to allocate the resources needed to undertake large mass 
treatment campaigns in rural communities in which a large proportion of the 
population were screened for parasites and treated. Mass campaigns were conducted 
to treat schistosomiasis infections in these areas, during which individuals older than 
5 years of age were treated with tartar emetic injections (Maegraith, 1963). The 
dangers of exposure to human blood were unappreciated at the time, and disposable 
needles and syringes were unavailable. Those programs were discontinued 20 years 
ago, but, given the substantial reservoir of infection, it is of utmost importance to 
identify not only current risk factors for transmission but also those factors that 
indicate higher risk of past infection. Many people were infected with both hepatitis B 
virus (HBV) and HCV during these schistosomiasis control campaigns. However, 
HBV caused chronic infections in only 5 % or less of infected children and adults, 
whereas HCV infection persisted in 70 % to 80 % (Frank et al, 2000). Unlike many 
Western countries (Alter et al, 1999 and Williams, 1999), intravenous drug use 
(IVDU) is rare in Egypt, especially in rural areas (Darwish et al, 2001), making this 
an unimportant mode of transmission, and exposure via tainted blood products has 
been minimized after the introduction of screening for anti-HCV (Medhat et al, 2002).
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Schistosomiasis is a parasitic infection transmitted to humans from snails that harbor 
the parasite. Most rural and peri-urban areas located in the Nile Delta are in close 
proximity to the distributaries of the Nile River or irrigation canals drawn from the 
Nile. These slow flowing waters are infested with snails that serve as the vector for 
the schistosomal parasite. Schistosomiasis infections, in addition to HCV are hyper 
endemic in the Nile Delta region (Abdel Wahab et al, 2000).
Sero-surveys conducted in the 1990’s in Egypt have reported positive associations 
between HCV infections and a history of schistosomiasis or a history of having 
received injections for the treatment of schistosomiasis (Darwish et al, 1993 a, 1996 
and 2001 and Frank et al, 2000). Based on this evidence, the studies suggest that 
inadequately sterilized needles and syringes used during the campaign were probable 
causes for transmission of HCV in the region (Habib et al, 2001). Recently reported 
data suggests that the very high prevalence of HCV infection in the adult population 
of rural areas of Egypt, particularly in men living in villages where schistosomiasis is 
endemic, is at least partially the result of extensive mass-control campaigns using 
parenteral tartar emetic conducted from the 1950s up until 1982 (Frank et al, 2000). 
Previous studies of hepatitis C viral infection in Egypt have shown a high prevalence 
of antibody to HCV (anti-HCV) among blood donors (Darwish et al, 1992; Kamel et 
al, 1992; Hibbs et al, 1993 and Arthur et al, 1997) and residents of rural areas 
endemic for schistosomiasis (Darwish et al, 1993 a). It is widely believed that 
parenteral exposure to the virus is the most important rout for acquiring infection in 
Egypt (Farghaly and Barakat, 1993 and Mohamed et al, 1996 a). Although the 
prevalence of infection among those too young to be exposed to these mass anti­
schistosomiasis injection campaigns is lower than among the older population, 
infection in this younger cohort indicates that other modes of transmission have
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perpetuated the infection in the community. Despite the use of oral drugs for the 
treatment o f schistosomiasis during the past two decades, HCV antibodies were 
detected in some children below fifteen years of age.
Uncertainty remains regarding the relative importance of various types of parenteral 
exposures and widely practiced community activities, such as circumcisions, goza 
(Hookah pipe) smoking in a group, or being shaved at a community barber (Habib et 
al, 2001), in addition to the exposures associated with medical procedures (parenteral 
medical treatment, blood transfusion, gastrointestinal endoscopy, surgery, 
hospitalization, dental procedures) that occur in developed countries (Medhat et al, 
2002). As found in the Delta community (Habib et al, 2001), circumcision among 
male subjects by an informal healthcare provider was associated with HCV infection 
(Medhat et al, 2002). The results of the investigation of Medhat et al, (2002) as well 
as previous reports did not demonstrate other unique community acquired exposures 
that caused HCV infections (Darwish et al, 2001 and Habib et al, 2001). Tattooing, 
hookah pipe smoking, shaving in a community barber were not associated with HCV 
infection (Medhat et al, 2002).
4.1.3. Marital Status and Vertical transmission
There was a significant association between marital status and anti-HCV prevalence 
(table 8). Those who were or had ever been married had higher anti-HCV prevalence 
(43.1%) than those who had never been married (13.1%). The association remained 
significant after adjusting for age among those between fifteen and thirty five years of 
age, with a Mantel-Haenszel RR of 1.8 (95 % Cl: 1.3, 2.6). Age adjustment was 
limited to this age group because there were very few unmarried individuals older 
than 35 years (Abdel-Aziz et al, 2000).
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Interestingly, marriage was found to be a very strong risk for HCV in the logistic- 
regression model. This association of HCV in spouses could be the result of sexual 
transmission or to common exposures. Very few researchers have reported that 
spouses of patients with HCV have an increased risk for acquiring HCV, and this risk 
increases with age and is proportional to the duration of marriage (Kao et al, 1992; 
Akahane et al, 1994; Goto et al, 1994 and Magder et al, 2005). In addition to potential 
sexual transmission, married couples share many exposures that could be risks for 
HCV transmission, both for transmission from a common source (Nafeh et al, 2000 
and Habib et al, 2001). Vertical transmission of HCV from infected mother to infant 
occurs in approximately 5 % of HCV infected mothers and is reported to increase 
with increasing viral loads (Zanetti et al, 1999).
HCV infections congregated among families, with spouses particularly husbands 
being at higher risk if their partner was infected with HCV, and children being at 
increased risk if their parents were infected (Magder et al, 2005). Mohamed et al 
(2005), observed that the risk of HCV infection was higher for children when their 
mothers rather than their fathers were anti-HCV positive and was higher when the 
parent had circulating HCV-RNA. For instance, he observed that 14% (87/612) of 
children whose mothers had HCV-RNA were HCV positive, in comparison with 7% 
(28/401) whose parents only had anti-HCV. Sequencing even showed ten out of 
eighteen families with both children and parents having HCV-RNA had genetically 
similar viruses. A prospective study of current risk of infection has shown the 
strongest predictor of incident HCV was having an infected family member 
(Mohamed et al, 2006). Parenteral exposures increased the risk o f HCV but were not 
statistically significant; 67 % of seroconverters were younger than twenty years old 
with highest incidence rate in children younger than ten years living with an anti-
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HCV positive parent in a Nile Delta village having 24% anti-HCV prevalence 
(Mohamed et al, 2006).
4.1.4. Sero-prevalence by age and gender
The overall anti-HCV prevalence was 24.3% (95% Cl: 23.0, 25.7), and the age and 
gender adjusted prevalence was 23.7% (Saeed et al, 1991). Anti-HCV prevalence of 
males (24.9 %; 95 % Cl: 22.9-27.0). However, there was a substantial association 
between anti-HCV prevalence and age, with a marked rise in the third decade, 
reaching a peak of over 60% in the fifth decade. Among those older than twenty years 
of age, males (45.8 %) were more likely to be anti-HCV positive than females 
(37.6%). However, no gender difference was detected for anti-HCV prevalence 
among participants twenty years or younger (9.3 % and 9.3 %, respectively) (Abdel- 
Aziz et al, 2000).
Males, who more frequently have schistosomiasis than females (Ghaffar et al, 1991; 
Kamel et al, 1994; and El-Khoby et al, 2000), and those more than thirty years of age 
who had risk of exposure to parenteral anti-schistosomal therapy (Frank et al, 2000), 
had much higher anti-HCV infection rates than females and those thirty years o f age 
and younger, respectively.
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Table 8: Anti-HCV prevalence by socio-demographic status
(Abdel-Aziz et al, 2000)
Total
(Number)
Anti-HCV Sero-positive
HCV PCR Sero- 
positive+
Number (%) Probability Number (%)
All participants 3,999 973 (24.3) 593 (65.5)
Gender 0.5
Female 2.172 316(65.4)
Male 1.827 277 (65.7)
Age (yr) <0.0001
<20 2.105 196 (9.3) 118(65.6)
>20 1.897 777 (41.0) 475 (65.6)
Education (>20 yr)* <0.0001
None 1.210 524 (43.3)
School 625 243 (38.9)
University 59 10(16.9)
M arital status
++(>16 yr) 0.0001
Never married 625 524 943.3)
Ever married 1.780 768(43.1)
15-20 years old 0.3
Never married 4398 60(13.7)
Ever married 71 13(18.3)
20-25 years old 0.001
Never married 135 13 (9.6)
Ever married 219 51 (23.3)
25-30 years old 0.2
Never married 39 7(17.9)
Ever married 262 75 (28.6
30-35 years old 0.2
Never married 8 1 (12.8)
Ever married 281 100 (35.6)
* Mantel-Haenszel P = 0.4 for education (none compared with school/university) across 10-year age strata, RR = 
1.0 (0.9,1.1)
+ HCV RNA among those who were anti-HCV-sero-positive
++ Mantel-Haenszel P<0.001 for marital status across 5-year strata between 15 and 35 years, RR = 1.8 (95% Cl, 
1.3,2.6)
4.1.5. Schistosomiasis and hepatitis C virus infections
Aside from the direct relationship between parenteral treatment of schistosomiasis and 
the country-wide prevalence of antibodies to hepatitis C virus (anti-HCV), Ghaffar 
and colleagues reported the relationship between HBV or HCV and hepatosplenic 
schistosomiasis (Ghaffar et al, 1991). The authors proposed that chronic 
schistosomiasis favored the persistence of the HBV (and non-A, non-B hepatitis)
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HCV infections, resulting in splenic enlargement. It is noteworthy that the 
relationship between HBV and hepatosplenic schistosomiasis was initially reported 
from Brazil, Egypt, and the Philippines (Lyra et al, 1976; Bassily et al, 1983; 
Domingo et al, 1983 and Madwar et al, 1989).
In addition, Kamal and colleagues reported that Egyptian patients with co-infections 
have higher HCV-RNA titers, more advanced liver disease, more hepatic 
complications, and a greater mortality rate than those infected with only HCV (Kamal 
et al, 2000 a). They also noted that patients with co-infections responded poorly to 
interferon therapy and had a higher relapse rate and higher HCV-RNA titers and more 
severe hepatic lesions than HCV patients not having concomitant schistosomiasis 
(Kamal et al, 2000 b).
4.2. HCV, cirrhosis and other chronic liver disease implications
j  Multiple studies have showed the importance of HCV in the causality of chronic liver
i
I disease in Egypt. In a study in the NLI, Waked et al, pointed out that 73.3 % of 1 023
! outpatients had anti-HCV. One hundred patients among them had liver biopsies
|
! showing that 89% had chronic hepatitis, cirrhosis, or hepatocellular carcinoma HCC,
I and 84% of theses had anti-HCV (Waked et al, 1995).
Residents of Egypt’s Nile river delta have among the world’s highest sero-prevalence 
of HCV infection. The findings are consistent with the increased prevalence and 
intensity of infection with Schistosoma in the populous Nile delta where exposure to 
canal water was occurring to several million farmers and their families which resulted 
in an increase in schistosomal fibrosis. In addition to the hypothesis that past mass 
parenteral chemotherapy campaigns for schistosomiasis facilitated HCV transmission 
and furthermore HCV may be a major cause of the high prevalence of liver cirrhosis 
| in Nile Delta villages (Darwish et al, 2001). It was reported that only 15-20% of
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people infected with HCV have an acute viral hepatitis syndrome, but the majority 
develop chronic hepatitis that is usually asymptomatic and undetected for many years. 
Over a course of 20 - 40 years nearly 20 % of those with HCV-caused chronic 
hepatitis progress to cirrhosis, and a proportion of these (possibly 2 - 3 % per year) 
die as a result of complications of cirrhosis of hepatocellular carcinoma (Alter et al, 
1992; Niederau et al, 1998; Rodger et al, 2000 and Thomas et al, 2000). It is unclear 
what the long-term outcomes of these infections in Egyptians will be, particularly 
since the predominant HCV genotype in Egypt (type IV) differs from genotypes 
found in many other parts of the world and since HCV of Egyptians act within a 
milieu of many other infectious assaults capable of causing chronic liver sequalae, 
including hepatitis B infection and schistosomiasis (Kamel et al, 1994; Angelico et al, 
1997 and Darwish et al, 1996).
Moreover, Darwish et al, (2001) demonstrated both an extremely high prevalence of 
cirrhosis and a notably high fraction of cirrhotic cases potentially attributable to HCV 
(Darwish et al, 2001), but could not project how the burden of HCV related cirrhosis 
will evolve in the Nile delta during the coming decades. Indeed, chronic liver disease 
due to HCV is thought to develop at a rather slow pace ordinarily taking decades 
(Waked et al, 1995; Medhat et al, 2002; Strickland et al, 2002 El-Zayadi et al, 2005; 
Kamal et al, 2005; Magder et al, 2005 and Mohamed et al, 2005) and with no way of 
dating the onsets of the infections detected in the Egyptian population. Adding to our 
uncertainties is the fact that little is known about the tendency of genotype IV of 
HCV, which predominates in Egypt (Angelico et al, 1997), to produce chronic liver 
disease. The pathogenic nature of HCV genotype IV is supported further by the fact 
that patients infected with genotype 4 show a meager response to alpha-interferon 
therapy similar to the more pathogenic HCV genotype lb, and a poor response
92
HCV in Egypt
compared to patients infected with the less pathogenic HCV genotypes II and III (El- 
Zayadi et al, 1996 and Zylberberg et al, 2000). Strickland et al, (2002) in a case- 
control study supported this belief that HCV is the predominant cause of liver disease 
and that there is a large occult reservoir of HCV induced chronic liver disease in the 
country. The sum of these findings raise concern that the extraordinarily high sero- 
prevalence of HCV now observed in the Nile delta may forebode an explosive 
epidemic of cirrhosis and other manifestations of chronic liver disease in this region 
(Darwish et al, 2001). HCC is now one of the three most frequently diagnosed cancers 
in Egypt (Abdel-Wahab et al, 2000) along with this, the increasing association with 
HCV, as the greatest risk factor (Hassan et al, 2001 and Ezzat et al, 2005) just as it is 
in the United States (Hassan et al, 2002). Chronic HCV infection has also been 
associated with increased risk for B-cell non-Hodgkin's lymphoma NHL. Egyptian 
NHL patients were 2.3 times more likely to have HCV-RNA in their sera than 
matched controls (Cowgill et al, 2004).
It is noteworthy to mention that the Egyptian Ministry of Health and Population has 
initiated a country wide program to prevent transmission of HCV and other blood 
bom infections. Health education campaigns and serological screening o f all blood 
transfusion have reduced HCV transmission (Stickland, 2006). In conclusion; the 
large reservoir of infection in human blood increases the incidence of new HCV 
infections and should encourage researchers to seek more information on its 
transmission to assist the Egyptian Ministry of Health and Population and health 
officials in their preventive efforts. Children with HCV infected parents are at 
particularly high risk and would benefit from efforts to reduce exposure to HCV 
contaminated blood and other biological fluids or to become immunized when and if a 
vaccine becomes available.
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4.3. Guidelines in Egypt
4.3.1. Protocol of diagnosis and treatment of HCV, Egypt 2001
The High Authority of Health Insurance in cooperation with the High Laboratory 
Commission in Egypt in 2001 came up with a very narrow minded limited protocol of 
treatment for HCV patients. The veiy fact that it is not used and was extracted from 
the archives just as reference and was included as part of the study.
First: The dangers of prescribing interferons due to their side effects, added to their 
lack of effectiveness against genotype IV positive in 90% of HCV cases in Egypt 
according to acknowledged scientific statistics and finally thin high expense, all lead 
to following rules and regulations to prescribing interferon.
The choice of a specialized hepatologist responsible for the application of this 
protocol and diagnosing and treating HCV patients as well as asking and approving 
the authenticity of the PCR.
The patient's liver enzymes should be more than twice as normal (SGOT >80 
units/liter- SGPT >70 units/liter).
Positive HCV antibody testing e.g. ELIZA
The number of white blood cells, platelets and haemoglobin should be normal. 
Platelets 200.000 -  400.000ML HB; male 14-18 x 100/100 ML; female 12-16 x 
1100/ML.
The lack of cirrhosis by ultrasonography
Genotyping the virus as 90% of cases in Egypt is fit for interferon treatment 
Presence of HCV in patient's serum after more than 800.000 units 
Second: Rules and regulation for PCR testing:
To prove the presence of HCV in patient's serum after more than 800.000 units using 
PCR
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In case of interferon prescription, it is dispensed for one month and response is 
depicted using PCR, and in case of success it is repeated for another six months then 
the test is repeated
In case of lack of response, interferon is repeated for another month in combination 
with ribavirin than PCR is repeated
Thirdly: If the patient did not respond after two months of interferon, it is
stopped
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The aim of this chapter is to explain in detail the methods used and the methodologies 
adopted to reach the written objectives of the study. The first section of the chapter 
starts by reinstating the aim of the research leading to the design and rationale behind 
the choices made regarding the use of health economics techniques and the choice of 
HCV as a case study. Subsequent sections examine the collection o f data and the 
extent to which economic evaluations are applied within the constraint of the 
available data sources and infrastructure. Then, the fieldwork is described within the 
various medical institutions. The perspective and stages of the analysis are explained 
up to the stage of the results interpretation.
5.1. Aim
The uniquely high prevalence of HCV in Egypt and the inhibitive cost of available 
treatment options make it a special political, social and medical situation. Doctors are 
bound by their oath to advise their patients as to their optimal therapy regardless of 
the cost. However, the vast majority of the patients are un-insured and cannot afford 
the financial cost of treatment, which creates a dilemma for physicians.
Moreover, several authors have focused on the high treatment costs of HCV rather 
than the treatment cost of its complications. However, no authors have studied a 
complete health economic comparison of the different treatments used in Egypt. This 
is related to the lack of awareness of the importance and implications of health 
technology assessment in developing countries in general (Strickland et al, 2002; 
El-Zayadi et al, 2005 and Kamal et al, 2005).
The economic, the psychological and the physical impacts of HCV are immense. The 
healthcare system is over-burdened by the high number of patients needing treatment, 
and hence stretching the scarce resources to a tight string. The government and the
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policy makers are overwhelmed by the ever-increasing burden of disease on the 
healthcare system, especially as the infected population gets older.
The magnitude of the problem and its impact on multiple sectors of the Egyptian 
population as mentioned above enhanced the importance of this study project. This 
project aimed to probe the extent to which HTA might yield data that could contribute 
to the decision-making process relating to healthcare provision and delivery in Egypt, 
using HCV as a case study. This was attempted through the estimation of the cost of 
HCV and its implications, the assessment of the effectiveness of the treatment options 
available in Egypt and the ultimate calculation of the cost effectiveness of those 
various treatment options in order to assess the burden of HCV care in a low resource 
society.
5.2. Design and rationale
This research was designed to assess both the cost of HCV disease and the cost of 
different treatment pathways of HCV, both their effectiveness and cost effectiveness 
in Egypt. The design was structured as a comparative analysis o f alternative courses 
of action, including anti-viral treatment options as well as no treatment option of the 
HCV infected patients in Egypt. This was done in terms of their costs and 
consequences (Drummond et al, 1997). The anti-viral treatment options included the 
combination of conventional interferon (IFN) with ribavirin for one year and the 
combination of pegylated (PEG) IFN with ribavirin for the same time period for HCV 
patients with compensated liver disease.
This research as mentioned above took place in Egypt, but the fact that this was held 
in a leading hospital and the largest of its kind in the Middle East situated in one of 
the highest populated areas with infected HCV patients in Egypt, contributed to the 
shaping and evaluation of the study.
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The rationale for using HCV as a model derives from the burden that it places on the 
Egyptian healthcare system, as a result of:
1. The high prevalence for HCV in Egypt, making it the most
important public health problem
2. The high cost of treatment for HCV patients
3. The long life cycle of the disease
4. The particularly more aggressive resistance of the Egyptian
genotype IV of the virus.
5. The ever present problem of healthcare budget constraints and
demands on it. Topped by the extra pressure on the Egyptian Ministry of 
Health and Population officials and the national health budget expenditure due 
to the particularly large number of chronic HCV patients.
5.3. Collection of data
A preliminaiy analysis was first undertaken to verify facts, to determine what the 
important concepts were, to frame all questions related to the research and to convert 
the questions into a search strategy. Questions were related to availability of any plans 
or guidelines for HCV therapy worldwide and in Egypt and were related also to costs 
of different current treatment strategies within the Egyptian system and within the 
various categories of medical service institutions in Egypt.
The research started in 2002 at the Bodleian library, Oxford University, where the 
sources of evidence were identified, and categorized according to their importance. 
The systematic reviews, as well as the secondary sources of data, were searched and 
both the extensive hard and comprehensive soft databases were also made use of. The 
search was initiated electronically using all terms related to hepatitis C virus, 
pharmacoeconomics, liver disease, health policy, technology assessment and health
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economics. Medline and Pubmed were surfed using the following websites: 
http://'www.pubmedcentral.nih.gov and http://www.ncbi.nlm.nih.gov. The keywords: 
hepatitis C, hepatitis C prevalence, hepatitis C management, hepatitis C treatment, 
hepatitis C consensus, treatment protocols, hepatitis C cost effectiveness and chronic 
liver disease were searched. This process lead to countless directly related papers to 
the research whose references were then used as base to construct a search for 
authors, books, publications and other online sources.
The most important information reached was concerned with HCV world prevalence 
data, HCV virology, diagnosis, transmission, and treatment. The parameters of 
clinical and cost effectiveness were also defined.
The identified parameters of clinical and cost effectiveness included:
• The clinical problem and population demographics
• Disease stages
• Treatment and medical settings providing care for patients with 
HCV, which were divided into public and private (for profit and non profit) 
medical institutions
• Alternatives to treatment (comparator)
• Principal health outcome either the cure or the eventual death
• Measures of cost
• Perspective which was the Egyptian healthcare system
• Time horizon over which benefits and costs will be assessed 
taking into consideration the long life cycle of the disease
• Other considerations related to the patients and their 
classification
• Special consideration of issues and limitations.
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It is noteworthy to mention at this point that even though the study was not part of any 
formal national or international research group or inter-university channel, there was a 
“pseudo” assessment group to make sure that the research point was innovative and to 
fine tune its focus and its boundaries. A panel was interviewed and consulted with the 
various issues related to the research.
The “pseudo” assessment group consisted of:
1- Dean of the School of Pharmacy. Cairo University, Professor Doctor 
Nadia Morsi (1998 - 2002)
2- Chairman of the National Pharmaceutical Holding Company, Doctor 
Galal Ghorab (1994 -  2004)
3- Several pharmaceutical companies' sectors heads
4- Egyptian Minister of Health and Population, Professor Doctor Awad 
Tag EIDin (2000-2005)
5- Head of National Laboratories in the Ministry of Health and 
Population, Senior Consultant Doctor Magda Rakha (2000 -  2006)
6- Marketing specialists in pharmaceutical companies that manufacture 
interferon
7- Clinical specialists and commentators in hepatology conferences 
attended
8- Public health professors and specialists in HCV treatment in Egypt; 
e.g. Professor Doctor Mostafa Kamal of Ain Shams University, Professor 
Doctor Thomas Strickland of Maryland University and head of the Wellcome 
Trust in Egypt
9- Prominent hepatologists and clinicians in Egypt; e.g. Professor Doctor 
Gamal Shiha of Mansoura University and Professor Doctor Fouad Thakeb,
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Professor Doctor Aly Moanes and Professor Doctor Gamal Essmat of Cairo 
University, last but not least the leader of the clinical part of this research 
Professor Doctor Imam Waked, Vice Dean of National Liver Institute of 
Menoufiya University.
Physical data and facts related to Hepatitis C virus were difficult to find, lengthy and 
effort consuming. The Ministry of Health and Population was visited, as well as the 
WHO library in Egypt, seminars and conferences about hepatitis C virus attended 
(National Liver and Kidney Diseases conferences from 2002 to 2005) and various 
research and teaching centres and universities were also called on and their main 
faculty members consulted and conferred with such as the Institute for Tropical 
Diseases.
Field study and visits to the department of pharmacy of the Ministry o f Health and 
Population were undertaken for the verification of treatment protocols and calculation 
of the cost o f drugs. Field visits were then extended to hospitals and other medical 
institutions for the cost assessment and identification of services given to HCV 
patients. These visits encompassed public and private medical centres and clinics for 
review of their patients' data and records. Public medical hospitals and centres 
included Kasr Al Aini University Hospital, Ain Shams Specialist Hospital, the 
National Liver Institute in Shebin ElKom and the Institute of Tropical Diseases. 
Private settings included Dar ElFouad Hospital (private for profit), Yassin Abdel 
Ghaffar Hospital (private non profit) and prominent clinicians' private clinics (private 
for profit).
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Figure 5: Setup of health institutions in Egypt
Health Institutions in Egyp
Public
HospitalsPrivate
Charity hospitals 
and clinicsHospitals and clinics
The fieldwork in NLI lead towards the realization o f  the aims o f  the study, that 
included the calculation o f  the various costs o f  drugs andscrvices related to the HCV 
patients' treatment options and the cost o f  the HCV complications.
This long exhaustive period lead to the decision to use the National Liver Institute in 
Shebin ElKom, Menoufiya as backbone and main data source o f  the research. This 
decision was based on the fact that it was the only accredited specialized centre with 
high constant patient traffic added to the verity that it was the largest liver patients’ 
referral centre in Egypt and the Middle East, not to mention the latest technologies for 
the treatment o f  HCV chronic patients adopted, as well as the liver transplants 
operations performed there as well. The costs o f  hospitalizations were estimated and 
added up. The prospective future costs o f  hospitalizations were anticipated by 
reviewing the price fluctuation in the preceding ten years and calculating an annual 
percent increase to be applied to following years. M arkov models from the published 
literature were followed to help in the cost effectiveness analysis.
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The research was constantly re-evaluated for any new or modified theories and facts 
supporting the emerging results. It was also updated to ensure currency of material 
and the inclusion of new developments. This is evidenced by the new interferon 
pricing policies uptaken by the Ministry of Health and Population in Egypt during 
December 2006 whose effects were incorporated in the results and discussion.
At the time the clinical data collection phase of the research was being conducted, the 
notion of international guidelines for management of chronic HCV was introduced via 
expert opinion and they were then searched, accessed and updated. The newer 
versions of the international guidelines and consensus were reviewed and referred to 
in the treatment algorithms used in this study. They included:
• Clinical guidelines on the management of HCV, 2001.
• National Institute of Health, Consensus Development 
Conference Statement, Management of Hepatitis C, 2002.
• Veteran Association (VA) treatment recommendations 
(Version 5.0). Patients with chronic Hepatitis C, Federal Practitioner, 2003.
5.4. Fieldwork, difficulties and limitations
The researcher was fortunate to receive a permit, which allowed access to all areas of 
the NLI hospital, its clinics, patients' wards and various administrative departments. 
The research proposal was first approved by the hepatology department board o f the 
faculty of medicine in Menoufia University to grant access to for the desired premises 
and then by the NLI hospital board also considered as the ethics committee to validate 
adoption of required ethical standards. The ethics committee quarterly monitored the 
progress of the fieldwork. In addition, the researcher ensured that patients' anonymity 
was maintained throughout the research, with no personal confidential data disclosed.
105
^napier d 
Design & Methodology
It is noteworthy to mention that no published Egyptian guidelines were found, and the 
Ministry o f Health and Population in Egypt did not have treatment management 
protocols. Egyptian physicians simply followed international consensus.
The various treatment alternatives of HCV were found to include treatment with 
interferon or its pegylated version in combination with ribavirin in varying periods of 
time and frequency. This was done in alternation with the supportive liver support 
treatment options, which is in fact a no treatment option.
One of the first limitations in the study was time and concerned the very long life 
cycle of the disease and the impossibility of tracking the various stages of the disease 
in any one patient in a prospective longitudinal study. Rather patients were chosen 
representing the different stages of the disease, which could be considered a 
representative sample of the natural history. These included outpatients with 
compensated liver disease (which usually lasts many years), outpatients with 
decompensated liver disease, and hospitalized patients with different complications 
representing the major causes of hospital admission that might occur in patients with 
advanced liver disease due to HCV (ascites, bleeding varices, coma, and liver cancer). 
This limitation was also overcome with the use of modelling.
The time frame first allocated for this research was three years. This had to be 
extended due to the lack of structured data and the extremely lengthy time it took to 
find the NLI as a location that would allow access of its premises for the patient 
information needed. The outpatient clinics of the NLI were first visited three times 
weekly from 9:00 am to 1:00 pm to access the raw source of data emanating from the 
actual patients themselves.
Another major real time consuming issue was seeing each patient with the clinician 
and interviewing him or her personally after making sure that he/she was HCV
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positive. Manual recording of the drugs prescribed, and listing all the tests performed 
or asked to be performed regularly with a maximum of ten patients per visit. This was 
needed because there were no records of any prescriptions issued per patient; simply 
records of quantities of drugs dispensed per day, prescriptions are issued on the spot, 
given to the patient, who then goes to the hospital pharmacy, where records of all the 
drugs given per day were kept but not per patient.
A list of all drugs prescribed to the entire patient group and their dose was compiled 
(it was compiled into a list of fifty three drugs). The list was then classified into ten 
drug categories for ease of manipulation and calculation. The price of each drug 
prescribed and the number of units in each pack was checked and reviewed from the 
market. The price per unit was calculated and the total cost of the treatment term 
(following international consensus) computed. This process was performed for all one 
hundred and twenty nine patients in the outpatient clinics and a similar process was 
followed for the inpatients, taking into consideration that one hundred and sixty-five 
patients were researched and they were found to be prescribed one hundred and sixty 
five drugs which were then classified into fifteen categories.
For research time restrictions and privacy limitations in private medical institutions, 
the figures and numbers gathered in the NLI were verified against corresponding 
patients' situations in each institution via interviews, consultations and expert 
discussions.
The problems encountered in the handling of this case study involved the highly 
sensitive political aspect of the subject matter and the scarcity of relevant information 
in Egypt.
Other limitations related to system constraints concerned with cost data breakdown 
availability and accessibility necessary for its calculation. In the NLI, it was more a
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question of availability than accessibility. However, in the private sector, limitations 
were more due to the accessibility of patient data and the classified financial records 
of profits and actual costs breakdown in the various private institutions.
Not only was cost classification in the NLI different from the internationally 
recognized formats and terminology but it was also unsystematically available, 
handled or saved in a manner to allow a more detailed standardized classification. 
This was overcome with the creation of constant cost categorization, later explained 
(section 5.7.1 & 2).
Cost assessment limitation in the private sector was overcome by constructing a
model of categorized costs from the NLI and performing a comparative study of
corresponding categories. This was done by comparing each cost categoiy to that in 
the private sector, and that patients in the private sector actually pay hospitalization 
and consultation fees that covers their cost and may or may not lead to a profit in 
private for profit or non profit institutions respectively. That led to a cost increment 
factor calculation for each cost category in the private institution relative to that same 
category in the NLI. This estimated comparative factor made the cost calculation for 
the various treatment pathways as well as the cost of disease assessment possible in 
the chosen medical settings, which in turn led to a more comprehensive research.
The other difficulties encountered were divided into two categories:
1. Personal difficulties
2. System difficulties
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They both covered the following:
■ General lack of data and the shortage of comprehensive 
database and information sources
■ Lack of support from government or research centres in Egypt
■ Public hospitals setup
■ Private clinics confidentiality policies and incomplete and 
deficient data
■ Inadaptability of data in Egypt to international methodologies 
and standards
■ Politicians' concepts of healthcare and its policies
■ Official medical body of the government regarding HCV as a 
very politically sensitive issue and personal hindrances from top officials to 
the research
■ No peer discussions identifying key difficulties in order to 
define relative solutions or alternatives to the clinical problems
■ Logistics: Menouflya, Swansea, Cairo
■ No standardized format for troubleshooting
■ Finding an Egyptian clinician who was aware of the concepts 
o f HTA and willing to help in the research
5.5. The medical settings of the study and patient classification
Five medical non-university centres, in addition to the NLI were chosen to give a
more comprehensive assessment of the disease in Egypt.
■ The first, the NLI, is a private non-profit hospital dedicated solely for 
patients with liver related diseases in Cairo.
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■ The second, a private for-profit hospital that has a large liver practice and
has the largest liver transplantation program in Egypt.
■ The remaining three were private hepatology clinics to compare with the
outpatient clinics of both NLI and private non-profit hospital.
It should be noted that there is no difference in patients' medical profiles between the 
various institutions (only variations in their social or financial status), nor are there 
any difference in treatment patterns. Not only do all Egyptian doctors and clinicians 
follow international treatment recommendations, but also mostly they have more than 
one practice, one private and the other either public or non-profit.
Prices of similar interventions and diagnostics were collected from both hospitals 
(private for profit and non profit) to calculate the cost of care of HCV patients in each; 
this was done by comparing the same evaluated categorised item from the NLI 
outpatients' clinics and inpatients' wards to their respective private settings such as the 
consultation fees, the imaging, the laboratoiy costs and the hospital stay. This 
comparison led to the final HCV patient cost of treatment estimation in the various 
medical settings of Egypt via a factor calculated for each chosen setting.
Liver diseased patients with HCV were classified in this research into three main 
classes based on their treatment guidelines for ease of cost calculation. Patients come 
to the NLI at different stages of the natural history of their liver disease, and receive 
management and treatments accordingly. Basically they are either outpatients not 
requiring hospitalization, or inpatients with advanced liver disease and different 
emergencies requiring hospitalization, each with subgroups ensuing different 
management decisions and cost implications as seen in the following figure.
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Figure 6: HCV Patient classification
Patients Classification
Outpatients Inpatients
Ascitis GroupDecompensated Group,
lompensated Group) Other Group
Patients prescribed 
antiviral treatment
HCV patients 
Undergoing 
liver transplantation
I. HCV outpatients who don't require hospitalization, which were then 
collectively categorized according to the stage o f l iv e r  cirrhosis into three groups:
1. Patients with compensated liver disease prescribed supportive
liver treatment (not being under antiviral prescription)
2. Patients with decompensated liver disease prescribed
supportive liver treatment (not being under antiviral prescription)
3. Patients with compensated liver disease with antiviral
prescriptions
II. H CV inpatients that need to be hospitalized. The patients were categorized 
according to the reason o f  their hospitalization into five groups:
1. Patients hospitalized for the m anagem ent o f  refractory ascites
that complicates liver cirrhosis (ascites group).
unapier d
Design & Methodology
2. Patients hospitalized for bleeding varices in the oesophagus and 
stomach due to portal hypertension secondary to liver cirrhosis (bleeding 
group)
3. Patients hospitalized for hepatic coma due to advanced liver
disease (coma group)
4. Patients hospitalized for liver malignancy and hepatocellular
carcinoma (HCC group).
5. Patients hospitalized for other complications due to liver
cirrhosis (others group).
III. HCV patients undergoing liver transplantation
5.6. The perspective and the measurement of costing used
The evaluation is undertaken from a healthcare and a societal perspective, it 
incorporates drug- and disease-related costs but does not include patient or unpaid 
caregiver time; thus the costs of treatment are assessed and the benefits weighed but 
the production losses are not included in the study (Gerard and Mooney, 1993 and 
Drummond et al, 2001). This is due to not only the difficulties involved in acquiring 
relevant data and the ever-present time constraint factor, but also to the actual 
availability of such data in the first place in an organized accredited format in the 
Ministry of Health and Population or any other governmental or private accredited 
institution in Egypt.
This research went through all three stages involved in the process of costing 
healthcare interventions (McPake et al, 2002) starting with identification o f costs, 
their measurement and their translation into a monetary value (Phillips, 2005).
The identification of costs stage involved listing the resource effect o f the treatment of 
HCV patients, based on the societal perspective considered. There were first the direct
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costs, which were subdivided into medication costs and direct non-medication costs. 
The indirect costs and the intangibles associated with healthcare and productivity 
costs were not considered in the study. The constant costs, a study specific cost 
category was used to depict all costs incurred due to the patient's treatment in a public 
hospital and not directly paid by the patient or his Healthcare payer (this is the value 
of government subsidy to the treatment of HCV patients).
The measurement of costs stage involved the quantification of the resources used in 
the treatment of HCV patients, and deciding which interventions and services’ costs 
were available to measure. This stage was performed through a collective appraisal of 
all services given to the outpatients and inpatients and processing the data to reach the 
most pertinent values. The collective appraisal was first done to the services given to 
outpatients then to inpatients via direct review of their hospital records.
Finally the valuation of costs and its translation into monetary value stage was done 
by means o f assigning prices to the categories chosen via micro costing or bottom-up 
approach (Raftery, 2000 and Brouwer et al, 2001). Micro-costing was the method of 
choice for costing in the research, where each component of resource used is 
estimated and a unit cost derived. It is noteworthy to point out that this method leads 
to the most precise estimates of costing (Drummond et al, 2001) however; it is never 
possible to do a perfect job.
5.7. The stages of the analysis undertaken and the specifications of the courses of 
actions
Initially, time was spent in the outpatient clinics of NLI, Menoufiya to personally and 
individually investigate HCV positive patients with either compensated or 
decompensated liver disease prescribed supportive liver treatment. Patients with 
compensated liver disease with antiviral prescriptions were also investigated at this
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first stage and were included in the research. The medical outcome of each treatment 
option, as well as its effectiveness, were also taken into consideration, their values 
were retrieved from the literature and from the NLI unpublished data.
The second stage was spent investigating the cost of treatment of hospitalized HCV 
patients in the NLI. This phase extended over the second and third year of the 
fieldwork; it served to identify, measure and value costs related to treatment of HCV 
patients in the NLI. The last of the field work stages was spent investigating private 
medical settings.
5.7.1. Stage one (outpatients’ investigations)
Outpatients' data was collected in the NLI, Menoufiya from one hundred and twenty 
nine outpatients attending the clinics for their routine examination checkups with 
either compensated or decompensated liver disease prescribed supportive liver 
treatment not requiring hospitalization. The cost of caring of each outpatient was 
evaluated. It was divided into three main components in this study;
1. The medication cost (the cost of drugs prescribed to the patient)
2. The direct non-medication costs (clinic admittance fee, 
laboratory tests and diagnostic investigations)
3. The constant costs directly and indirectly incurred by patients 
per visit (in this case subsidized government costs calculated from classified hospital 
records including the salaries and staff, water, electricity, etc....) (NLI is a subsidized 
public medical institution)
The identification of cost components was followed by the measurement of frequency 
and quantity related to that component and ended by the valuation o f the cost 
component then summing them up to reach the total cost for drugs and services 
rendered to the HCV patient. In both patient groups the monthly costs of drug
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treatment (medication cost), of investigations and of follow up were assessed (direct 
non medication cost).
This breakdown was done in order to highlight the cost weight or percentage that each 
of these cost components contributes to the total cost and to evaluate effectively the 
actual impact it has on the treatment effectiveness in general. The cost breakdown was 
also used to compare the cost of each disease stage across the various medical 
settings; university versus private profit and non-profit hospitals.
Data was collected, checked, revised and tabulated in excel sheets (Microsoft Excel; 
Version 2003). Duplicate data entry was performed to ensure quality control.
The cost of antiviral therapy and its outcome were obtained via the calculation of 
the medication costs of treatment of two groups of patients in the NLI each prescribed 
one form of interferon combination therapy.
Cost categories were divided into the same previously mentioned three segments. 
However the medication cost in that case included the antiviral drug combination 
cost.
• Two hundred and twenty outpatients in the NLI were prescribed 
conventional IFN 3 million units 3 times weekly for one year in combination with 
ribavirin 1200 mg per day (Zaraski, 1999; Dusheiko et al, 2000; Buti et al, 2002; 
Dusheiko, 2002 and Davis et al, 2003), with a sustained virological response (SVR) 
of 15.9 % (NLI unpublished data).
•  Another one hundred patients were prescribed pegylated IFN 180 
micrograms once a week for one year in combination with ribavirin 1200mg per day 
(Zaraski, 1999; Dusheiko et al, 2000; Buti et al, 2002; Dusheiko, 2002 and Davis et 
al, 2003) with an SVR of 54% (NLI unpublished data). The sustained viral response 
rate to pegylated interferon and ribavirin in Egyptians infected with HCV genotype IV
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(causing approximately 90% o f infections in the country), ranges between 29% and 
69%, with the higher value in those treated 36 weeks or longer (El-Zayadi et al, 2005 
and Kamal et al, 2005).
Two important issues should be stressed at this stage: the first is that that the Ministry 
o f Health and Population of Egypt mandates very rigid drugs' pricing policies and 
regulations in all Egyptian medical institutions and centres whether they are public or 
private. The second is that the prices of medical services and testing given and 
performed in the NLI are actually the price of that service in Egypt, this is due to the 
fact that the medical services’ pricing are also constant throughout all government, 
public and university settings in the country and only varies in private settings.
5.7.2. Stage two (inpatients’ investigations)
Time was then spent in the NLI, Menoufiya inpatients wards and patient data 
archiving departments to investigate different causes of hospitalization and costs of 
treatment of HCV inpatients.
The inpatients’ data was collected in the NLI, Menoufiya from one hundred and 
eighty three patients and their records during hospitalization and from the records of 
twenty patients who underwent liver transplantation. The cost of caring for each 
patient by reason of hospitalization was assessed and the total cost of hospitalization 
was evaluated. Cost categories were divided into the following four main segments;
1. The medication cost
2. The direct non medication costs
3. The blood costs (included separately, as the blood costs were found 
prominently substantial from the hospital records and were unevenly 
distributed over the various studied groups).
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4. The constant costs (in this case subsidized government costs calculated 
from classified hospital records per patient per bed per day).
The direct non medication costs included all the services specially offered to each 
particular patient during hospitalization including the hospital stay in its subsidized 
value, operations, laboratories, injections, disposables, imaging, endoscopy and 
endoscopic injection sclerotherapy for bleeding varices.
The constant costs included besides electricity, water food, etc... the physicians and 
nurses salaries which were considered, and calculated from classified hospital records 
and budgets as an overhead per bed per day. This classification is different from the 
internationally recognized classification and terminology as the study was performed 
in a government-subsidized hospital. It should be noted that total constant costs are 
actually reached ffom the hospital classified records; this number was then broken- 
down to the number of beds in inpatient wards or number of visits in outpatient clinics 
and named as constant cost per patient in public settings. This directly relates to the 
fact that for the private institutions the actual cost could not be reached; as this was 
too private cost benefit information for any researcher to know and we had to make 
do with price comparisons in each cost component that produced factors; these factors 
help us to reaching the final calculations needed.
The total cost of hospitalization was then calculated, based on actual directly 
incurred inpatient costs calculated ffom the hospital classified records (not prices as 
they are all subsidized, lowest cost with no profit). Again, medication costs were 
available, direct non-medication costs, blood transfusion costs were also incorporated 
separately and finally constant costs for the whole of inpatient wards broken-down to 
cost per bed per day (which include medical staff, light, electricity ....).
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Data was collected, checked, revised and tabulated in excel sheets (Microsoft Excel; 
Version 2003). Duplicate data entry was performed to ensure quality control.
5.7.3. Stage three (private settings’ investigations)
Field visits and general assessments were conducted in private non-profit and private 
for profit clinics to evaluate both the supportive treatment costs and antiviral 
treatment costs for HCV outpatients with compensated and decompensated cirrhosis. 
Cost categories were divided into the following three main segments; as also seen in 
the outpatients’ investigations:
1. The medication cost (antiviral drug combination or supportive treatment
cost)
2. The direct non-medication costs (tests and consultation fees according 
to the standardized norms)
3. The constant costs (none in the private clinics’ case)
An estimated factor was worked out for the comparison of the direct non-medication 
costs segments in the private non-profit and the private for-profit clinics in relation to 
that of the NLI and was found to be 1.7 and 2.5 times that of the NLI fees 
respectively.
Similarly, field visits and general assessments were conducted in private non profit 
and private for profit hospitals to evaluate the hospitalization costs (medication costs, 
direct non medication costs, constant costs and blood transfusion) of the two medical 
settings chosen for comparison were assessed for each cost category by direct 
comparison to the public NLI setting and calculated for both the private for-profit and 
non-profit hospitals.
Cost categories were divided into the following four main segments; as also seen in 
the NLI inpatients investigations:
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1. The medication cost
2. The direct non-medication costs (tests and consultation fees according 
to the standardized norms)
3. The blood costs (included separately, due to the uneven distribution of 
blood costs over the various studied groups).
4. The constant costs (none in the private clinics case)
The data collected was used to obtain the annual cost of caring of patients with 
hepatitis C virus prescribed liver support treatment, first only as outpatients with 
compensated liver disease then with decompensated liver disease but still not needing 
hospitalization. The outcome of antiviral therapy and its cost were also obtained and 
compared with the supportive treatment's data collected and finally various 
indications of hospitalization costs of HCV inpatients were also processed and 
assessed.
5.8. Analysis and interpretation of data
A Markov model reflects the progression of the disease through different states. In 
each state costs are associated, which enables resources utilized at each stage of 
progression to be computed (Bender, 2000). It is thus possible to consider the impact 
of treatment on patient progression and resource utilization. Furthermore, Markov 
models provide a way to assess effectiveness, as the treatment creates a different set 
of probabilities of a patient moving from one stage to the next.
In this research, a model was constructed to aid the calculation of the cost of disease 
over the life cycle of the patients with hepatitis C virus following the Markov model 
of hepatitis C virus according to D'Amico et al, (1986), Arroyo et al, (1999) and 
Wong et al, (2000). The cost of each treatment plan was calculated from the data 
collected.
119
cnapter d
Design & Methodology
The quality o f the model should not be in question because of the internationally 
recognized structure of the model used for the life cycle of the disease (Wong et al, 
2000). Moreover the data used for the study was personally collected by the 
investigator directly from its original sources in the largest hepatology centres in 
Egypt dealing with HCV with a totally unbiased aspect (there was no reason or 
pressure for any bias).
The Markov model (Figure 4) of the disease life cycle over twenty years after the 
diagnosis was as follows: Patients with compensated liver disease will remain 
compensated for fifteen years following diagnosis. Sixty percent of patients will 
remain compensated for another five years (D'Amico et al, 1986; Arroyo et al, 1999 
and Wong et al, 2000). Alternatively, the remaining forty percent will develop 
decompensated cirrhosis for five years and get hospitalized for the various reasons of 
hospitalizations on average four times in the last two two years before either death or 
the eligibility of a liver transplantation (nearly one third of the patients with 
decompensated liver disease, NLI unpublished data). Patients who receive antiviral 
therapy and achieve a sustained virological response (SVR) will be considered cured 
and are excluded from further calculations (15 % for standard IFN and 55 % for PEG- 
IFN). The remaining 85 % and 45 % respectively will continue in the calculation of 
the cost as the previously described natural history model.
Nine flow charts were developed, three for each medical institution setting; one for 
the supportive liver disease treatment pathway without antiviral treatment, the second 
for the standard IFN treatment pathway and the third for the PEG-IFN treatment 
pathway; for each of the NLI, the private non-profit, and the private for-profit medical 
setting.
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Costs of disease of HCV patients were calculated and compared with the aid of the 
abovementioned flow charts and Markov models, using computer cohorts of one 
hundred patients under the three different scenarios and computed and statistically 
analysed; the supportive liver disease treatment pathway, the standard IFN treatment 
pathway and the PEG-IFN treatment pathway in each of the studied settings. Data was 
entered into a Microsoft Excel (Version 2003). Duplicate data entiy was performed to 
ensure quality control. Data was first entered concerning each group of interviewed 
patients from the hard copies compiled in NLI then each data entry was revised a 
second time by direct comparison of both hard and soft copies. The cost of each 
scenario was computed and compared among the three different settings. Data 
analysis was performed with a statistical package for personal computer and presented 
in tabular and graphical forms using SPSS version 12 for windows (SPSS, Inc., 
Chicago, IL).
Costs of the numerous treatment pathways calculated at the earlier phases of the 
research were integrated in these models assuming a conservative 5 % annual increase 
based on the fact that the rate of inflation in Egypt is 6 % and the interest rate is 8.5- 
9% according to the Central Bank of Egypt data, 2006. The chosen 5 % value is low 
because the Egyptian government has strong regulations on the pricing of drugs and 
medical services (Prices of medication and healthcare increased only 50 % or more in 
the last 10 years!).
Other facts considered while processing the calculated values in this disease 
calculation is the long life cycle of the hepatitis C virus. This led to the subjection of 
the future costs and benefits to discounting, to bring them into line with present 
values. Discounting at the recommended 3% annual rate was also integrated into the
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final figures calculated for money spent over the twenty year period of the cycle of 
the disease (Drummond et al, 2001 and Wong, 2006).
Cost effectiveness analysis (CEA) was adopted as a form of economic evaluation 
where both the costs and consequences of health treatments or programs are 
examined; it was based on existing medical evidence and literature of effectiveness 
(Gold et al, 1996 and McCombs, 1998). The costs incurred from each adopted 
substitute treatment pathway was broken down into several components and 
calculated. The benefits in terms of patient lives saved were also determined. The 
measure of effectiveness chosen is the lives saved by the health program selected, this 
gives a clear dimension to the objective of the intervention.
5.9. Summary
In Chapter two, the healthcare and economics relationship was explained along with 
the role of health technology assessment and the various procedures of economic 
evaluation. Chapter three was all about hepatitis C, its history, its infection and its 
treatments. Chapter four drew attention to the special problem of HCV in Egypt. In 
this chapter, the need to more practical prevailed, and the methodologies used to reach 
the objectives o f the study were explained and the choices made have been advocated. 
All the data collected and the field work described and performed lead to many 
outputs and results that will be explained in the coming chapter before being 
discussed in the one following that.
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The research was conducted in the National Liver Institute (NLI) Menoufia, Egypt; a 
specialized tertiary referral hospital. Access was granted via an acceptance letter from 
the hospital board, allowing presence in the staff resticted areas, in the outpatients' 
clinics and in the inpatients wards. Patient confidentiality was respected throughout 
the research, the cases were treated as anonymous cases to adhere to the ethically 
approved procedures of anonumity required by the NLI board considerd as the ethical 
committee for the hospital. The NLI is a governmental subsidized hospital. It is 
appendaged to the Medical School of Menoufia University. It is the only specialized 
center solely dedicated to liver disease. NLI has one hundred and twenty beds, it also 
has the busiest outpatient clinics with 100 000 (one hundred thousand) visits per year 
where patients are referred from all over Egypt, starting from Alexandria in the north 
to Assiut in the south. It is also noteworthy to mention that it was the first hospital in 
Egypt to initiate a liver transplant program. In addition to the NLI, specialized private 
hospitals were investigated for data comparaison; the first, a private non profit 
hospital dedicated solely for liver disease having both inpatients's wards and 
outpatients' clinics, the second, a private for profit hospital, chosen particularly 
because it is the only private hospital that performs liver transplants in Egypt; data 
concerning its inpatients was accessed. Data and costs about outpatients frequenting 
private for profit clinics were collected from three specialized and prominent 
outpatient centers.
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Figure 7: Schematic representation of the institutions under study and the 
stepwise data collection from each
Results were obtained from
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6.1 Outpatient Data
6.1.1. Cost of outpatients' treatment prescribed supportive treatment in the NLI
Data was collected from patients attending the clinics for their monthly examination 
routine checkups in the NLI. One hundred and twenty nine patients with positive 
HCV were examined, 75 of whom were males (p=0.39) and 54 were females. Those 
outpatients were divided according to the stage of liver disease into two main groups: 
patients with compensated liver cirrhosis and patients with decompensated liver 
cirrhosis prescribed supportive treatment.There was no significant difference in the 
gender distribution between the two groups (table 9).
The cost of treatment incurred by each patient was evaluated by dividing it into three 
main segments; medication costs, direct non medication costs and constant costs. 
Table 9: Gender distribution for patients grouped by severity of liver cirrhosis
Males Females Total X2 P
Compensated 43 (55%) 35 (45%) 78
Decompensated 32 (63%) 19 (37%) 51 0.735 0.391
Total 75 (58%) 54 (42%) 129
The medication costs are those of the drugs prescribed. The direct non medication 
costs are those incurred due to the direct monthly clinic admittance fee per patient and 
all the tests and the diagnostics which are shown in the following table.
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Table 10: Direct non medication cost breakdown and frequency for outpatients 
prescribed supportive treatment
Expense Cost Frequency
Clinic admittance fee 5 LE every one month
Ultrasound 40 LE every three months
Blood picture 10 LE every three months
Liver tests 40 LE every three months
Alfa feto protein 50 LE every six months
Total 520 LE For one whole year
The constant costs are those paid by the hospital and/or subsidized by the government 
as a total overhead directly injected into the hospital and calculated from its budget 
and its classified records to be 35 LE per patient per visit.
The mean total annual cost per patient per year grouped by severity o f  liver cirrhosis 
(values in Egyptian pounds) in table 11 shows that the medication cost o f the 
decompensated group at 1 675 LE is significantly higher than the 1 306 LE o f  the 
compensated group at p<0.05 (table 11). Those values constitute 58% and 64% o f  the 
mean annual cost for the compensated and decompensated groups respectively. This 
value is shown to decrease slightly in the private non profit hospital (53.3% for 
compensated patients and 59.4% for decompensated patients) and is nearly halved for 
private for profit hospitals, with values 32 % and 37.8 % respectively (Table 16 and 
17).
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Table 11: Means of annual cost per patient per year grouped by severity of liver
cirrhosis in the NLI (Values in Egyptian Pounds)
Compensated Decompensated
Constant** 420 (35*12) 420 (35*12)
Direct non medication 520 520
Medication 1,306 1,675*
Mean total annual cost 2,246 2,615*
* Significant at the 0.05 level using t-test
**The C onstant costs are those subsidized by the government as total overhead calculated from the 
hospital classified records as 35 LE per patient per visit.
All patients were prescribed variable combinations o f 53 drugs (table 12). For 
statistical analysis similar drugs were then grouped in 10 categories as follows; 
lactulose, hepamerz & neomycin drug category, liver support category, vitamins 
category, diuretics category, propranolol & mononitrate (B blockers category), acid 
suppressants category, antidiabetics, antihypertensives, antispasmodics and others’ 
category (table 13).
Table 14 shows the breakdown o f the means o f annual medication costs per patient 
per year grouped by severity o f liver cirrhosis. The table shows the significantly 
higher value o f liver support drug category for the decompensated patient group 956 
LE versus that o f the compensated patient group 533 LE (p<0.05). However, the 
significantly lower value o f acid suppressants drug category for the same patient 
group (p< 0.05) is also seen. The values are evenly distributed over the remaining 8 
drug categories with the propranolol & mononitrate category noticeably lower than 
the other categories (82 LE and 72 LE for both patient groups) while the lactulose, 
hepamerz & neomycin category especially higher than the other categories (1,231 LE 
and 916 LE for both patient groups).
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Table 12: List of drugs prescribed to HCV outpatients
1 Legal on 15 Aldactone 100 29 Ranitidin 300mg 43 Ultraproct supp
2 Vit E 100 16 K viton 30 Ranitidol 150 mg 44 Omipac lOmg
3 Vit E400(Pharco) 17 K viton 31 Ranitak 150mg 45 Omipac 20mg
4 Vit E400(Mepaco) 18 E viton 32 Ranitak 300mg 46 Dactarine
5 Vit B Complex 19 Dipovit amp. 33 Monomac 20 47 Ventoline
6 Colospasmin 20 Neomycin 34 Amaryl lg 48 Captopil
7 Antox 21 Hepamerz 35 Amaryl 2g 49 Diflucan
8 Farcovit 22 Multivitoplex 36 Amaryl 3g 50 Insulin
9 Zantac 23 Motinorm 37 Burinex 51 Mixtard
10 Spasmo digestin 24 Amrizol 500mg 38 Burinex 52 Migracid
11 T r i - B 25 Copoten 39 Citrocid 53 Edimex
12 Indral 26 Konakion 300mg 40 Domperidone
13 Ursofalk 27 Lactulose 41 Epimag Eff
14 Heamaton 28 Ranitidinl50mg 42 Capoten 25mg
Table 13: Drug categories prescribed to HCV outpatients
1 Lactulose, Hepamerz & Neomycin
2 Liver Support
3 Vitamins
4 Diuretics
5 Propranolol & Mononitrate
6 Acid Suppressants
7 Antidiabetics
8 Antihypertensives
9 Antispasmodics
10 Others
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Table 14: Mean annual medication costs per patient grouped by severity of liver 
cirrhosis (Values in Egyptian Pounds)
Drug categories Compensated Decompensated
Lactulose, Hepamerz & Neomycin 916 1,231
Liver Support 533 956*
Vitamins 165 141
Diuretics 299 420
Propranolol & Mononitrate 82 72
Acid Suppressants 677 501*
Antidiabetics 545 576
Antihypertensives 360 504
Antispasmodics 257 230
Others 177 200
* Significant at the 0.05 level using t-test
Figure 8 illustrates the percentages of the mean annual medication costs per patient 
per year grouped by severity of liver cirrhosis in a relative pie chart with the 
decompensated group larger than its counterpart. This figure shows that the acid 
suppressants and liver supports drug categories are significantly larger (p<0.05) in the 
decompensated group. Table 15 and figure 8, emphasizes the difference in values and 
percentages respectively along with highlighting a difference in the antispasmodics
|
category values for both groups which was not otherwise apparent.
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Figure 8: Percentages of means of annual medication costs per patient per year 
grouped by severity of liver cirrhosis (Values in Egyptian Pounds)
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Table 15: Total annual medication costs in each drug category grouped by 
severity of liver cirrhosis (Values in Egyptian Pounds) and means of 
annual Drug categories costs’ percentages per patient group
Drug categories Compensated Decompensated
Lactulose, Hepamerz & Neomycin 8248 8.1 % 9851 11.53 %
Liver Support 39444 38.73 % 43989 51.48 %
Vitamins 5774 5.67 % 4357 5.1 %
Diuretics 2688 2.64 % 11344 1 3 .28%
Propranolol & Mononitrate 1148 1.13 % 792 0.93 %
Acid Suppressants 27099 26.61 % 9018 10.55 %
Antidiabetics 2726 2.68 % 576 0.67 %
Antihypertensives 720 0.71 % 1008 1 .1 8 %
Antispasmodics 13122 12.88 % 3906 4.57 %
Others 884 0.87% 600 0.70 %
Total 101854 1 0 0 %  85441 1 0 0 %
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Table 15 shows the total annual medication costs in each drug category grouped by 
severity of liver cirrhosis for all 129 patients, the liver supports are understandably the 
highest costing category; they are then followed by the acid suppressants and the 
diuretics in the compensated and decompensated groups respectively. The breakdown 
of the means of annual medication costs percentages’ per patient per year grouped by 
severity of liver cirrhosis (table 15) shows the higher value of liver support in addition 
to lactulose, hepamerz & neomycin drug categories on the weight of the total 
medication cost (46.8%) for the compensated drug group versus (63.1%) the 
decompensated patient group. However, vitamins drug category values are nearly 5 % 
in both patients groups. Figure 9 colourfully illustrates the relative weight of the 
various drug categories on the total cost of treatment in each patient group as 
percentages. The lactulose, hepamerz & neomycin and liver support drug categories 
are prominent in both patient groups, and acid suppressants stand out in the 
compensated group, while diuretics do so in the decompensated patients's 
prescriptions. Following the line of prescription analysis figure 9 also shows the 
parallelism of values in the liver support, Lactulose; Hepamerz & Neomycin and 
vitamins drug categories while diuretics and acid suppressants alternate by being 
weightlier in the decompensated and compensated patients' groups respectively.
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Figure 9: Medication costs (% of total) in each drug category grouped by 
severity of liver cirrhosis
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6.1.2. Cost o f outpatients' treatment prescribed supportive treatment in private 
clinics
Field visits and general surveys were conducted in private non profit and private 
profit clinics to assess the supportive treatment costs for HCV patients with 
compensated and decompensated cirrhosis. The medication costs in both private 
settings are similar to those o f the NLI due to the mandatory regulations o f the 
Ministry o f Health and Population standardizing the price o f drugs throughout all 
medical institutions and outlets in the country. It is vital to point out that there are no 
constant fees in the private medical settings as they are financially independent non 
subsidized medical entities.The direct non medication costs were calculated by 
comparing the values o f the consultation fees, and medical tests: ultrasound, blood 
picture, liver tests, alfa feto protein, and working out a factor in relation to the direct
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non medication costs for the outpatients in NLI. This factor was calculated to be 1.7
and 2.5 times o f the non medication direct costs o f the NLI for the private non profit
and the private for profit clinics respectively (Tables 16 & 17).
Table 16: Means of annual cost per patient per year grouped by severity of liver 
cirrhosis in private non profit hospital
Compensated Decompensated
Medication 1,306 1,675
Direct non medication 1142 1142
Constant NA NA
Total 2,448 2,817
The direct non medication cost is 1.7 times that of the NLI. The cost of consultation is 30 LE.
Table 17: Means of annual cost per patient per year grouped by severity of liver 
cirrhosis in private for profit clinics
Compensated Decompensated
Medication 1,306 1,675
Direct non medication 2,750 2,750
Constant NA NA
Total 4,056 4,425
The direct non medication cost is 2.5 times that of the NLI. The cost of consultation is the average o f 80LE, 
120LE and 300LE.
6.1.3. Cost of outpatients' treatment prescribed antiviral drug treatment 
- In NLI
Patients with compensated liver disease, visiting the outclinics o f  the NLI, who were 
prescribed ribavirin and interferon (IFN) or pegylated interferon combination therapy 
were investigated and included in the research.
The antiviral combination treatment course included: conventional IFN injections 
three million units three times weekly and 1200 mg ribavirin daily, for one year 
(Zaraski, 1999; Dusheiko e t  al, 2000; Buti e t  al, 2002; Dusheiko, 2002 and Davis e t
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al, 2003), or pegylated IFN injections three million units once weekly and 1200 mg 
ribavirin daily for one year (Zaraski, 1999; Dusheiko et al, 2000 and 2002; Buti et al, 
2002 and Davis et al, 2003).
Patients were given the antiviral medication and the viral load was monitored for the 
first three months, when the responders and the non responders were indentified. The 
non responders were given the supportive treatment alternative and were excluded 
from this study group. While responding patients, those with a decreased viral count, 
continued to take the medication for the remainder of the 12 months.The success of 
the treatment was assessed by the sustained virological response (SVR) six months 
after cessation of treatment.
Two hundred and twenty patients were treated with conventional IFN injections in 
combination with ribavirin, they had viral count laboratory testing (PCR) performed 3 
months after initiating the treatment, 12 months and finally 18 months later to 
determine the SVR which turned out to be 15.9%; i.e 35 patients were cured from 229 
patients.
Another group of one hundred patients were treated with pegylated IFN injections in 
combination with ribavirin, they had viral count laboratory testing (PCR) performed; 
3 months after the beginning of the treatment, 12 months and finally 18 months later 
to determine the SVR which was calculated to be 54%; i.e 54 patients were cured 
from 100 patients.
The direct non medication costs are those incurred due to the clinic admittance or 
consultation fee totalling 30 LE in 18 months and all the laboratory testing which 
were performed during the whole treatment period; according to the following table.
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Table 18: Direct non medication cost breakdown and frequency for NLI 
outpatients prescribed antiviral treatment
Expense Cost Frequency
Blood picture 10 LE every one month
Liver function tests 40 LE every one month
Polymerase chain reaction (PCR) 500 LE every three months
Consultation fee 5 LE every two months
Total direct non medication cost 2630 LE For one whole year
The constant costs are those paid by the hospital or subsidized by the government as 
a total overhead cost, directly injected in the hospital and calculated from its budget 
and its classified records. Its value was calculated to be 210 LE per patient in 18 
months.The clinic admittance or consultation fee, the laboratory testing costs and the 
constant costs are grouped together in table 19 and added to have total non medication 
cost (2,840 LE) grouped seperatly in this case o f total antiviral treatment costing for 
ease o f calculation.
The medication costs are assessed by summing the drugs prices o f the combination 
therapy prescribed and calculated as follows:
A. The standard interferon injection costs 45 LE, amounting to 
135 LE for three times per week and the pegylated form costs 
485 LE and is given once weekly. The total interferon and 
pegylated interferon treatment one year course costs 6 480LE 
and 23 280 LE respectively.
B. Ribavirin dose is 1200mg/ day and 12 capsules 400mg cost 
72 LE, totaling 6 570 LE per patient per year.
137
Results
From A & B: The medication costs for a patient treated with of interferon - ribavirin 
combination would be 13 050LE which is the sum of both interferon 6 480LE, and 
ribavirin 6 570 LE.
The total treatment cost for the same patient treated with interferon combination 
therapy is the sum of the antiviral medication cost and the total non medication cost 
(<clinic admittance or consultation fee, the laboratory testing costs and the constant 
costs) as per the frequency of the table 19 would be 15 890 LE (table 20).
From A & B: The medication costs for a patient treated with pegylated interferon - 
ribavirin combination would be 29 850 LE which is the sum of both interferon 
23 280LE and ribavirin 6 570 LE.
The total treatment cost for the same patient treated with the pegylated interferon 
combination therapy is the sum of the antiviral medication cost and the total non 
medication cost (<clinic admittance or consultation fee, the laboratory testing costs 
and the constant costs) as per the frequency of the table 19 would be 32 690LE (table 
21).
The difference in the cure rate is a little more than tripled (15.9% versus 54%) and the 
difference in the price of the interferon / pegylated interferon weekly dose is a little 
less than quadrupled (6 480:23 280) but the final comparison of the total treatment 
cost of both alternatives is more than doubled (15 890:32 690).
- In private medical settings
The same calculations were done for the two other private medical settings, namely 
the private for profit and the private non profit clinics that were chosen for the study. 
The total non medication costs {clinic admittance or consultation fee, the laboratory 
testing costs and the constant costs) as per the frequency of the table 19 for the private 
non profit hospital and the private clinics was determined to be 4 780LE and 8 100LE
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respectively. It is important to point out that there are no constant fees in the private 
medical settings as they are financially independent non subsidized medical entities. 
The total treatment cost for a patient treated with the interferon combination therapy 
would be 17 830LE and 21 150LE in the privat non profit hospital and the private 
clinics respectively (Table 20). While the total treatment cost for a patient treated 
with the pegylated interferon combination therapy would be 34 630LE and 37 950LE 
in the private non profit hospital and the private clinics respectively (Table 21).
A very important detail was observed from tables 20 and 21; the total cost o f the 
cured patient (integration o f both the cure rate and the total treatment cost) treated 
with the seemingly more expensive pegylated interferon combination therapy is less 
than the standard interferon alternative in a ll three medical settings.
Table 19: Comparison of total non medication cost/year in the NLI, the private
non profit hospital and the three private clinics
N am e of
medical
institution
N am e and 
frequency o f  test
Menoufiva
NLI
/ Y e a r
Private non 
profit hospital
/ y e a r
Private
clinics
/ Y e a r
Monthlv blood picture 120 LE 204 LE 300 LE
Monthlv liver function 
tests 480 LE 816 LE 1200 LE
Ouarterlv PCR 2000 LE 3400 LE 5000 LE
Consultation fee 
(6times/vear) 30 LE 360 LE 1600 LE
Constant cost ** 210 LE OLE OLE
Total cost 2 840 LE 4 780 LE 8 100 LE
**The C onstant costs are those subsidized by the government as total overhead calculated from the 
hospital classified records.
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Table 20: Total cost of treatment of each cured patient treated with interferon 
and ribavirin combination in the three medical settings
Menoufiya
NLI
Private non 
profit hospital
Private for profit 
clinics
Cost o f  each pt of  
the 220 pts
13 050+2 840 = 
15 890 LE
13 050+4 780 = 
17 830 LE
13 050+ 8 100 = 
21 150 LE
Cost per cured 
pt (n=35) * 99 880 LE 112 074.28 LE 132 942.85 LE
* is the num ber o f  cured patients
Table 21: Total cost of treatment of each cured patient treated with pegylated 
interferon and ribavirin combination in the three medical settings
Menoufiya
NLI
Private non 
profit hospital
Private for profit 
clinics
Cost per patient 
(1 OOpts)
29 850+2 840 = 
32 690 LE
29 850+4 780 = 
34 630 LE
29 850+8 100 = 
37 950 LE
Cost per cured 
patient (n=54) * 60 537.03 LE 64 129.62 LE 70 277.77 LE
* is the num ber o f  cured patients
6.2. Inpatient Data
One hundred and eighty three positive HCV hospitalized patients' records were 
examined in the NLI; nearly 10% o f the total number o f patients in 2003; 165 patients 
were males and 18 patients were females. Table 22 shows that patients were mostly 
males in all subgroups and there was no statistical significance in the gender 
distribution o f the different groups (p =0.699).
Table 22: Gender distribution for patients grouped by reason of hospitalization
Males Females Total X 1 P
Ascites 25 (96%) 1 (4%) 26
Bleeding 65 (89%) 8(11%) 73
Coma 44 (90%) 5(10%) 49 2.201 0.699
HCC 3 (75%) 1 (25%) 4
Others 28 (90%) 3 (10%) 31
Total 165 (90%) 18(10%)
ocT—l
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The patients were then arranged according to the reason of their hospitalization, into 
five groups as follows:
•  Group 1: Patients hospitalized for the management of refractory ascites that 
complicates liver cirrhosis (ascites group).
•  Group 2: Patients hospitalized for bleeding varices in the esophagus and 
stomach due to portal hypertension secondary to liver cirrhosis (bleeding 
group)
• Group 3: Patients hospitalized for hepatic coma due to advanced liver disease 
(Coma group)
• Group 4: Patients hospitalized for liver malignancy and hepatocellular 
carcinoma (HCC group).
• Group 5: Patients hospitalized for other complications due to liver cirrhosis 
(others group).
The cost of care given to each patient was evaluated starting with categorizing it into 
four main segments;
1. the medication cost
2. the direct non medication costs
3. the blood costs
4. the constant costs (as labelled in this study)
The medication costs (medication costs) are the costs of drugs given to the patient 
during hospitalization. The direct non medication costs include all the needs and 
services offered to the patient during hospitalization including the hospital stay, 
operations, laboratories, injections, disposables, imaging, endoscopy and endoscopic 
injection sclerotherapy for bleeding varices. The blood costs are those incurred by 
blood transfusion and were separately included due to the uneven distribution of 
blood over the various studied groups. The constant costs are those directly paid by 
the Ministry of Health and Population in the form of subsidy to the NLI and including 
the physicians' and nurses salaries, electricity, water, food, etc as calculated from
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classified hospital records as an overhead per bed per day. This is based on the fact 
that this study was mainly performed in the NLI, a public hospital, and that the 
government of Egypt subsidizes the medical services given in all public medical 
institutions.
This is different from the internationally standardized terminology since the 
breakdown of the hospital budget was not laid out to complement the data needed for 
the international format and only included costs paid by patients or institutional payer 
and then there was the government subsidy to the hospital which was then processed 
to a value per patient per bed. The data lacked the indirect cost seperatly categorized 
as is the norm.
The breakdown of the means of costs of caring per patient grouped by reason of 
hospitalization as shown in table 23, highlighted that blood transfusion cost was 
significant in patients hospitalized for bleeding and ascites compared to the other 
groups (p>0.05). Table 23 also shows that ascites patients have the highest constant 
costs' values versus the bleeding patients who had the lowest values though non 
significantly so (p>0.05). This could be related to the mean length of hospital stay 
shown in figure 12. The mean total cost is high for the group of patients labelled 
others and HCC patients (5 481 LE and 4 670 LE respectively), which is very 
apparent in figure 13. However, the significantly high medication costs for bleeding 
patients 1 038 LE at p<0.05 affected the mean total costs of 3 713 LE but not enough 
to overcome the mean total costs of the ascites group 4 019 LE which comes third in 
decreasing order of the means of the total costs that ends with 3 477 LE for the coma 
patients. On the other hand, the direct non medication costs' values were greatest for 
the patients labelled others group and least for the bleeding group but still non 
significantly so (p>0.05). The medication and blood costs were found significantly
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higher for the bleeding patients. This is graphically represented by a bar chart in 
figure 11.
Table 23: Means of costs per patient grouped by reason of hospitalization 
(Values in Egyptian Pounds)
Ascites Bleeding Coma HCC Others
Medication 594 1,038* 632 460 362
Direct non medication 776 676 753 1,890 2,677
Blood 242** 302** 117 85 109
Constant 2,407 1,697 1,975 2,236 2,333
Total 4 019 3 713 3 477 4 670 5 481
* Significant when compared to groups: ascites, coma and others 
** Significant when compared to groups: coma and others
Figure 11: Breakdown of the means of costs per patient grouped by reason of 
hospitalization (Values in Egyptian Pounds)
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The bar chart (figure 12) illustrates the mean length o f hospital stay per patient group 
grouped by reason of hospitalization (values in days). The ascites patients come first 
with 9.2 days, followed by the others, HCC and coma patients with values o f 8.9, 8.5 
and 7.5 days respectively, bleeding patients tail the groups with a value o f 6.5 days.
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Figure 12: Mean length of hospital stay per patient grouped by reason of 
hospitalization (Values in days)
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Figure 13: Mean total costs per patient grouped by reason of hospitalization 
(Values in Egyptian Pounds)
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All patients were prescribed variable combinations o f 154 drugs shown in table 24. 
For statistical analysis similar drugs and drugs used for similar conditions were then 
grouped in 15 categories as follows; lactulose, hepamerz & neomycin drug category,
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mononitrate (B blockers category), acid suppressants category, antidiabetics category, 
antihypertensives category, antispasmodics category, vasopressors category, 
analgesics category, fluid replacements, immunosuppressants, antibiotics and others' 
category shown in table 25.
Table 26 shows the breakdown of the mean cost of medication per patient for each 
drug group grouped by reason of hospitalization (values in Egyptian Pounds). The 
highest mean cost is the fluid replacements category followed by antihypertensives 
and antibiotics. All three categories' values were evenly distributed among the various 
patient groups. However the vasopressor category was significantly higher for the 
bleeding group 578.7 LE compared to the ascites 212 LE, coma 211.8 LE and others 
group 98 LE, while the diuretics category was significantly lower for the same group 
1.7 LE compared to the ascites 6.1 LE and coma 4.4 LE groups. The others drug 
categoiy was noticed to be 79.3 LE for HCC patients, significantly higher compared 
to all other groups at p <0.05.
Figure 14 is a relative pie chart representating the means of totals of medication costs 
per patient in each drug group, it points to the discernible impact of vasopressors 
(578.7 LE) cost on the total cost of the bleeding patients (1037.8 LE), while the fluid 
replacements drug category is noticeable in both the ascites and HCC patient groups 
(449.8 LE of 593.7 LE) and (277 LE of 460 LE) respectively, finally, the antibiotics 
drug category (241.1 LE) cut a sizeable chunk of the HCC group pie (460 LE).
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Table 24: List of drugs given to inpatients for all reasons of hospitalization
1 1 Alfa amino 53 Cyclocabron 104 Lignocain Oint
2 Acupan 54 Cyclocortiv 105 Losec
3 Adrenalin 55 Dactarin gel 106 Markin Vial
4 Adrenaline amp 56 Depotrex 107 Maxim Vial
5 Airocsol oint 57 Diamicron 108 Mediatic
6 Albumin 58 Dicinone 109 Metomycin
7 Aldacton 59 Dipovit Amp 110 Micazol oint
8 Aldacton cap 60 Dopamin 111 Minophillin
9 Amarol 61 Dormicam 112 Minophillin Surup
10 Amax Tab 62 Dysflatyl 113 Mitophillin
11 Aminophillin 63 E Viton 114 Morphin amp
12 Aminophillin Syp 64 Edimex 115 Motillium
13 Aminovit amp 65 Emox 116 Mucopect syrup
14 Amoran Tab 66 Epideron 117 Muril Amp
15 Amoxil 67 Epilat 118 Neomycin
16 Amoxillin 68 Ethanol 119 Novalgin
17 Amprexol syrup 69 Ethanol amine 120 Omipac amp 10ml
18 Amricol Syrp 70 Evox 121 Omipac amp 20ml
19 Amrizol 71 Evox 20ml 122 Osipect syrup
20 Anital 72 Farcoline 123 Paramol
21 Antox 73 Filden gel 124 Paramol Syrp
22 Apidram Vial 74 Flagyll 125 Pecidin
23 Atropin 75 Fortum 126 Pecidin
24 Augmentin 76 Frutal 127 Penicillin 40 unit
25 Avil 77 Garamycin 128 Penicillin 80 unit
26 Avrin Amp 78 Garamysin oint 129 Phenytoin gel
27 Biomex 500-bedamex 79 Gastrovit 130 Potassium Chloride
28 Bisolvan 80 Geramysin oint 131 Potassium Syp
29 Bisolvan amp 81 Glycerin 132 Primpran
30 Bronchofen 82 Glyopressin 133 Prisanine
31 Buscopan 83 Hepamyrs 134 Salperazone
32 Calcimat 84 Heparin 135 Sandostatin
33 Calcimat amp 85 Histoacryl 136 Sodium bicarbonate
34 Calcium 86 Histryl 137 Solukortif
35 Calma Tab 87 Ibrazol 138 Spasmodigestin tab
36 Capiton 88 Ibrazol tab 139 Tavanic
37 Capoten 89 Indral 140 Tavanic Vial
38 Capotril 90 Insulin 141 Teramycin
39 Cedofaxin amp 91 K Viton 142 Theragran
40 Cefopid 92 Kantolock 143 Tramal
41 Cefotax 93 Klaforan 144 TriB amp
42 Cifarol 94 Klosram 145 Unasyn Vial
43 Cilimarin 95 Konakion 146 Ursocol
44 Cipro 96 Konakion tab 147 Ursofalk
45 Cipro vial 97 Kostram 148 Valium syrup
46 Cital 98 Kupect 149 Ventanyl amp
47 Cital tab 99 Lactulose 150 Zantac
48 Claritine 100 Lanoxin 151 Zantac Tab
49 Clixan 20ml 101 Lasix 152 Zestrel
50 Clixan 40ml 102 Legalon tab 153 Zylocain
51 Colimex syrup 103 Levanox 154 Saline for dehydration
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Table 25: Drug categories given to inpatients for all reasons of hospitalization
1 Lactulose, Hepamerz & Neomycin
2 Liver Support
3 Vitamins
4 Diuretics
5 Propranolol & Mononitrate
6 Acid Suppressants
7 Antidiabetics
8 Antihypertensives
9 Antispasmodics
10 Vasopressors
11 Analgesics
12 Fluid Replacements
13 Immunosuppressants
14 Antibiotics
15 Others
Table 26: Mean cost of medication per patient for each drug group grouped by
reason of hospitalization (values in Egyptian Pounds)
Drug categories Ascites Bleeding Coma HCC Others
Lactulose, Hepamerz & 
Neomycin 22.3 17.5 59.5 7.9 24.7
Liver Support 18.7 7.3 25.3 - 16.5
Vitamins 4.9 3.8 6.9 3 4.7
Diuretics 6.1 1.7* 4.4 6.1 4.4
Propranolol & Mononitrate 0.6 0.3 0.3 - 0.6
Acid Suppressants 18 20.5 21.9 39.8 25
Antidiabetics 16.3 26.2 18 - 93
Antihypertensives 280.1 275.1 282.1 - 165.1
Antispasmodics 2.4 1.4 0.9 - 2.3
Vasopressors 212 578.7** 211.8 22.6 98
Analgesics 3.4 1.7 1.7 3.5 2.2
Fluid Replacements 449.8 74.3 506.7 277 157.9
Immunosuppressants 4.4 7.4 10 5.8 3.8
Antibiotics 246.9 196.4 227.2 241.1 216.8
Others 9.7 7.8 8.4 79.3*** 13.1
Significant when compared to groups: ascites and coma at p < 3.05.
** Significant when compared to groups: ascites, coma and others at p <0.05. 
*** Significant when compared to all other groups at p <0.05.
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Figure 14 shows the effect o f the cost weight o f the antibiotics and vasopressors drug 
categories on the grand total and each drug group total, the antihypertensives and fluid 
replacements are also emphasized throughout the groups. Figures 14 equally illustrate 
the weight o f each drug category in each patient group, emphasizing the perceptible 
cost effect of the antihypertensives and the vasopressors drug categories on all but the 
HCC patient group while the fluid replacement drug category cost is more evident in 
that group. Figure 15 illustrates also the percentage o f each drug category on the total 
medication costs for each group o f inpatients.
14: Mean medication costs per patient in each drug group grouped by
reason of hospitalization (values in Egyptian Pounds)
A s c ite s 1037.8 C o m a
.6
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Figure 15: M edication costs of inpatients (% of total)
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Table 27 shows the means o f costs per patient p e r  d a y  grouped by reason of 
hospitalization (values in Egyptian Pounds). It shows the significantly higher values 
o f both the medication (193 LE) and blood costs (52 LE) for the bleeding patients 
compared to all groups (p<0.05). The table also shows the constant value o f 263 LE 
o f the constant costs for all groups. It was calculated from hospital records as a value 
per bed per day.
Finally there was no significant difference in the values o f the direct non medication 
costs throughout the groups with the others group having the highest value o f 484 LE 
per day and the ascites group having the lowest with 88 LE.
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Table 27: Means of costs per patient p e r  d a y  grouped by reason of hospitalization 
(Values in Egyptian Pounds)
A scites B leeding C om a H C C O th e rs
M edication 64 193* 89 61 49
Direct non medication 88 117 126 183 484
Blood 29 52* 20 8 12
Constant 263 263 263 263 263
Total 444 625 498 516 809
• Significant when compared to all other groups
Figure 16 shows the mean total costs per patient p e r  d a y  grouped by reason of  
hospitalization (values in Egyptian Pounds). The mean is high for the others patients’ 
group (809 LE) followed by the bleeding patients’ group with 625 LE per day, while 
the mean becomes low for the coma patients’ group (498 LE per day) and lowest for 
the group o f ascites (444 LE).
Figure 16: Means of costs per patient p e r  d a y  grouped by reason of 
hospitalization (Values in Egyptian Pounds)
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Figure 17: Means of total costs per patient p e r  d a y  grouped by reason of
hospitalization (Values in Egyptian Pounds)
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Table 28: Means of costs per patient grouped by reason of hospitalization in 
private non profit hospital (Values in Egyptian Pounds)
Ascites Bleeding Coma HCC Others
Medication 594 1,038 632 460 362
Direct non medication
( th e o ld  va lu e s  h a ve  
h o s p ita l  s ta y  in c lu d ed )
1368 1222 1356 3610 5176
Hospital Stay 690 488 563 638 668
Medical Supervision 1104 780 900 1020 1068
Blood 242 302 117 85 109
Total 3 998 3 829.5 3 567.5 5 812.5 7 382.5
The cost o f  direct non m edication treatm ent is two and a ha lf times that o f  the NLI. The cost o f  
consultation is the average o f  SOLE, 120LE
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Table 29: Means of costs per patient per day grouped by reason of hospitalization
in private non profit hospital (Values in Egyptian Pounds)
Ascites Bleeding Coma HCC Others
Medication 64 193 89 61 49
Direct non medication
(ithe o ld  v a lu e s  h ave  
h o s p ita l  s ta y  in clu ded )
156 214 232 346 948
Hospital Stay 75 75 75 75 75
Medical supervision 120 120 120 120 120
Blood 29 52 20 8 12
Total 444 654 536 610 1 204
The cost o f  direct non medication treatment is twice that o f the NLI. The cost o f  medical supervision is 
120LE. The cost o f  hospital stay is 75 LE.
Table 30: Breakdown of the means of costs per patient grouped by reason of 
hospitalization in a private for profit hospital (Values in Egyptian 
Pounds)
Ascites Bleeding Coma HCC Others
Medication 594 1,038 632 460 362
Direct non medication
{th e  o ld  v a lu e s  h ave  
h o sp ita l s ta y  in clu ded)
6 840 6 110 6 780 18 050 25 880
Hospital Stay 3 680 2 600 3 000 3 400 3 560
Medical Supervision 2760 1950 2250 2550 2670
Blood 242 302 117 85 109
Total 14 116 12 000 12 779 24 545 32 581. V > . . . . . . . .
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Table 31: Means of costs per patient per day grouped by reason of hospitalization
in a private for profit hospital (Values in Egyptian Pounds)
Ascites Bleeding Coma HCC Others
Medication 64 193 89 61 49
Direct non medication
{th e  o ld  va lu es h ave  
h o s p ita l  s ta y  in clu ded)
780 1 070 1 160 1 730 4 740
Hospital Stay 400 400 400 400 400
Medical supervision 300 300 300 300 300
Blood 29 52 20 8 12
Total 1 573 2 015 1 969 2 499 5 501
The cost o f  direct medication treatment is ten times that o f  the NLI. The cost o f  medical supervision is 
300LE. The cost o f  hospital stay is 400LE.
6.3. Cost of disease and cost effectiveness of antiviral treatment
6.3.1. Computed cost of disease
The aforementioned calculated data and figures, collected from the NLI, used as 
backbone model for the study and from the private settings (both for profit and non­
profit), used as comparative models for a more comprehensive study, were entered 
into a Microsoft Excel (Version 2003). Duplicate data entry was performed to ensure 
quality control. The data was assessed using SPSS according to a computer cohorts o f  
100 patients constructed based on the Markov models adopted from the literature 
(D'Amico e t  al, 1986; Arroyo e t al, 1999 and Wong e t  al, 2000). It is noteworthy to 
mention that the hepatitis C virus disease costs are incurred constantly over the life 
cycle o f the disease, assuming a twenty year follow-up period. Data analysis was 
performed with a statistical package for personal computer SPSS (version 9; SPSS, 
Inc., Chicago, IL) to calculate the cost o f each year o f the disease for a full cycle. 
Because the time horizon for development o f complications from HCV infection may 
be twenty years, Markov computer models have been developed to simulate the likely 
outcomes with a cohort o f 100 patients for the three treatment scenarios studied; the
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supportive treatment alternative pathway and both antiviral treatment alternatives; the 
interferon ribavirin combination pathway and the peginterferon ribavirin combination 
pathway.
The official inflation rate in Egypt is 11.8 % and the mid Central Bank interest rate 
corridor is 9.75 % (CBE, 2006), incorporating this data with the fact that due to the 
government regulations and control on the pricing of drugs and medical services, the 
prices of drugs increased nearly 50 % over the last ten years, lead to the incorporation 
o f a 5 % annual increase over the projected twenty years of the study, this over a 
twenty year period would lead to an increase of 110 % on any sum spent today. With 
all considerations of virus developments, inflation and discounting as well as liver 
transplantation costs were integrated into the final results; estimating the cost of 
disease, the cost of treatment and the number of lives saved by each of the treatment 
pathways chosen in each of the three medical settings under study; the National Liver 
Institute, the private non profit and for profit hospitals.
Processing and calculating the total costs of the disease and the treatment for the one 
hundred patients over a twenty year period is as follows: In the absence of antiviral 
treatment, the lifetime undiscounted costs of disease via the supportive treatment 
pathway including the cost of treatment and of complications, particularly 
decompensated cirrhosis and liver transplantation as computed in this study amounts 
to: 144 872 LE, 187 373 LE and 339 041 LE per patient in each of the medical 
settings included; namely the National Liver Institute, the private non-profit and the 
private for profit hospitals respectively. In the presence of the antiviral treatment, the 
lifetime undiscounted costs of disease via the standard interferon treatment pathway 
amounts to: 92 155.61 LE, 111 807.58 LE and 196 054.74 LE per patient in each of 
the medical settings included; namely the National Liver Institute, the private non­
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profit and the private for profit hospitals respectively, while the lifetime undiscounted 
costs of disease via the pegylated interferon treatment pathway amounts to: 75 704.6 
LE, 89 179.5 LE and 142 573.5 LE per patient in each of the medical settings 
included; namely the National Liver Institute, the private non-profit and the private 
for profit hospitals respectively (Table 32).
Table 32: Undiscounted cost of the disease according to the various treatment 
pathways per patient in 20 years in each of the chosen medical settings
Pathway
Menoufiya
NLI
Private non 
profit hospital
Private for 
profit hospital
Cost /  patient in 20 years Supportive
treatment
144 872.23 LE 187 373.83 LE 339 041.37 LE
Cost / patient in 20 years Interferon
treatment
92 155.61 LE 111 807.58 LE 196 054.74 LE
Cost / patient in 20 years Pegylated
interferon
treatment
75 704.61 LE 89 179.5 LE 142 573.49 LE
Table 33: Total cost of disease and treatment and mortality over 20 years of all 
one hundred patients according to the various treatment options 
available in each of the chosen medical settings using SPSS computer
software
Pathway
Menoufiya 
NLI cost
Mortality 
over 20 
years
Private non 
profit 
hospital 
cost
Mortality 
over 20 
years
Private for 
profit hospital 
cost
Mortality 
over 20 
years
Supportive
treatment
14 487 223 
LE
20
18 737 383 
LE
20 33 904 137 LE 20
Interferon
treatment
9 215 561
LE
10
11 180 758
LE
10 19 605 474 LE 10
Peevlated
interferon
treatment
7 570 461 
LE
6
8 917 950
LE
6 14 257 349 LE 6
Taking into consideration that hepatitis C virus disease cycle extends over a twenty 
year period and this study considers money expenditure; money spent today is not like
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money spent years later so a discount factor of the standard 3% was used as well as 
inflation and interest rates on the costs was incorporated into the cost calculations 
using SPSS computer software.
It is important to mention that the above calculated values were undiscounted so the 
same calculations were repeated after discounting all future costs from the cost of the 
disease and cost of treatment in the various pathways chosen to further emphasize the 
effectiveness of one route versus the others and adjust to the long term life cycle of 
the disease. This was performed by substracting the immediate costs (first year costs) 
(Tables 34-36) from the total costs of disease and treatment over the 20 years cycle.
Table 34: Total discounted cost of disease and treatment over 20 years of the one 
hundred patients according to the various treatment options available 
with its breakdown to the first year immediate costs and all future 
costs in the National Liver Institute using SPSS computer software
Pathway
NLI total 20 
year cost 
(Table 33)
Immediate
costs
Future costs
Discounted 
Future costs 
values
Totals
Supportive
treatment
14 487223 LE None incurred 14 487 22 LE 8 021 575.38 LE 8 021 575.38 LE
Interferon
treatment
9215 561 LE 960 353 LE 8 255 208 LE 4 570 908.67 LE 5 531 261.67 LE
Peevlated
interferon
treatment
7 570 461 LE 2 378 140 LE 5 192 321 LE 2 874 988.138LE 5 253 128.14 LE
In the absence of antiviral treatment, the lifetime discounted costs of disease via the 
supportive treatment pathway including the cost of treatment and of complications, 
particularly decompensated cirrhosis and liver transplantation as computed in this 
study amounts to: 80 215.8 LE, 103 748.9 LE and 187 727.2 LE per patient in each of 
the medical settings included; namely the National Liver Institute, the private non­
profit and the private for profit hospitals respectively. In the presence of the antiviral
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treatment, the lifetime discounted costs of disease via the standard interferon
treatment pathway amounts to: 55 312.6 LE, 66 696.24 LE and 114 569.7 LE per
patient in each of the medical settings included; namely the National Liver Institute,
the private non-profit and the private for profit hospitals respectively. While the
lifetime discounted costs of disease via the pegylated interferon treatment pathway
amounts to: 52 531.3 LE, 60 634.46 LE and 91 523 LE per patient in each of the
medical settings included; namely the National Liver Institute, the private non-profit
and the private for profit hospitals respectively (Tables 34-36).
Table 35: Total discounted cost of disease and treatment over 20 years of the one 
hundred patients according to the various treatment options available 
with its breakdown to the first year immediate costs and all future 
costs in the Non profit private hospital using SPSS computer software
Pathway
Non profit 
private hospital 
total 20 year 
cost (Table 33)
Immediate
costs
Future costs
Discounted 
Future costs 
values
Totals
Supportive
treatment
18 737 383 LE
None
incurred
18 737 38 LE
10 374 888.97 
LE
10 374 888.97 
LE
Interferon
treatment
11 180 758 LE 1 072 91LE 10 107 85LE
5 596 716.545 
LE
6 669 624.545 
LE
Pepvlated
interferon
treatment
8 917 950 LE 2 522 02LE 6 395 93 LE
3 541 426.441 
LE
6 063 446.441 
LE
Not only is the pegylated interferon combination antiviral therapy route for hepatitis C 
by far the cheapest alternative in terms of total lifetime disease discounted costs for 
patients admitted in the three medical settings included in the study when compared 
with both the supportive treatment and the standard interferon treatment pathways 
(Tables 35 -37), it also saves more lives as compared to the other alternatives. Only 6 
lives are lost in the pegylated interferon route while 20 lives are lost in the supportive 
treatment route and 10 in the interferon treatment pathway alternative (Table 34).
157
Chapter 6
Results
Then comes the interferon treatment pathway alternative in terms of total lifetime 
disease discounted costs when compared to the supportive treatment pathway 
alternative in all three medical settings.
Table 36: Total discounted cost of disease and treatment over 20 years of the one 
hundred patients according to the various treatment options available 
with its breakdown to the first year immediate costs and all future 
costs in the private for profit hospital using SPSS computer software
Pathway
Private hospital 
total 20 year 
cost (Table 33)
Immediate
costs
Future
costs
Discounted 
Future costs 
values
Totals
Supportive
treatment
33 904 137 LE None incurred
33 904 137 
LE
18 772 720.66 
LE
18 772 720.66 
LE
Interferon
treatment
19 605 474 LE 1 347 578 LE
18 257 896 
LE
10 109 397.02 
LE
11 456 975.02 
LE
Peevlated
interferon
treatment
14 257 349 LE 2 818 740 LE
11 438 609
LE
6 333 557.803 
LE
9 152 297.803 
LE
Both the undiscounted and discounted cost effectiveness computed figures and values 
in this study strengthen the previous undiscounted cost of disease data in general, they 
show that the antiviral treatment is a better choice in terms of numbers o f lives saved 
(table 39) and in terms of cost in the long run along with cost effectiveness values 
(table 36-41). The number of lives saved by each treatment alternative is a key factor 
in the cost effectiveness calculation, it is considered as the effectiveness endpoint of 
the interventions (treatment options) under study. It was estimated from the Markov 
models for each alternative allowing for the very pertiment fact that the 5 years 
survival rate of the decompensated patients is 30-40% (60-70% 5 year mortality) 
(D’Amico et al, 1986 and Arroyo et al, 1999). The following calculated cost 
effectiveness values, first, emphasized the pegylated interferon combination antiviral 
therapy treatment alternative for hepatitis C as the cheapest alternative in terms of
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total lifetime disease discounted costs for patients admitted in the three medical 
settings included in the study against the other alternatives available, and second, 
shedded more light on the effectiveness of this treatment pathway of choice when 
compared with both the supportive treatment and the standard interferon treatment 
pathways. This was put into view via the negative values displayed for the antiviral 
standard interferon and ribavirin combination treatment pathway versus the 
supportive treatment pathway in all three medical settings, the same goes for the case 
of the antiviral pegylated interferon and ribavirin combination treatment pathway 
versus the standard interferon and ribavirin combination treatment pathway. Finally 
the negative values of cost effectiveness of the antiviral pegylated interferon and 
ribavirin combination treatment pathway against the supportive treatment pathway 
option was also hightlighted in all three medical settings namely: the National Liver 
Institute, the non-profit private hospital and the for profit private hospital settings.
Table 37: Comparative values of number of lives saved per treatment pathway in 
the three chosen medical settings
Number of lives saved / 
Treatment pathway
Menoufiya
NLI
Private non 
profit hospital
Private for 
profit hospital
Supportive treatment 20 20 20
Interferon treatment 10 10 10
Pegylated interferon treatment 6 6 6
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Table 38: Cost effectiveness of the total undiscounted cost values in the National
Liver Institute according to the constructed Markov model of the 100
patients' computer cohort
Pathway
NLI total 20 year 
cost (Table 33)
Deaths/ 
100 pts
Cost
comparison
Lives saved/ 
100 pts
C/E ratio 
(cost / life 
saved)
Supportive
treatment
14 487 223 LE 20
Interferon / 
Supportive
9 215 561 LE 10
-5 271 662 
LE
10 <0
Pegylated 
interferon / 
Supportive
7 570 461 LE
6
-6 916 762 
LE 14 <0
Pegylated 
interferon / 
Interferon
-1 645 100 
LE
4 <0
Table 39: Cost effectiveness of the total discounted cost values in the National 
Liver Institute according to the constructed Markov model of the 100 
patients' computer cohort
Pathway
NLI total 20 year 
cost (Table 34)
Deaths/ 
100 pts
Cost
comparison
Lives saved/ 
100 pts
C/E ratio 
(cost / life 
saved)
Supportive
treatment
8 021 575.375 LE 20
Interferon / 
Supportive
5 531 261.67 LE 10
-2 490 313.705 
LE
10 <0
Pegylated 
interferon / 
Supportive
5 253 128.138 LE 6
-2 768 447.237 
LE
14 <0
Pegylated 
interferon / 
Interferon
-278 133.532 
LE
4 <0
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Table 40: Cost effectiveness of the total undiscounted cost values in the Non
profit private hospital according to the constructed Markov model of
the 100 patients' computer cohort
Pathway
Non profit private 
hospital total 20 
year cost (Table 33)
Deaths/ 
100 pts
Cost
comparison
Lives saved/ 
100 pts
C/E ratio 
(cost / life 
saved)
Supportive
treatment
18 7373 83 LE 20
Interferon / 
Supportive
11 180 758 LE 10 -7 556 625 LE 10 <0
Pegylated 
interferon / 
Supportive
8 917 950 LE 6 -9 819 433 LE 14 <0
Pegylated 
interferon / 
Interferon
2 262 808 LE 4 <0
Table 41: Cost effectiveness of the total discounted cost values in the Non profit 
private hospital according to the constructed Markov model of the 
100 patients' computer cohort
Pathway
Non profit 
private hospital 
total 20 year 
cost (Table 35)
Deaths/ 
100 pts
Cost
comparison
Lives saved/ 
100 pts
C/E ratio 
(cost /  life 
saved)
Supportive
treatment
10 374 888.97 LE 20
Interferon / 
Supportive
6 669 624.545 LE 10 -3 705 264.425 
LE
10 <0
Pegylated 
interferon / 
Supportive
6 063 446.441 LE 6
-4 311 442.529 
LE 14 <0
Pegylated 
interferon / 
Interferon
-606 178.104 
LE
4 <0
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Table 42: Cost effectiveness of the total undiscounted cost values in the private
for profit hospital according to the constructed Markov model of the 100
patients' computer cohort
Pathway
Private hospital 
total 20 year 
cost (Table 33)
Deaths/ 
100 pts
Cost
comparison
Lives saved/ 
100 pts
C/E ratio 
(cost / life 
saved)
Supportive
treatment
33 904 137 LE 20
Interferon / 
Supportive
19 605 474 LE 10
-14 298 663
LE
10 <0
Pegylated 
interferon / 
Supportive
14 257 349 LE
6
-19 646 788 
LE
14 <0
Pegylated 
interferon / 
Interferon
-5 348 125 
LE
4 <0
Table 43: Cost effectiveness of the total discounted cost values in the private for 
profit hospital according to the constructed Markov model of the 100 
patients' computer cohort
Pathway
Private hospital 
total 20 year 
cost (Table 36)
Deaths/ 
100 pts
Cost
comparison
Lives saved/ 
100 pts
C/E ratio 
(cost / life 
saved)
Supportive
treatment
18 772 720.66 
LE
20
Interferon / 
Supportive
11 456 975.02 
LE
10
-7 315 745.64 
LE
10 <0
Pegylated 
interferon / 
Supportive
9 152 297.803 
LE
6
-9 620 422.857 
LE 14 <0
Pegylated 
interferon / 
Interferon
-2 304 677.217 
LE
4 <0
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7.1. Introduction
This study documents the feasibility o f health technology assessm ent and health 
econom ic techniques within the Egyptian healthcare system. The importance o f  econom ic  
research is explicitly emphasized in the course o f  this study for both the welfare o f  
Egyptian patients, for the healthcare budget and for the society at large.
The antiviral treatments’ options for hepatitis C virus (HCV) and their outcomes' data for 
the full twenty year cycle o f  the disease were investigated. Their costs, their effectiveness 
and cost effectiveness were also measured. The outcomes o f  the supportive treatment (no 
treatment) option were also documented and their costs assessed; including cost o f  
hospitalization, physician fees, hospital charges and hospitalization days. This was done 
principally in the M enoufiya National Liver Institute (NLI), the largest liver tertiary 
referral centre in the Middle East. The resultant data o f  the NLI was then compared with 
two other private institutions; the first a non profit private hospital and the second a for 
profit institution.
The study revealed that the cost o f  pegylated interferon combination therapy for NLI 
patients over the full cycle o f  the disease was the most cost effective alternative 
amounting to 75 704 .61LE per patient versus 92 155.61LE and 144 872.23LE for the 
standard interferon and the supportive treatment (no treatment) pathways respectively and 
thus the cost effectiveness values o f  the pegylated interferon alternative were negative 
compared to the other pathways. The same results were found to be true for patients 
attending private for profit and non profit medical settings. Thus the early intervention 
with pegylated interferon treatment proved to be the most appropriate route from a social 
aspect, the cheapest alternative to the healthcare budget and consequently the best choice
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to aspiring policy makers and healthcare reformers. This was different than the initial 
predictions o f  this study, since the supportive treatment option was seem ingly a lot 
cheaper than the much more expensive antiviral option.
This Egyptian study thus adds to the growing international recognition that the HTA 
process must be scientifically sound, consistent across applications, transparent and o f  
practical use in both policy-making and health-care practice (Jonnson, 2002 and Zentner 
e t  a l, 2005). Further, more countries are placing greater emphasis on ensuring that the 
results o f  HTA are considered in key decision-making processes (Sorenson e t  a l, 2008).
7.2. Im portance of technology health assessment
In Europe, HTA provides important benefits by empowering governments to make value- 
driven decisions, supporting innovation and providing patients and physicians with the 
information for making the best treatment choices (Sorenson e t  a l, 2008). In Egypt, 
governments are still unaware o f  the benefits o f  such a tool, and this study was an 
opportunity to emphasize the importance o f HTA to the Egyptian clinicians and policy 
and decision makers through a high impact example such as HCV treatment alternatives 
assessment.
Countries em ploy a wide array o f  approaches to control the costs o f  health technology  
and support the optimal use o f  new treatments and HTA has assumed an increasing role 
in national priority-setting, decision making and health-policy processes. In recent years, 
various European States have developed systems to evaluate innovations and treatments 
determining their relative value for investment and mechanisms for equitable and 
accessible treatment provision (Sorenson e t  a l, 2008). Alternatively, this assessm ent is
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the first to be used in Egypt for optimal treatment support with no official system  
determining values for treatment provision accessibility.
Sorenson, Drummond and Kanavos (2008) thought that decision-makers are more likely 
to utilize HTA if  there are established policy instruments (e.g. reports, practice 
guidelines) and commitments to use them effectively. Furthermore, they thought that 
patient demand and the cost effectiveness o f a technology can change so it is important to 
review HTA recommendations on a consistent basis (Sorenson e t  a l, 2008). This is 
thought to be also true for Egypt and would thus require greater participation and 
collaboration am ong stakeholders particularly HTA personnel, government officials, the 
industry, health providers and patients. Without adequate input and understanding o f  the 
HTA process, stakeholders may mistrust the evidence and subsequent recommendations.
M oreover, H TA ’s effectiveness rests on accurate assessments and the appropriate 
implementation and use o f  subsequent recommendations. HTA can encourage a 
particular treatment i f  assessments o f  that treatment alternative are performed properly 
and consider a wide range o f  long term associated costs and benefits rather than focusing  
solely on short term costs. This study showed that, HCV pegylated interferon 
combination therapy long term costs and benefit were far less costly than the seem ingly  
short term cheaper alternatives.
However, H TA’s value in encouraging innovation and value-added healthcare also 
depends on the assessm ent process; including when and how the review was performed 
and the resulting decision-making procedures (Busse e t  a l, 2002; Anell, 2004; Zentner e t  
a l ,  2005 and Drummond, 2006).
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This health technology assessment o f HCV treatment alternatives is among the first o f  
such assessm ents to the author's knowledge to be performed in Egypt. This Egyptian 
HTA typically entailed: 1) identifying the policy question; what is the best treatment 
option for HCV in Egypt? 2) systematic retrieval o f  scientific and non-scientific  
evidence, and analysis, from the NLI and the other chosen medical settings and 3) 
appraisal o f  evidence, including judgments regarding the meaning o f  the evidence and its 
applications to inform the decision-making process (Sorenson e t  al, 2008).
The scope o f  this study was wide enough to encompass many issues o f  interest 
surrounding the methodology itself and the HCV as a subject o f  study. The assessm ent 
phase included the systemic review o f  evidence, which was then follow ed by the 
econom ic evaluation. The study ended with an appraisal and an interpretation o f  the 
outputs o f  the assessment.
7.2.1. Policy implications
Econom ic evaluation's and HTA’s role and usefulness in the future depend on how they 
were developed as practical aids to decision-making (Gilbody and Petticrew, 1999). 
Econom ic evaluation should be used as an “aid to thought”; through the system ic 
collection o f  evidence and classification o f choices, it offers a powerful tool to the 
organization o f  evidence and rational decision making (Gilbody and Petticrew, 1999). 
Australia, Canada, Finland, N ew  Zealand, Norway and others have made subm ission o f  
econom ic evaluations an official mandatory requirement for placement o f  medication on 
their national formulary (Hoffman and Graf von der Schulenburg, 2000), then Denmark 
and France have started to encourage such submissions (Hoffman and Graf von der 
Schulenburg, 2000). The National Institute for Health and Clinical Excellence (NICE) o f
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the UK expects companies to submit a dossier o f  evidence o f  clinical and cost 
effectiveness relating to the product, the treatment or the particular technology when an 
assessm ent is being undertaken.
Clearly, evidence from economic evaluation is just one input contributing to a com plex 
decision making process. For HTA to be o f  optimal benefit, the assessm ent process needs 
to be linked with innovation and other aspects o f  policy-making, recognizing the 
com plexities o f  decision-making that require consideration o f  subjective and normative 
concerns. Without these links, HTA may have limited power to inform the policy process 
and facilitate access to new and effective treatments (Sorenson e t  a l, 2008). This is 
particularly true for healthcare decision-makers in the Egyptian Ministry o f  Health and 
Population.
However, som e impediments to HTA’s optimal benefit and use in Egypt, as deduced 
from this research, include “communication” between health econom ists and decision­
makers, as well as clinical imperatives, availability o f  data or rather unavailability o f  data 
and appropriate management systems and finally, the lack o f  knowledge and expertise in 
econom ic evaluation.
The lack o f  expertise and knowledge in economic evaluation and HTA shades all sectors 
o f  the healthcare system  in Egypt; including clinicians, policy makers, health workers and 
medical institution managers, as well as the scarcity o f  trained health econom ists. The 
appropriate management systems include the decision making system  itself where 
decisions are often made quickly mostly to serve political imperatives. The lack o f  data 
was also a key issue as there is often insufficient well structured evidenced-based data 
available on which to build the evaluation.
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Finally, the ever present strife between clinicians and healthcare personnel on one hand 
and health econom ists on the other, is also emphasized when it com es to evaluating 
clinical outcom es and health expenditures, considering that effective implementation o f  
HTA requires the involvement o f key stakeholders. A recent OECD study found 
stakeholder acceptance to be one o f  the key determinants o f  whether decisions are 
actually put into practice within health systems (OECD, 2005). Those are all assumptions 
based on problems met in the course o f this research and the survey o f  historical reviews 
and papers concerned with implementation and application o f  health econom ics in other 
countries (Ross, 1995 and Sorenson e t  a l, 2008).
Econom ics and health assessment will only be used to any great extent in healthcare 
when efficiency becom es a key day to day objective o f  healthcare services. M ooney, 
(1999) reported that the average doctor frequently has little incentive to try to pursue 
efficiency and this is believed to be true for the average doctor in Egypt as well. M ooney 
also adds that the lead has to come from the top, especially from politicians prepared to 
be answerable to their electorate for the sensible stewardship o f  healthcare funds and not 
to the emotionalism  that so often surrounds healthcare decision-making at the political 
level (M ooney, 1999). Moreover, Berg e t  al, (2004) suggest that the lack o f  integration 
between HTA evidence and guideline development may be attributable to a number o f  
factors including a disconnect between the requirements o f  clinical practice and data 
generated by HTA and the medical profession’s aversion to combining econom ics and 
health (Berg e t  a l ,  2004). What is rather depressing in Egypt is the relatively poor quality 
o f  some o f  the strategic decision-making that emanates from the Ministry o f  Health and 
Population and its departments. Policy-makers as they are everywhere, although they
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seek to save the public’s interest have one severe restriction to overcome: their positions 
(Gyldmark and Morrisson, 1993; Mueller, 1997 and Sauerland, 1999).
That means i f  research comes up with results in policy advising, that are scientifically  
| reasonable but politically unpopular, there is a great chance that those suggestions will 
not be implemented. Politicians often look for short-term solutions (that com e up with 
short-term benefits and long-term costs) rather than performing real reform projects (that 
w ill have high costs in the short-term and positive effects only in the long run) 
(Sauerland, 1999), and this is typically the case o f  HCV management in Egypt. 
| O bviously, w e have to look for institutions that provide politicians with incentives to look 
for long term policies (Buchanan, 1993).
7.2.2. Cost effectiveness as an assessment tool
Cost effectiveness or cost-utility analyses are most often considered appropriate 
analytical designs, particularly when the proposed product has significant clinical 
advantages over the comparator and relative benefits need to be considered against costs 
(Sorenson e t  a l, 2008).
The cost effectiveness method was used in this research project because o f  the 
measurable health benefits and measurable cure via the blood viral load. The cost is also 
measurable in monetary form. It was also used because it is an assessm ent tool for 
efficiency (W illiam s, 1974) and it involves the same disease, same outcome and same 
area o f  m edicine. Ultimately, there were no norms or benchmarks needed for this study 
due to the negative values for the effectiveness o f  the treatment with pegylated interferon 
option, a surprise to all.
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The study approach was direct and repetitive throughout and the extrapolation o f  events 
over time and the health outcomes follows literature, as well as all criteria o f  
generalizability, transferability, accessibility and quality was there in the analysis 
(M axw ell, 1984), which made the sensitivity o f  analysis not needed.
7.3. H epatitis C virus as a case study for economic evaluation
The high prevalence o f  HCV and its expensive long term repercussions have prioritized 
the need for informed policy-makers, not only for allocating sufficient resources to cover 
the treatment costs for those most in need but also for selecting those best able to benefit, 
and selecting and adopting the treatment o f  choice according to standardized 
m ethodologies. Furthermore, the urgency also arises due to the fact that HCV is 
frequently asymptomatic until liver cirrhosis develops, at which time treatment is less 
effective and not always successful and thus creating a huge health burden as W ong and 
co-workers reported (W ong e t  al, 2000). This was also found to be true in Egypt in 
addition to the decreased effectiveness o f  the antiviral treatment on the Egyptian strain o f  
the virus (type IV) in comparison to strain types I II and III (Waked e t  a l, 1995 and 
Strickland, 2006). Despite HCV latency, given prevalence ranging from 0.1% to 5% in 
different countries worldwide and the staggering 15-20% in Egypt (A ngelico e t  a l , 1997; 
Frank e t  a l , 2000 and Rao e t  a l, 2002). Chronic HCV infection has becom e the leading 
cause o f  chronic liver disease and liver transplantation, and has also led to rising rates o f  
hepatocellular carcinoma in Egypt (Hassan e t  al, 2001 and 2002 and Ezzat e t  a l ,  2005). 
Adding to the high cost o f  treatment, the cost o f  the long term effects o f  untreated 
patients, makes hepatitis C virus a perfect example both to emphasize the importance o f
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econom ic evaluation and to enhance the efficiency o f  the financial resources o f  
healthcare.
7.3.1. Public health and individual implications
In a molecular evolutionary analysis o f the HCV genetics, Tanaka and his co workers 
traced the Japanese HCV epidemic back to the 1930-40s and traced the US epidemic to 
the late 1960s, while the Egyptian epidemic was traced to the mass parenteral anti- 
schistosom al therapy in the 60s (Tanaka e t  al, 2002). These analyses suggest that the 
HCV epidem ic in the US and Egypt may be twenty to thirty years behind that in Japan, 
and thus HCC morbidity and mortality may rise. Supporting this hypothesis, El-Serag and 
M asson found a rising HCC incidence within the US-based Surveillance, Epidem iology, 
and End Results (SEER) database over the past two decades with a progressive shift to 
younger individuals (El-Serag and Masson, 1999). Because o f  the high prevalence o f  
infections with HCV in Egypt, it has become the greatest risk factor for HCC (Hassan e t  
a l, 2001 and Ezzat e t  a l , 2005). Similarly to what is happening in the United States 
prevalence o f  HCC is increasing in Egypt as well, along with its increasing association  
with HCV (Hassan e t  a l, 2001 and Ezzat e t  a l , 2005). HCC is now one o f  the three most 
frequently diagnosed cancers in Egypt as reported by Abdel-Wahab e t  a l, (2000) and by 
the National Cancer Institute (NCI) age adjusted death rate data (Abdel-W ahab e t  a l,
1 2000).
Despite the decline in HCV incidence in the late 1980s, projections by the US Centre for 
Disease Control and Prevention suggest that the number o f  patients infected with HCV in 
the coming decade will continue to increase, perhaps quadrupling from 750 000 in 1990 
to 3 m illion in 2015, because o f  the high incidence in the 1970s and early 1980s and the
I
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persistent HCV latency (Armstrong e t  a l,  2000 and Kim e t  a l ,  2002). Numerous 
mathematical predictive and Markov models project that annual HCV related mortality 
may double or triple over the next 10-20 years for France, Switzerland, Canada, Australia 
and the US (Deuffic e t  a l, 1999; Wong e t  al, 2000; Zou e t  a l , 2000; Hepatitis C 
Australian council, 2002; Sagmeister e t  al, 2002 and Davis e t  a l, 2003). An analysis 
comparing the HCV and HIV epidemics in France suggests that HIV mortality is likely to 
be falling while that from HCV infection will likely rise to exceed that from HIV 
infection (Deuffic-Burban e t  a l, 2004). There is no study to the author's knowledge that 
predicts the HCV-related mortality and the direction o f  the HCV epidemic in Egypt.
7.4. H indrances and obstacles
In finding the evidence, in converting the search question into a strategy and in 
identifying the sources o f  evidence many hindrances were encountered by the researcher. 
The first obstacle was met with at the start o f  the fieldwork; as much as the clinical expert 
opinions were important in shaping the course o f this study, the political experts were 
very ungenerous with their knowledge due to the very sensitive political impact o f  HCV 
treatment in Egypt. The Minister o f  Health and Population, at the time, even advised  
towards the abortion o f  the project.
The second limitation was related to the secondary sources o f  information in the Egyptian 
healthcare system  and the unavailability and accessibility o f  reviews relating to the 
treatment and the prevalence data in Egypt. However a comprehensive search o f  all 
relevant studies that were both consistent clinically and statistically was still performed 
via a strenuous effort to locate original reports by means o f  hand searching, reference 
lists and expert data.
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A. major obstacle in this study was met within the period o f  preparation o f  the econom ic 
evaluation, when it was discovered that no historical data was available in the medical 
institutions visited. No information was kept, especially for outpatients, no records about 
the prescriptions, the tests performed, nor was there even a written protocol o f  treatment 
follow ed, just an unwritten oral know-how passed on from one clinician to the other. This 
fact necessitated a personal interview with patients and the physical presence o f  the 
researcher during the routine clinical examination process. This hindrance was 
compounded in the private sector fieldwork phase, as no private clinic would allow  an 
external researcher to be present during the medical examination and comprom ise its 
reputation and the privacy o f  its patients. This problem was solved in using the NLI as 
backbone o f  data and reference benchmark to the research.
A permit was granted from the NLI, after the studying o f  the research protocol to allow  
the researcher access to its outpatient clinics and inpatient wards as w ell as its 
accountancy classified records. This permit was a rebirth to the study and an 
acknowledgm ent to its important objectives. The fact that NLI was a university hospital 
made the researcher presence around the patient totally acceptable and in many cases 
patients were happy to help and very generous with their time and in sharing their 
experience.
To help formulate clear and equitable decisions, economic evaluation o f  healthcare 
interventions must be based on good quality information. Ideally, good quality data 
should be available on the importance o f  the topic, the effects (effectiveness and safety) 
o f  interventions that are available either at present or in the future and, naturally, on the 
economic consequences o f  their adoption. Unfortunately, good quality, multi­
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dimensional information is seldom available in an easily accessible format particularly in 
Egypt. Econom ic evaluation is sometimes based on either incomplete data or partial 
already-available data (Sauerland, 1999) and this study practically showcased this fact 
not only regarding all the missing information about HCV and its econom ic implications 
in Egypt but also regarding the entire missing data infrastructure that would contain such 
information.
A major stumbling block in the course o f this study was the international classification o f  
cost sectors’ inadaptability in the research. The indirect costs components could not be 
measured, calculated or reached in the course o f  this analysis for neither the public NLI 
setting nor the private settings. NLI actually lacked the data and the private settings 
would not impart with such classified financial information. A research inherent constant 
cost component was thus introduced to cover both part o f  the internationally known 
indirect cost and the government subsidy to healthcare in its public institutions.
Other hindrances met were more personal than so far mentioned. The stretched distances 
and locations o f  the research; Menoufiya, Cairo and Swansea were also taxing and time 
consum ing but the exposure was very enriching towards the end result.
The lack o f  relation to a structured research body, government or research centre in 
Egypt; to support through clinical and academic problems and to guide through a 
standardized format o f  trouble shooting was also problematic. This turned out to be a 
positive aspect though in appraising the evidence and relevance o f  the data and the 
results. This was because there was no conflict o f  role in question or bias towards any 
end result in particular. The facts that all stages o f  the investigation were valid and open
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to external scrutiny, that patients were randomly included and blinded as w ell as P values 
calculated were a standpoint that added strength to the final results.
7.5. Results and their implication
The results reached were important in terms o f  both their individual values and their 
collective ones in that they represented unbiased data from randomized blinded patients. 
They quantify the cost o f  treatment o f  hepatitis C virus patients and the cost o f  the 
disease for the first time in Egypt.
The quantitative products o f  the results are also crucial in showing the prescription 
patterns for the patients with inclusion o f  significance measures.
7.5.1. O utpatien t Data
1- Cost of outpatients prescribed supportive treatm ent in Egypt
The cost evaluation o f  the supportive treatment was not an easy process, it started with 
visiting many o f  Egypt's prominent clinicians, private centres and hospitals both private 
and public. The lack o f  any sort o f  records and the lack o f  a standard written treatment 
protocol and prescription format was a great obstacle in knowing factually what was 
being done and to what extend was it repeated. Even though the NLI in M enoufiya was 
no different in the sense that no written protocols were mandated and no records kept, the 
high HCV patient traffic made the reaching o f  the information feasible yet strenuous. 
Each patient visiting the clinics was examined, his or her condition and the drugs 
prescribed recorded. The handling and computing o f  the data was then performed and the 
pattern deduced and proven. This was the stage where the cost o f  the drugs prescribed 
was calculated per unit per patient then collectively per group per patient condition. The 
same was done for all other direct non medication procedures costs. The results showed
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the patterns follow ed, and ultimately the efficiency o f  the unwritten treatment protocols 
from a medical point o f  view. The numbers reached should be looked at closely by 
healthcare policy and decision makers to increase effective delivery o f  appropriate 
healthcare and expenditure decisions in Egypt.
The data o f  outpatients with positive HCV showed that the decompensated patient yearly 
medication cost values are expectedly and significantly higher at 1 675 LE than the 1 306 
LE o f  the compensated group at p<0.05. These two figures are constant throughout the 
three chosen medical settings due to mandatory drug pricing policies by the Egyptian 
Ministry o f  Health and Population. The numbers o f  mean total cost o f  treatment in the 
result section (2 246 LE, 2 448 LE and 4 056 LE per year per compensated patient treated 
in the NLI private non profit and private for profit institutions) show that the cost o f  the 
quality medical service provided in the medical private sector far outweighs (nearly 
double) the cost o f  treatment, taking into consideration that the consultation fees in the 
NLI and the private non profit hospital clinics are 5 LE and 30 LE respectively which  
jumps to a staggering 200 LE per visit in the private for profit setting. Therefore, a 
revised rational prescription policy would only have a great impact on the mean total cost 
in the former two settings while it would not greatly affect the mean total cost o f  
treatment in the latter setting.
The breakdown o f  the means o f  annual medication costs per patient per year grouped by 
severity o f  liver cirrhosis shows the significantly higher value o f  liver support and acid 
suppressants drug categories on the weight o f  the total medication cost (38.73 % - 
26.61%  respectively) for the compensated drug group versus (51.48 % - 10.55 % 
respectively) for the decompensated patient group. However, diuretics drug category cost
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percentage reaches 13.28% o f  the total amount for decompensated cirrhosis cases spent 
w hile it barely exceeds 2 %  for compensated cirrhosis patients. Vitamins drug categories 
on the other hand collects nearly 5 % o f  the cost o f  drugs for both types o f  patients but 
have no real treatment value to the patient and can be easily removed from prescriptions 
and thus decreasing costs o f  medication by that 5%. This and other similar calculations 
w ill lead to the improvement o f  prescribing policies, to the increased awareness o f  
physicians to this evidence based data to promote the decrease in the cost o f  medications 
for outpatients o f  HCV and the decreased treatment burden o f  HCV patients in both non 
profit and public hospital and thus maximizing the economic efficiency o f  resources 
used.
A prescription audit data body for assessing drug trends and com piling annual spending 
on prescriptions must be made available in order to accomplish a satisfactory informative 
system and consequently better future studies.
The lack o f  proper breakdown o f  expenditures leads to a discrepancy in usage o f  
standardized and internationally recognized cost nomenclature and ultimately in resource 
allocation. This issue was addressed in this study by the usage o f  direct and constant costs 
o f  HCV and its treatment instead o f  direct and indirect costs (c o n s ta n t  c o s t in g  d i r e c t l y  
r e la te s  to  th e  s u b s id i z e d  c o s t  in c u r r e d  b y  H C V  th r o u g h o u t i ts  c y c le  a s  s h o w n  in  th e  
M a r k o v  m o d e l  a d o p te d ) .
The constant costs as defined in this study are the costs paid by the NLI as an overhead 
calculated from the hospital classified budget as 35 LE per outpatient per visit and those 
figures could be in a way considered as the subsidized cost sponsored by the Egyptian 
Ministry o f  Health and Population for each patient admitted to the hospital along with the
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cost o f  the medication prescribed to each; this constant cost amounts to 18.7% and 16% 
(com pensated and decompensated patient groups respectively) from the mean annual cost 
per patient per year grouped by severity o f  liver cirrhosis. These subsidized costs could 
be greatly reduced i f  the patients visit the hospital fewer times, meaning every two or 
three months to perform the testing needed since the most frequent test is a quarterly one, 
instead o f  the monthly visit routine adopted. This would mean providing the patients with 
quarterly prescriptions thus lessening the burden in terms o f  clinic admittance and 
constant cost. Furthermore, it might have a positive effect on patients’ moral and that o f  
their fam ilies, to decrease frequency o f  hospital visits. The costs decrease would amount 
to 14.2% if  patients visit the hospital every three months (quarterly) for prescription 
filling, laboratory testing and ultrasound, provided that prescription's refills are for the 
full three months period. It should be mentioned that the patients are not only examined  
in hospital’s outpatient clinics for disease progression but they are given their medication 
as w ell under the rules o f  the national healthcare system in Egypt.
In conclusion, to decrease the mean annual cost o f  supportive treatment for HCV 
patients, it is worthwhile for the governmental and non governmental medical institutions 
to reconsider the prescribing policies or write up a prescribing protocol to reduce waste o f  
econom ic resources on drugs o f  no medical value to the patient. In addition, the 
government and any medical care payer body or institution, should also reconsider or 
design the protocols o f  treatment with lesser physician consultation frequencies to cut o ff  
a major chunk o f  direct non medication costs incurred by such patients' visits, this should
I .
be done after studying the cost effectiveness o f  the effect o f  such visits on patients 
morale, and psychological health state.
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II- Outcom e and costs of anti-viral treatm ent
All randomized controlled drug trials have focused on short-term outcomes such as 
normalization o f  transaminases, improved liver histology or treatment-induced viral 
negativity. Peginterferon plus ribavirin yield sustained viral negative responses 
(persistent loss o f  viraemia six months after discontinuation o f  antiviral treatment) in 
45% - 61% o f  patients (Manns e t  al, 2001 and Fried e t  a l, 2002). Response rates are 
higher in patients who are younger, have genotype II or III (as high as 88%), and those 
without bridging fibrosis or cirrhosis (as high as 61%) (Manns e t  a l, 2001 and Fried e t  a l, 
2002). Likewise in NLI trials, the effectiveness o f  viral treatment neared 60% (54%) in 
the peginterferon plus ribavirin combination case in genotype IV while it was only 35% 
in case o f  interferon plus ribavirin (this according to the unpublished data o f  the NLI).
The cost effectiveness ratio o f  the anti-viral treatment option in relation to the supportive 
alternative was negative in value in addition to the lives saved via the antiviral treatment; 
therefore, the use o f  antiviral treatment was good to both healthcare budget and to the 
patient’s welfare. Randomized drug trials demonstrated that sustained viral responses 
result in improved survival and decreased liver complications though long-term follow - 
up o f  patients are lacking. Despite some controversy and some negative results (Harper 
and Dienstag, 1996; Koretz, 1996 and Poynard and Opolon, 1998) increasing numbers o f  
non-randomized clinical studies suggest that viral eradication improves liver histology, 
decreases the risk for HCC or cirrhosis and decompensation and perhaps improves 
survival (Kuwana e t  a l , 1997; Schalm e t  a l , 1997; Benvegnu e t  a l, 1998; Niederau e t  al, 
1998; and Serfaty e t  al, 1998). Treatment-induced viral eradication also restores impaired 
QOL measures in those with chronic HCV infection (Foster e t  a l, 1998; Bonkovsky and
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W oolley, 1999; Foster, 1999; Ware e t  al, 1999 and Hassoun e t  a l, 2002). One recent 
study suggests that, even in the absence o f viral eradication, antiviral treatment improves 
QOL as measured with the Medical Outcomes Study 36-items Short Form survey 
instrument (SF-36) (Wright e t  al, 2005). Similarly, even in the absence o f  viral 
eradication, a study suggests that treatment may decrease the rate o f  fibrosis progression 
(Sobesky e t  a l , 1999), perhaps forestalling the development o f  advanced liver disease and 
permitting the development o f  further therapeutic advances. Other studies suggest that 
treatment-induced normalization o f  transaminases in the absence o f  viral eradication may 
decrease the future risk o f  HCC (Imai e t  al, 1998; Ikeda e t  a l, 1999; Yoshida e t  a l, 1999 
and Shiratori e t  a l, 2005).
A well informed evidence-based account submitted to healthcare officials and policy 
makers enhances their ability in the decision making process and strengthens their 
perception regarding the importance o f  pharmacoeconomics as a tool o f  efficiency and 
effective resource allocation to the various alternatives, thus improving overall societal 
healthcare benefits. In this case study, a well informed evidence-based account leads to 
the saving o f  costs o f  treatments o f  complications and enhancing the recourses utilized by 
HCV patients according to data discussed later.
A- Costs of standard  interferon anti-viral treatm ent
This study was designed as an attempt to answer some o f  the questions that physicians 
need to address and patients need to consider and decision and policy makers need to 
confront when undertaking treatment o f  HCV infection. It was also performed to 
highlight any other additional issues that need be addressed, amended and/or altered 
when undertaking treatment decisions regarding HCV.
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I Cost estim ates used in pharmacoeconomic analyses for standard interferon treatment in 
Egypt 45 LE (AW P) assuming full dose and compliance, the AWP o f  52 w eeks o f  
ribavirin 1200 mg daily for patients <75kg, and 3 million units o f  interferon three times a 
week, is 13 050 LE (2006 values). When considering monitoring costs, follow-up and 
average w holesale drug costs in Egypt, in the various medical institutions chosen (2006  
values), estim ates ranged from 15 890 LE to 21 150 LE in the NLI and the private for 
profit hospital respectively for 48 weeks o f ribavirin and interferon administered as 
above. Comparatively interferon treatment in the US have ranged from $US 2300 AWP  
to $US 2150 AW P to SUS 2511 including drug-induced costs for six months and SUS 
3800 AW P for 12 months (Bennett e t  a l, 1997 and Kim e t  a l, 1997) (1$ US converts to 
nearly 5.1 LE). An Australian publication estimated the net cost o f  six months o f  
interferon treatment (treatment costs minus conventional management) to be SUS 1098 
(based on the Australian healthcare system price using the same conversion rate) (Shiell 
e t  a l , 1994). In a US veterans Administration study, ribavirin and interferon pharmacy 
costs alone were reported to be SUS 5100 and SUS 10 200 for 24 and 48 weeks (Inadomi 
and Sonnenberg, 1999).
Antiviral treatment for genotype IV in Egypt is usually for 48 weeks. An evaluation for 
viral response typically occurs at week twelve, and those who are viral positive with a 
less than 2-log drop in viral load may discontinue therapy because the likelihood o f  a 
sustained viral response is low (Davis, 2002). Subsequent analyses o f  viral monitoring 
during therapy suggests that antiviral therapy should be discontinued among patients not 
becoming viral negative or not achieving a 2-log viral load drop by w eek tw elve (Davis 
e t  a l, 2003). With this stopping rule, the implementation o f  a twelve w eek evaluation o f
184
Chapter 7
D iscu ssion
treatment response lowered antiviral drug costs compared with full dose treatment for 48 
weeks.
B- Cost range of cured patients using standard interferon in various medical 
institutions
The estimated costs' range for standard interferon treatment combination therapy was 
99 880 LE and 132 942.85 LE (2006 values) for 48 weeks o f  combination therapy 
administered as above depending on weight for the NLI and the private for profit hospital 
respectively, when accounting for the cost per cured patient according to the 15.9 % cure 
rate and when accounting for discontinuation o f  therapy for twelve week non-responders 
and when combining actual dosages received after adjusting for drug discontinuation, but 
adding office visits, and laboratory tests.
C- Cost range of cured patients using pegylated interferon in various medical 
institutions
In addition, cost estimate o f  a complete 48-week course o f  parenteral pegylated interferon 
administered at 1.5 pg/kg per week in combination to ribavirin with fixed administration 
at 1200 mg per day is 29 850 LE (2006 values). When considering monitoring costs, 
follow-up and average wholesale drug costs in Egypt, in the various medical institutions 
chosen (2006 values), estimates ranged from 32 690 LE to 37 950 LE in the NLI and 
the private for profit hospital. Because o f dose reductions, discontinuations for the 
absence o f  a viral response after twelve weeks, at an efficiency o f  54% as calculated in 
the NLI during the course o f  the research. Using Egyptian AW APs in 2006, these 
numbers are readjusted to range from 60 129.62 LE to 70 277.77 LE for the same 
medical institutions. Less recently in Europe, a complete 48-w eek course o f  pegylated
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interferon administered at 1.5 pg/kg per week plus ribavirin with fixed administration at 
800 mg per day or weight-based administration >10.6 mg per kg per day or weight-based  
administration, including monitoring costs and follow-up was initially estimated to cost 
Euro 21 601 per fixed and Euro 23 716 for weight-based administration o f  ribavirin plus 
pegylated interferon, but actual costs would be 33% lower at Euro 13 085 and Euro 14 
480 respectively (using German AWAPs in 2000), because o f  dose reductions, 
discontinuations for adverse effects as occurred in the trial or for the absence o f  a viral 
response after 24 weeks (Siebert e t  al, 2003).
It should be noted that such therapy is expensive and HCV infection usually progresses 
slow ly, raising questions about the value or cost versus the effectiveness o f  treatment 
(Liang, 1998). However, this research tried to answer this question within the boundaries 
o f  the Egyptian situation. Multiple other pharmacoeconomic studies have been performed 
and suggest that antiviral combination therapy should be cost effective (Buti e t  a l, 2002; 
Siebert e t  a l, 2003; Wong e t  a l , 2003; Sullivan e t  a l, 2004 a and Shepherd e t  a l, 2005) 
and one analysis found pegylated interferon plus ribavirin to be cost saving versus 
interferon plus ribavirin (Sullivan e t  al, 2004 b).
7.5.2. Inpatient Data
I- Cost of inpatients with HCV complications
Although Egyptian clinicians were familiar with the reasons for hospitalization o f  HCV 
patients from both the international Markov models and their practical experience, the 
cost o f  hospitalization o f  each reason was not known, nor was the average length o f  
hospital stay, neither the types o f  drugs prescribed nor their cost in relation to their 
medical importance. Thereby this phase o f  the research albeit m onotonous in its
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collection stage, became very illuminative in its analytical stage and as a quantitative 
product.
Breakdown o f  the means o f  costs per patient grouped by reason o f  hospitalization (values 
in Egyptian pounds), mean length o f  hospital stay per patient grouped by reason o f  
hospitalization (values in days), mean total costs per patient grouped by reason o f  
hospitalization (values in Egyptian pounds) and mean cost o f  medication per patient for 
each drug group grouped by reason o f  hospitalization are all steps in the path o f  assessing  
the cost o f  HCV treatment and their cost effectiveness in Egypt. They are all also tools to 
I evaluate the effectiveness o f  treatment strategies while adopting evidence based 
m ethodologies. These calculations may also be considered as quantitative guidelines to 
m axim ize effective healthcare delivery by adopting health technology assessm ent 
techniques. Furthermore these figures inform doctors and clinicians about the econom ical 
impact o f  their medical decision in explicit numbers. This will prompt them to consider 
all aspects o f  their treatment decisions on patients, on medical institutions and ultimately 
on the w hole community.
Nearly 10 % (183 patients) o f  the total number o f  patients admitted in the NLI during 
2003 were studied. The costs o f  caring for HCV patients hospitalized for the various 
com plications o f  decompensated liver cirrhosis in the NLI and the private non profit 
hospital are nearly the same, with the private non profit 14 % higher in cost average than 
the NLI; this is very little difference considering that the NLI is being subsidized by the 
government. The fact that its costs are nearing those o f  a private hospital means the 
management need to consider the high constant costs that it incurs per patient that ranges 
from 43 % to 60 % in the total cost o f  hospitalization. Those figures should be a warning
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bell to the management so as to reduce costs or restructure the administrative and the 
management system s, this would lead to decrease their constant costs and to maxim ize 
the use o f  their resources. On the other hand, this small difference in hospitalization cost 
in the private non profit institution in relation to the NLI also leads us to credit the private 
non profit hospital for an efficient and economical management.
Direct costs for HCV infection in the US were estimated to exceed SUS 1 billion in 1998 
(Kim, 2002 and Grant e t  a l, 2005).Those figures place antiviral treatment costs which  
appear to be relatively expensive, in context. In the 187 patients examined in this study 
and diagnosed with end-stage liver disease between 2003 and 2006, the mean hospital 
charges and costs including laboratory tests, medications ranging from 3 477 LE to 5 481 
LE per patient per hospitalization time in a public hospital NLI, 3 567.5 LE to 7 382.5 LE 
in a private non profit hospital and in a private for profit setting these figures multiply to 
reach 12 000 LE to 32 581 LE. The charge data included laboratory tests and medications 
but did not include terminal care support.
In 153 patients with end-stage liver disease between 1991 and 1995, W ong and co ­
workers, found mean hospital charges (not costs) ranging from SUS 39 235 to $US 222  
968 ( 2 2 7  5 6 3  L E  to  1 2 9 3  2 1 4  L E ) per patient (Wong e t  a l , 1997). The charge data did 
not include outpatient visits, laboratory tests, home support services, m edications or 
terminal care support, so the costs for treating end-stage liver disease are likely to far 
exceed those for antiviral treatment.
In this study it was shown that all patients were prescribed variable combinations o f  154 
drugs. Similar drugs and drugs used for similar conditions were then grouped in fifteen 
categories as shown in results. This was done for the convenience o f  statistical analysis,
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at the same time; it highlighted the patterns for prescriptions and the cost o f  each drug 
category. The parallelism o f  rational prescribing patterns o f  physicians to the cases and 
m edical situations was thus emphasized. If this research was done as a form o f  random 
m edical prescriptions assurance, the results are clear as to the type o f  medical treatment 
the patients get in the NLI. The cost o f  each drug group, show the patterns and 
recurrence o f  drugs used and the complementary relationship they have with the various 
conditions under study but no economizations are evident for the inpatients’ costs as all 
the m edications prescribed are well rationed and pertinent to the condition o f  the patients. 
This study revealed that the lack o f adoption o f evidence-based perspectives caused the 
discrepancies o f  high cost and inefficient resource allocation in the healthcare system  as 
evidenced from the length o f  hospital impact on inpatient costing in HCV patients. It is 
noteworthy to mention that the length o f hospital stay affects the final cost o f  treatment. 
This; combined with the fact that the indirect costs are too large in terms o f  their effect on 
the final cost and that they depend directly on the length o f  hospital stay, should be taken 
into consideration with each admittance and exit permit written. The release order 
responsibility should be well regarded as it is not just another day but a major chunk o f  
m oney that could be better spent on patients elsewhere!
7.5.3. T reatm ent pathw ays’ choices
Technological advancements, developments in medical science and increasing expectations 
o f  communities from healthcare providers continue to focus attention on the healthcare 
dilemma. There is great concern, on an international level, that healthcare costs continue 
to rise, while evidence o f  improved patient wellbeing is difficult to find in many areas. 
Similarly, anti-HCV treatment appears to be expensive particularly when it com es to a
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developing country like Egypt. Therefore the costs o f  treatment must be weighed against
the cost o f  illness and the benefits o f viral eradication. Simple comparisons o f  drug and
disease costs do not account for drug effectiveness, so these kinds o f  analyses in isolation
do not characterize the ‘value’ o f a drug. Since, pharmacoeconomic analyses consider not
only treatment costs but also disease costs, the present study measured for the first time
the efficiency o f  response, the probability o f  progressive liver disease, and the costs o f
antiviral treatment. This measurement took into consideration the disease itse lf and the
end-stage liver disease in Egypt as others did elsewhere in the world (Davis e t  a l, 1998;
Sinha and Das, 2000; Buti e t  a l, 2002; Sullivan e t  a l, 2004 a & b and Grieve e t  a l, 2006).
Even though not all patients develop liver complications, numerous econom ic evaluation
o f  HCV infection suggest that, in the absence o f  antiviral treatment, costs o f  supportive
treatment, costs o f  complications, particularly liver transplantation and decompensated
cirrhosis, lead to lifetime undiscounted disease costs which were computed in this study
to be 144 872 LE, 187 373 LE and 339 041 LE per patient in each o f  the centres included
namely the NLI, private non profit and for profit hospitals respectively (Kim e t  a l, 1997
and Younossi e t  a l, 1999). These figures were discounted to be 80 215.75 LE, 103 748.88
LE and 187 727.20 LE respectively, and could be used to compare with those in the
literature for the US and Germany; the lifetime discounted disease costs ranging from
$US 24 600 to SUS 38 700 (1995 and 1998 values respectively) for cohorts with a range
o f  histological stages (Kim e t  a l, 1997; Kim, 2002 and Younossi e t  a l, 1999). Comparing
the Egyptian values with the German numbers taking into consideration that one US $
equals 5.1 Egyptian pounds, the numbers are quite close indicating the extremely high 
.
cost o f  the disease in Egypt; bearing in mind that it is a developing country and
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consequently this burden is magnified compared to other more developed rich countries. 
This study thus allows decision makers to reassess the clinical implications o f  the disease 
and to reconsider the treatment options and maybe even to develop a mandatory protocol 
o f  treatment that might be beneficial to all stakeholders involved, namely; the patients, 
the government and its politicians and its policy makers and ultimately the w hole society. 
Not only is the pegylated interferon treatment route for HCV by far the cheapest 
alternative in terms o f  lifetime costs for patients admitted to the three centres included in 
the study when compared with both the supportive and the interferon treatment pathways, 
it is also the treatment alternative that saves the most lives as compared to the other two 
pathways. This is further clarified and emphasized when a cost effectiveness calculation 
is performed. It is noteworthy to mention that another international analysis found 
peginterferon and ribavirin to be cost-saving versus interferon plus ribavirin (Sullivan e t  
a l, 2004 b).
Importantly, cost-effectiveness analyses typically discount costs and outcome projections 
to reflect the higher present value o f  money. Discounting is particularly relevant to 
analyses o f  the cost o f  HCV because anti-HCV infection treatment costs occur now, and 
the costs o f  potential end-stage liver disease occur in the future. Integrating the currently 
recommended 3 % annual discount rate in the cost evaluations (Sagmeister e t  a l, 2001; 
Sennfalt e t  a l, 2001; Buti e t  al, 2002; Grieve and Roberts, 2002; Salomon e t  a l , 2003; 
Stein e t  a l, 2002 and Sullivan e t  al, 2004a & b). In two recent studies discounting at the 
recommended 3 % annual rate reduces HCV costs in the absence o f  antiviral treatment 
$US 33 404 to SUS 18 301 and from Euro 25 500 to Euro 14 100 (Siebert e t  a l, 2003 and 
Wong e t  a l, 2003), while in NLI it decreased from 144 872.23 LE to 80 215.75 LE and in
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the presence o f  antiviral treatment it decreased from 75 704.61 LE to 52 531.28 LE less 
than SUS 10 000.
I In Egypt there is no threshold, below which a therapy may be considered to be “cost 
effective”. Thus SUS 10 000 cost o f  pegylated interferon combination treatment may not 
be within the range o f  other widely accepted or mandated medical interventions such as 
treating hypertension, coronary artery by-pass surgery, haemodialysis or screening for 
colorectal or breast cancer; but it is definitely less than what the same disease would cost 
i f  otherwise treated and the disease is an inescapable fact in the country o f  the pyramids. 
Although the Egyptian HCV epidemic ended twenty five years ago, the very high "silent” 
reservoir o f  infection makes HCV, instead o f  schistosomiasis, Egypt's m ost important
j public health problem. It is important to mention though that current antiviral treatment 
regimens w ill have little impact on the HCV reservoir o f  infection (Strickland, 2006). 
Clinical management o f  the estimated five to seven million Egyptians with chronic HCV 
infection is also a national problem that will not be resolved until more effective, less 
toxic, and less expensive chemotherapeutic agents become available. As only a fraction 
o f  HCV infected Egyptians can pay for, or have insurance that covers, treatment with the 
currently available antiviral regimens. However, the Egyptian Ministry o f  Health and 
Population could reassess the use o f  its available, though insufficient resources, to 
provide a more adequately managed treatment option-based-evidence based 
m ethodologies o f  economics and health assessment. In this case, provide treatment at an 
early stage o f  chronic infection rather than wait for the full cycle o f  the disease with all 
its costly repercussions; consequently a larger segment o f  the population would benefit 
from therapy (Grieve e t  a l , 2006).
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Robinson, (1993 a) gave a simple definition or raison d'etre to econom ic evaluation as a 
technique that was developed by economists to assist decision making when choices have 
to be made between several courses o f  action. In essence, it entails drawing up a balance 
sheet o f  the advantages (benefits) and disadvantages (costs) associated with each option 
so that choices can be made. Although the precise forms o f  econom ic evaluation may 
vary, the “cost-benefit” framework is common to all o f  them. This research was no 
exception to that framework, as the benefit o f  using antiviral combination therapy for 
HCV was calculated against the cost o f  not treating patients.
This research proved that economic evaluation and technology assessm ent are feasible 
techniques within the Egyptian healthcare system and showed their direct relevance to 
health service decision making. It identified routes to overcome the implications and 
barriers o f  their incorporation in the process o f  medical decision making in the country. It 
further proved that better healthcare does not necessarily always require additional 
resources; the same resources could have enhanced results if  invested more prudently in 
the appropriate time and adequate treatment option. There is ample evidence handled in 
the results and discussion to demonstrate that informed policy decisions can have a 
positive effect on the health budget and consequently on the health status o f  Egyptian 
communities.
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8.1. Introduction
The aim of this project was to explore the feasibility of incorporating health technology 
methodologies within clinical decision making and medical policy making in Egypt using 
treatment of hepatitis C virus (HCV) as a case study.
The study data was collected primarily in the National Liver Institute (NLI) in Menoufiya 
(a tertiary referral university hospital) during the period of 2003-2004. The results were 
then compared with corresponding data from two non university settings: the first a 
private non profit hospital dedicated to liver disease in Cairo, and the second, a private 
for profit hospital; the only private setting in Egypt that performs liver transplants.
The data collected in this study was used to calculate the cost of caring for patients during 
different stages of liver disease benchmarked by an internationally recognized Markov 
model illustrating the extended life cycle of the disease which was calculated to be 
144 872.23 LE for the NLI and 187 373.83 LE for the private non profit hospital and 
339 041.37 LE for the private for profit hospital over twenty years. Those figures were 
found to be higher when compared to the cost of interferon and ribavirin combination 
therapy; 92 155.61 LE for the NLI and 111 807.58 LE for the private non profit hospital 
and 196 054.74 LE for the private for profit hospital. The lowest treatment pathway cost 
in twenty years time was found to be the pegylated interferon and the ribavirin 
combination therapy; 75 704.61 LE for the NLI and 89 179.5 LE for the private non 
profit hospital and 142 573.49 LE for the private for profit hospital. This is totally 
surprising because the cost of treatment for one patient per year prescribed the supportive 
treatment was calculated to be 2 840 LE for the NLI and 4 780 LE for the private non 
profit hospital and 8 100 LE for the private for profit hospital while the cost for treating 
one patient per year with the pegylated interferon and the ribavirin combination therapy
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was calculated to be 60 537.03 LE for the NLI and 64 129.62 LE for the private non 
profit hospital and 70 277.77 LE for the private for profit hospital.
8.2. The outcomes of the study
The results, in terms of cost effectiveness of the treatments options, impacted the whole 
society. It was more cost effective to use antiviral therapy in relation to the cheaper 
supportive option where not only cost effectiveness ratio was negative for both the 
regular interferon and the pegylated interferon alternatives but also 10 % and 14 % of 
lives were saved respectively. Moreover, among both antiviral treatments studied 
pegylated interferon option was more cost effective and saved 4 % more lives. Antiviral
I
j treatm ent costs have been shown for the first time to the author’s knowledge, to be nearly
| completely offset by the prevention of future liver-related complications. Peginterferon!
plus ribavirin, or the interferon combination options were quantitatively shown to reduce 
future morbidity from liver complications, to improve survival and to be cost effective. 
This fact was accentuated by the initiation and the implementation of the national new 
mandatory HCV antiviral treatment centres throughout the country by decree of the 
Minister of Health and Population in January 2008.
The main policy implication deduced from this work is that health economics and health 
technology assessment methods should form a main tool for policy developers and 
clinicians. This is because in my opinion, those methods are optimum for developing 
clinical decisions that include consideration of multiple dimensions of evidence
I
I (effectiveness, costs) of the various treatment alternatives.
!
I Because better healthcare does not always require additional resources, there is sufficient
I
i  quantitative evidence in the results to demonstrate that altered policy decisions can have a
i
| profound effect on the health status of communities in Egypt. This research has sought to 
emphasize as Coast (2004) did, the need for whole systems thinking, based on good
i
197
Chapter 5  
Summary
quality evidence, and a broader long term perspective. This might of course involve an 
investment of resources at early stages in the healthcare spectrum, dealing with problems 
in their very early stages, with the aim of removing people from the healthcare system 
rather than ‘moving them on’ to a more complex and expensive part of the system. 
Effectiveness data and data describing cost issues can successfully be calculated as part 
of a profile of treatment attributes and decision criteria. It is also clear that, when used 
appropriately; health technology assessment processes can provide valuable input into 
decision making, policy making processes and rational therapy promoting.
8.3. Proposed suggestions
|
| While working on this case study a range of unanswered questions were identified, some 
of which are directly related to the consideration of costs and their calculation within the 
Egyptian healthcare system and some of which relate to practical implementation of 
health economics more generally.
Despite the emphasis on evidence relating to both effectiveness and cost-effectiveness in 
policy documentation, the fruit of applicability and birth of health economic evaluations 
and HTA in Egypt are related to the development of guidelines and adequate databases 
for the conduct, design and methodology of such studies (Hoffman and Graf von der 
Schulenburg, 2000). This would lead economic evaluations to become part of normal 
practice and organizational environments. This is important as HTAs are useful only if 
they are expected to contribute to the decision-making process. Moreover, if the
i
[ necessary data and resources are insufficient or lacking, the assessment will not be
|
| helpful and may even delay access to treatments (Sorenson et al, 2008). This would first
i\
j have an impact on the healthcare budgetary system and general population benefit and 
also would hinder matching world trends in innovative economic health technologies.
198
^napier o
Summary
Given the complexity and scale of the healthcare problems in Egypt, hospitals, 
laboratories, doctors and clinics need to be connected. The current situation is just too 
fragmented for any long term effective solutions. Together, health economists and 
decision makers share the responsibility of education; the first should provide materials 
for teaching and the latter should encourage and fund it. Fundamental educational and 
professional training is highly recommended to the current decision making personal in 
addition to the next generation of healthcare and policy makers. This would lead to a 
systematic involvement in the medical decision making and in the provision of policy 
advice as economic evaluation and HTA would be directly linked to both cost reductions 
and increase efficiency of the policy and decision making process. It would also pave the 
way to the development of evidence-based practice, heading into implementation and 
practical realization of the need for fairness in resource allocation and service provision, are 
major steps along the road to providing prosperity to the community as an interlinked 
entity. This should be done in parallel with a total cultural change throughout all the 
echelons of providers, decision makers, suppliers, professionals and workers in the health 
care and medical fields.
To overcome the barriers to the use of economic evaluation, the need to balance 
evidence, economics equity and patient empowerment within a system of multiple 
constraints and limited manoeuvrability. Furthermore, to make health assessment fit with 
decision making imperatives; action falls on the health economists and the decision 
makers, each on their own or together. Overall, greater stakeholder involvement is 
needed to improve the implementation of decision and policy and manage uncertainty 
while simultaneously allowing access to safe technologies.
Health economists should get a better understanding of the needs and constraints under 
which decision makers work if pharmacoeconomics is to be applied in a useful way to
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them. They should look at the practical approach and understand the internal issues, 
pressures and political problems as analytical and predictive power often comes from 
standing back and taking a broader view.
Decision makers should improve the system by enhancing data collection and processing 
of both costs and outcomes of treatments and medical services as well as reassessing the 
guidelines for data availability and accessibility particularly beyond the high 
administrative personnel and government officials.
A clear and well-communicated decision-making process must be in place before HTA’s 
recommendations can be implemented. Lack of a defined process can create doubts about 
the legitimacy of decisions and make them less likely to be supported by stakeholders 
(Neumann, 2004 and Drummond, 2006).
Other points to be considered to promote research in the field of health economics and 
implementation of HTA in the future are:
■ Fair access to services and health information
■ Setting national standards and service models to increase efficiency of the
healthcare system
■ Address the organizational issues and cultures
■ Initiate consensus and protocols for treatment and prescription
■ Audit treatment programs
■ Computerizing the system and initiate national security number relation to 
healthcare
■ Studying hospital stay impact effect on health budget
All this should be done taking into consideration that the multi-faceted intricacies of
organizational cultures and politics added to the differences in personalities combine to 
produce a spectrum of outcomes, ranging from utter failures to highly successful
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programs and policies. More work is needed to assess the effectiveness of intra- 
organizational, inter-organizational, inter-professional, and collaborative approaches to 
the organization and delivery of services (El Ansari et al, 2001 and El Ansari and 
Phillips, 2001) in order to accompany the effectiveness and efficiency research and 
analysis.
In conclusion, the study showed that economic analysis and HTA in Egypt founded on a 
sound understanding of current practice, effectiveness and cost effectiveness data can 
actually and practically change and improve clinical practice and healthcare decisions 
and increase the efficiency of a wonderfully altruistic medical system but an 
unfortunately economically failing one.
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